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Chapter1
The chemistry of heterocycles and their biological
applications
1.1 Introduction
The chemistry of heterocycles represents a modern interesting divi-
sion of organic chemistry that collects cyclic compounds having at least
two different elements, as defined by IUPAC, commonly identified as
carbon and nitrogen, oxygen or sulphur.[1] For this reason, it’s possi-
ble to divide ring systems on the basis of the heteroatom and, in each
group, on the basis of the dimension of the resulting structure defined
by the other atoms too;[2] moreover, they can be divided in aromatic or
aliphatic heterocycles, which properties are influenced by the presence
of strains attached to the ring and which are considered analogues of
amines, esters, ethers, amides etc. These features are responsable for
the different physiochemical properties of the heterocycles and of the
compounds that contain themselves. In fact, heterocyclic cores can have
various applications in several fields of chemistry, but in particular in
medicinal chemistry to synthesize compounds with anti-bacterial, anti-
inflammatory, anti-cancer and anti-fungal properties. The usefullness of
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these systems is linked to the possibility to modulate the properties of a
drug by the introduction of these motifs. Heterocycles can be considered
bioisosteric replacements of parts of a drug, so they can guarantee the
keeping of lipophilicity, hydrophilicity, polarity or reactivity of a drug or
modulate its properties, altering or influencing the mechanism of action
of the pharmaceutical agent.[3][4]
1.2 Heterocycles as isosteres in bioactive compounds and pep-
tidomimetics
The potential of peptides and proteins as therapeutics is well known,
as their limited stability to proteolysis and their inability to cross cell
membranes. So, the general approach to overcome these limitations
is the introduction of modifications on the peptide/protein to keep un-
changed or improve the biochemical properties associated to an effi-
cient drug action.[5] These results can be obtained changing the back-
bone structure of the peptide or incorporating peptide bond isosteres. In
general, peptidomimetics are molecules in which the pharmacophore,
the foundamental element responsible for the biological efficacy of the
compound, is represented by a structure that mimics a peptide or a pro-
tein in their 3-dimensional disposition and in their biological behaviour.
This class of molecules allows to overcome some problems associated
to peptidic compounds, like low biodisponibility and low stability to-
wards proteolysis, and in some cases to improve efficacy and receptor
affinity and selectivity. So, peptidomimetics have great relevance in drug
discovery programs.[6] Generally, the attempt is to substitute as much
part of the peptide as possible with non-peptidic elements in order to
enhance the lipophilicity and so the biodisponibility of the molecules.
Then, the substitution of amide bond is required to improved the resis-
tance to proteolysis and to make the compound metabolitically stable.
2
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Finally, conformational modifications in order to improve the flexibil-
ity and to guarantee a better interaction with the proper binding sites
are evaluated.[7] It’s possible to distinguish four different types of pep-
tidomimetics: the type I mimetics are peptides backbone mimetics (so
strictly defined peptidomimetics), that match peptide backbone atom-for
atom keeping some foundamental functionalities required for the interac-
tion with the proper binding site; the type II mimetics are small molecules
that act as functional mimetics, with good affinity toward the peptide re-
ceptor; the type III mimetics are novel structures which possess func-
tional groups acting as topographical mimetics; the type IV mimetics
are GRAB-peptidomimetics (GroupReplacementAssisted-Binding) that
keep functional properties like type I mimetics, but they can bind re-
ceptor forms not accessible with the last mentioned.[8] A widely used
technique in the design and synthesis of peptidomimetics is the replace-
ment of amide-bond, the most suitable for proteolitic degradation, with
amide-bond analogues or isosteres, which allows to understand the pro-
tease enzyme activity when the structure of the isoster mimics the transi-
tion state of the hydrolitic degradation.[9] The employment of bioisosters
is one of the most rational approach used in medicinal chemistry to mo-
dify a lead compound to generate other molecules with better biological
properties. One of the first examples was reported in 1919 by Lang-
muir who compared the physiochemical properties of some atoms and
molecules, like N2 and CO2, founding them similar. With this study,
he found 21 groups of isosteres, defined as group of atoms or com-
pounds with the same number and arrangement of electrons.[10][11]
This work represent the basis of the modern concept of bioisosterism.
The first definition proposed by Friedman was founded on the ability of
a group of atoms or molecules to repropose the biological beahviour of
a well-defined compound. The concept was extended by Burger, includ-
ing all those compounds with near-equal molecular shape, volume and
3
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electronic disposition to those of the target compounds, acting as ago-
nist or antagonist.[12][13] Bioisosteres can be divided in two classes:
classical and non-classical isosteres. The first class includes monova-
lent/divalent/trivalent atoms, tetrasubstituted atoms and ring equivalents;
the second class can be divided in ring vs noncyclic systems and ex-
changeble groups and includes systems which can have a number of
atoms, steric and electronic properties different from the molecules that
they should substitute.[14] We focused our attention in particular on non
classical bioisosteres since they are widely used in the design and syn-
thesis of drugs and bioactive compounds. Infact, one of the most lable
functionalities is the ester, since esterases are ubiquitous in the organism
and they can easly hydrolize it. The substitution of an ester with an het-
erocycle is a solution to enhance the stability toward hydrolysis of these
molecules. It was discovered the ability of the heterocycles to create effi-
cient hydrogen bonds with the receptor binding site: for this reason, it is
of common practice the use of Brönsted proton basicity scale as alterna-
tive to hydrogen bond capacity of heterocycles, in order to classify them.
In the Figure 1.1 hydrogen bonding capacity (pKBHX ) and Brönsted
basicity (pKHB) are reported for some 5-membered heterocycles.
Figure 1.1: Hydrogen bonding (pKBHX ) and Brönsted basicity (pKHB ) of 5-membered heterocy-
cles.
Another element that should be considered is the strenght of the C-
H bonds of these systems. Infact, depending on their distance from
the heteroatoms, these bonds can form hydrogen bonds strong enough
to induce conformational and particular binding behaviour in the drug
4
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candidate.[15] Lipophilicity is an important parameter that can influence
the efficacy of a drug. In general, ClogP < 5 is considered founda-
mental to guarantee low lipophilicity and so good metabolic stability.
Heterocyclic scaffolds can low ClogP if compared with the respective
all-carbon counterpart. However, this aspect can be not always consi-
dered an advantage, if cell membrane penetration is reduced. Acqueous
solubility is another property that can be modified by the introduction
of heterocycles, more able of their corrisponding all-carbon analogues
to create hydrogen bonds. But between the heterocycles, it’s possible
to detect differences: for example, the isoxazole is more water-soluble
than thiophene, due to the possibility to form hydrogen bonds with nitro-
gen and oxygen.[16] Heterocycles can be applied as cyclic or noncyclic
bioisosteres in the synthesis of peptidomimetics. They can be used to
recognize the different subtypes of receptor, since particular conforma-
tions of a peptide can show specificity only for one of them. For this
reason, heterocyclic-based constrained peptidomimetics and mimetics of
peptide secondary structures can be employed to study the conformation
able to link specific receptor subtype. An example is the use of heterocy-
cles to substitute non cyclic peptides in order to induce specific torsion
angles and study the effects of conformational restrictions on biological
activity. As esters, amide bonds are often substituted with bioisosteric
analogues in the synthesis of peptides or drugs. In this case, cyclic vs
noncyclic bioisosteres can be used: 1,2,4-oxadiazoles, 1,3,4-oxadiazoles
and 1,2,4-triazoles are good bioisosteres of esters and amides (Figure
1.2). To these, 2-isoxazoline and imidazoline can be added, with specific
applications in medicinal chemistry.[17][18][19]
The correlation of physicochemical parameters with the biological
activity of a molecule is important to understand the little modifications
introduced by bioisosteric heterocycles. They are used to optimize the ef-
ficacy and selectivity of a drug by means of pharmacokinetic e toxicolog-
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Figure 1.2: Heterocycles isosteres of amide bond.
ical properties. Even if the introduction of heterocycles in a compound
can affect negatively the parameters of a drug, their careful manipolation
can reach the good compromise between improvement and toxicity.
1.3 Aim of the thesis
As declared in the previous section, the rilevance of heterocycles in
medicinal chemistry and the inclusion of them in more complex struc-
tures represents a central matter. For this reason, the research towards
new cyclic isosteres of functional groups and the optimization of their
synthesis have been one of the basis of this work. In particular, the atten-
tion was paid to three different heterocycles: isoxazolines, isoxazolidi-
nones and 3,4-dehydro-β-prolines (Figure 1.3).
Figure 1.3: Structure of the synthetized heterocyles.
The synthetic protocols developed for them are based on the electro-
phylic properties of alkylidene acetoacetates, malonates, acetoacetamide
esters and malonamides that show great versatile reactivity. The prepa-
ration of these intermediates will be presented in Chapter 2 and it will be
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focused on the development of two different protocols: the first one is the
Knöevenagel condensation, a well-known reaction, performed at room
temperature; the second one is a microwaves-assisted protocol, particu-
lary interesting considering the growing application of these technology
in organic synthesis. For this last topic, two examples of application
will be reported: a microwave-assisted protocol for the Yonemitsu-type
trimolecular condensation and the microwave-assisted one-pot two-steps
synthesis of alkylidene acetoacetamide esters for the preparation of β-
dehydropeptides. The reactivity of alkylidene derivatives will be studied
in Chapter 3. The reactivity towards indoles, amines and diprotected-
hydroxylamines will be discussed , since 1,4-Michael addition of C- and
N-nucleophyles on α, β-unsaturated electrophyles is the ground for the
synthesis of isoxazolines and isoxazolidinones, differently substituted.
Then, the Luche-reduction of these unsaturated intermediates will be pre-
sented and the consequent enzymatic resolution for the enantioselective
preparation of 3,4-dehydro-β-prolines. Connected to the theme of the ril-
evance of bioisosteres in medicinal chemistry, applications of the synthe-
sized heterocycles in molecules with biological target will be presented
in Chapters 4 and 5. Since isoxazolidinones and 3,4-deydro-β-prolines
can be considered bioisosters of oxazolidinones, the pharmacophore of a
big family of drugs with antibiotic activity, we worked on the synthesis
of a small library of antibiotic compounds based on the two synthesized
heterocycles (Chapter 4) (Figure 1.4).
The structure of the compounds in the library reminds to the structure
of Linezolid, an oxazolidinonic antibiotic active against gram-positive
bacterial strains resistant to other antibiotic treatments, like those with
Methicillin and Vancomycin. The oxazolidinones are pharmacophores
of another important class of drugs too: the inhibitors of MonoAmino
Oxidase (MAO), enzymes responsible for metabolism of monoamine
neurotrasmitters. For this reason, the library has been tested in its an-
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Figure 1.4: Structure of antibiotic compounds based on isoxazolidinone and 3,4-dehydro-β-proline.
tibiotic activity on specific bacterial strains and in its MAO-inhibitor ac-
tivity on two isoforms of human monoamino oxidase. Considering their
good activity towards MAO-A and B, docking experiments will be pre-
sented to understand their behaviour. The 3,4-dehydro-β-prolines and
the isoxazolines are the focus of the second topic presented in Chap-
ter 5: the synthesis on peptidomimetic integrin ligands. Going back to
the importance of peptidomimetic chemistry in the subsection of medi-
cinal chemistry, we studied the role of vascular cell adhesion molecule
1 (VCAM-1), in the regulation of cell membrane activity governed by
α4β1 integrins during inflammatory desease, and the role of fibronectin
(FN) and RGD-peptides, in the regulation of αvβ3 and α5β1 integrin ac-
tivity. The 3,4-dehydro-β-proline was employed as heterocyclic bioisos-
teric scaffold for the synthesis of peptidomimetic analogues of the natural
ligands of α4β1 integrins: two different pattern of functionalizations of
the heterocyclic core produced two classes of α4β1 ligands, whose bio-
logical activity was evaluated. The isoxazolines were employed in the
synthesis of α5β1 and αvβ3 integrin peptidomimetic ligands as systems
for drug or fluorescent molecules delivery (Figure 1.5). The structure of
these ligands keeps some fundamental features required to be active on
these proteins: good water solubility, flexybility, small dimension and
amidic and acidic functionalities properly oriented and distanced. The
designed ligands have a alkyne as substituent of the heterocycle, opening
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the way to the "‘Click chemistry"’, widely used in the design of bioactive
compounds: this allowed us to create a library of molecules by changing
the side chain attached to the triazole ring obtained by this cycloaddition.
The library was then tested on integrins to evaluate its eventual biological
efficacy.
Figure 1.5: Structure of integrin ligands based on isoxazoline and 3,4-dehydro-β-proline.
Figure 1.6: Structure of fluorene-based pi-conjugated oligomer for the synthesis of red-shifted self-
assembled nanoparticles
In a parallel way, the attention was paid on systems that can be deliv-
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ered by the integrin ligands so synthetized. So, during the period spent
in Prof. Brunsveld’s laboratory in the Technische Universiteit of Eindho-
ven, the work presented in Chapter 6 has been developed: the synthesis
of red-shifted self-assembled nanoparticles as tools for bioimaging (Fig-
ure 1.6). The emerging class of fluorescent pi-conjugated oligomer based
nanoparticles was studied as interesting probes for sensing and cellular
in vivo imaging. In order to overcome the problem of autofluorescence
usually observed during the in vivo tests with fluorescent agents, in this
chapter the synthesis of nanoparticles based of fluorene pi-conjugated
oligomer and the preparation of nanoparticles starting from them will be
discussed. The caratherization and the comparison with not red-shifted
analogues will be described too.
10
Chapter2
Alkylidene derivatives as building blocks
2.1 Introduction
In order to perform studies on the reactivity of alkylidene deriva-
tives for the synthesis of more complex structures, it’s important to de-
velop solid, versatile, efficient and easy-to-do protocols for their synthe-
sis. Knöevenagel condensation is the most widely employed reaction
for the synthesis of these derivatives starting from an aldheyde and a
methylene-active compound, in presence of a base or a Lewis-acid as
catalyst. The first example was reported in 1894 by Knöevenagel and
it involves formaldehyde and diethyl malonate or ethyl benzyloxyacetate
in presence of ethylamine, to obtain in a reversible way (in a sort of
extension of the aldol reaction) a functionalized olefin.[20] [21] The effi-
ciency of the reaction depends on several factors: not only on the relative
reactivity of reagents but also on the solvent and the base employed and
on the chosen methodologies to remove the water produced during the
reaction. The particular usefulness of dicarbonyl compounds in this re-
action depends on the presence of a second carbonyl moieties that acts as
electron-withdrawing group enhancing the nucleophilicity of the methy-
11
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lene group: for this reason compounds in which the carbonyl is combined
with nitro, cyano, sulfonyl or carbonyl moieties are mainly employed
as nucleophilic counterpart of the reaction. Examples are malonic acid,
malonic esters, malonic amides, Meldrum’s acid, acetoacetates and ace-
toacetamides. At the same time, the electrophylic carbonyl compound is
often an aldehyde, in particular 2-hydroxybenzaladehyde, benzaldehyde,
isobutyraldehyde and salicylaldehyde. The reaction is generally cataly-
zed by strong bases, like NaOH, KOH and sodium ethoxide, or weak
bases, such as tetrabutylammonium hydroxide, morpholinium acetate,
piperidine, pyridine and amino acids; these bases can be immobilized on
solid-state support too.[22] In addition, the reaction can be modified to
be performed in ionic liquids or under microwave assistance.[23][24][25]
There are two proposed mechanisms for this reaction: the first proposed
on the basis of the results carried out by Knöevenagel in 1898; the second
developed few years later by Hann and Lapworth. The first derives from
two trials performed by Knöevenagel: an aldehyde, ethyl acetoacetate
and an amine (primary or secondary), on one hand, and an alkylidene-
bis-amine and ethyl acetoacetate, on the other. He found for both the
cases the same product, alkylidene-ethyl acetoacetate, with two equiva-
lents of diamine as coproduct in the second case. So he postulated that
the second reaction can well describe the mechanism of a base (amine)
catalyzed-condensation: the amine form a Shiff base with the aldehyde
which is the real electrophile that undergoes the nucleophilic attack of
methylene active compound. Related to the second part of the reaction,
that is to say the activation of the nucleophile, the hypothesis regards the
role of the amine catalyst (pyridine in the first trials performed by Hann
and Lapworth in 1904): they assumed that the base allows the forma-
tion of a carbanion (or enol) resonance-stabilized intermediate from the
methylene active compound, that added the aldehyde giving an hydroxyl-
containing adduct. The hydroxyl-intermediate in them both the cases
12
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undergoes β-elimination to give the final olefin. The sterochemical defi-
nition of the product depends in great part on the steric hindrance of the
substituents during the condensation.[26]
2.2 Results and discussions
2.2.1 Synthetic protocols base or Lewis acid founded
After the first example reported by Knöevenagel and Hann-Lapworth,
changes were made using pyridine as solvent and piperidine as catalyst,
which became known as Döebner Modifications. According to this hy-
pothesis, the two previously described mechanisms can be considered
concerted (Figure 2.1): the pyridine represents the base responsable for
the formation of the methylene-active intermediate that acts as nucleo-
philic species, in the same way in which Hann and Lapwroth described
their mechanism; the piperidine allows the formation of the Shiff base
starting from the aldehyde, as proposed by Knöevenagel.[27] A lot of
Figure 2.1: Mechanism of Knoevenagel condensation according to the Doebner’s modifications.
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works regarding the attempt to improve the protocols for this reaction
have been reported, especially to make it less energy intensive and more
green, rapid and safe. In fact, the use of pyridine should be avoided
for many reasons, above all because it is a cancerogenic substance, haz-
ardous for the environment and the operators and difficult to be han-
dled in big scales.[28] Traditionally the reaction is performed in pyri-
dine as solvent and piperidine as catalyst: this choice is particulary rile-
vant when the reaction involves substrates that can be in situ decarboxy-
lated, like malonic acid. For this purpose, we recently reported exam-
ples of Knöevenagel condensation catalyzed by proline for the synthe-
sis of alkylidene and arylidene malonates.[29] In this case, the chirality
of the catalyst was not relevant for the aim of the project, but allowed
the development of a very mild condition-based protocol that involves
dimethylmalonate, several alkylic or arylic aldehydes and 10% of pro-
line in DMSO at room temperature, obtaining without the use of a de-
hydratating agent the alkylidene or arylidene malonate with yields upper
70%. Other examples in which the pyridine is substituted by a mix-
ture of TEA/piperidine are reported in literature, particularly useful for
the synthesis of arylidene and alkylidene malonate in high boiling point
solvents and with the assistance of microwaves to reduce the reaction
time.[30] As described before, the Knöevenagel condensation can be per-
formed with the use of Lewis acid as catalyst too. Ti(Cl)4 and its ana-
logues are often used for this application even if there are few examples
in literature regarding its employment as catalyst in the abovementioned
condensation. In 1970’s Lehnert and in 1980’s Reetz described Ti(IV)-
catalyzed Knöevenagel reactions for the synthesis of alkylidene or aryli-
dene malonate,[31] [32] ethyl acetoacetate, ethyl nitroacetate[33], tri-
ethyl phosphonoacetate [34] and ethyl (diethoxyphosphoryl)acetate [35].
Examples were proposed later with the substitution of pyridine with tri-
ethyl amine.[36][37]
14
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In a first approach, we developed a protocol for a solvent-free con-
densation to prepare alkylidene methyl malonylamides [38] and alkyli-
dene tert-butyl acetoacetate. The reaction was performed with excess
of aldehyde in presence of 15 mol% of piperidine: this choice was pos-
sible since the excess of aldehyde acts a solvent of the reaction and it
is easily removable by flash chromatography or by evaporation as con-
sequence of their low boiling point. In this case, there is no need of
dehydrating agents to obtain the desired olefin, as 1/4 mixture of Z/E
isomers. The limit of this reaction is in the long reaction times, from 12h
to 3 days. (Figure 2.2) The unsatisfactory yield observed for alkylidene
Figure 2.2: Synthesis of alkylidene malonamide and acetoacetate at room temperature.
acetoacetate 4 (calculated on two steps, since the aldheyde is synthetized
by Swern oxidation of the corresponding 5-hexyn-1-ol) was attributed
to side chain reaction of the alkyne moiety, due to its acidity. For this
reason, we proceeded with a second approach on the model reported by
Cruciani et al.[39] The Knöevenagel condensation was perfomed after
protection of the alkyne moiety of the starting alchol with TMS group,
by the employement of TMS-Cl and n-BuLi as base. The quantitative
conversion to give the intermediate 5 allowed to achieve the oxidation
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product 6 in the same condition reported for intermediate 3. As conse-
quence of the presence of TMS-base sensitive group, the condensation
was optimized using a mixture of TiCl4 and pyridine, in THF, obtain-
ing the desidered product with yield of 83% (Figure 2.3). The assumed
Figure 2.3: Synthesis of alkylidene tert-butyl acetoacetate Ti(IV )-catalyzed.
mechanism postulates the formation of a 1:1 complex between tert-butyl
acetoacetate and TiCl4, where the Ti(IV) acts as a bidentate coordinat-
ing metal. Deprotonation of the acid proton gives the tetrachlortitanium
enolate that reacts with the aldehyde, whose carbonyl moiety replace
one of the carbonyl functions of the acetoaceate in the coordination with
the metal. There are two possible pathway according to which carbonyl
group (ester or ketone) is replaced by the aldehyde, but the mechanism
is the same for them both. The intramolecular aldol reaction allows the
formation of a six-membered metallacycle with two stereogenic centers;
then the dehydration occurs by deprotonation of the last acid proton by
pyridine (Figure 2.4).[40]
2.2.2 Microwaves-assisted synthetic protocols
Microwave assisted organic synthesis (MAOS) is a growing area of
research that gives the chance to significantly reduce reaction times from
hours to minutes, enhancing in same cases the reactivity of systems that
in conventional heating conditions are less reactive. In recent years, a lot
of examples of microwave-assisted reaction have been reported starting
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Figure 2.4: Mechanism of Ti(IV )-catalyzed condensation.
from cycloaddition and solvent-free reactions, going to heterocyclic and
medicinal chemistry, but important effects can be observed in particu-
lar in the preparation of isotopically labelled drugs [41] and in catalyzed
reactions where the short reaction times reduce the tendency of the ca-
talyst to decomposition, increasing its efficiency.[42] The results can be
explained by the existence of the so-called "‘microwave effect"’. This ef-
fect is a combination of several contributes like thermal and non-thermal
effects, overheating, hot spots and selective heating.[43] The microwave-
assisted technology is based on the "‘microwave dielectric heating"’ ef-
fects of a chosen material: it means that different materials (reagent or
solvent) have different ability to absorb microwave energy that will be
converted in heat. This is what we call thermal effect. Irradiation by
microwaves gives allineation of dipoles or ions present in the sample ac-
cording to the applied electric field. Since it oscillates, the dipoles and
ions try to realign themselves with the alternating field: during this pro-
cess there is loss of energy in the form of heat. This means that the
amount of heating developed depends on the ability of the components
of the sample to follow the oscillations of the field; if the dipoles don’t
have enough time to realign with the electric field no heating is produced.
For this reason, the microwave-induced heating happens in homogeneous
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way in all the sample, while the conductive heating starts from the sur-
face and diffuses itself in heterogeneous way to the rest of the volume.
In fact, the conventional heating occurs through external sources like oil
bath: the heat has to penetrate through the vessel in the solution, with a
great loss of units of temperature between the vessel itself and the vo-
lume inside it. So, the conductive heating process is slower and more
inefficient if compared to the microwave-assisted one. The last produces
internal heating and, as consequence of the material commonly used for
the reaction equipment, the gradient of temperature is inverted if com-
pared to the previous described.[44] This effect can be used to explain
the higher yields and the enhanced efficacy of some microwave-assisted
reactions. Due to the theory behind this technology, it is clear that po-
lar substanced are easly heated while apolar ones are not affected by the
radiation, so they are not heated. Selective heating of solvents, reagents
and catalyst can be observed. In particular, the polar nature of the ca-
talysts brings to the definition of different temperatures for the catalyst
and the bulk solution, which implicates that some catalyzed reaction are
more efficient under microwave-assistance.[43]
Taking into account all these considerations, we proceeded setting the
conditions to perform the Knöevenagel reaction previously mentioned
(i.e. catalysis by 15 mol% of piperidine) under the assistance of mi-
crowaves for the synthesis of various alkylidene malonates, malonamides,
acetoacetates and acetoacetamides. As regard alkylidene malonates and
acetoacetates, we started with the optimization of the reaction of dimethyl-
malonate or tert-butyl acetoacetate with isobutanal: the reaction occurs
with equimolar amount of the two reactants in presence of 15 mol% of
piperidine under microwave-irradiation at 250 Watt for 7 min, obtain-
ing the isobutylidene tert-butyl acetoacetate 8b or isobutylidene dimethyl
malonate 8a with yield of 90% after flash chromatography (Figure 2.5)
[45]. The same reaction was previously reported in literature with the
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catalysis of proline (10mol%) at room temperature in DMSO for 16 h
with yield of 72% [29] or with great excess of aldehyde (10 equivalents)
under irradiation by microwave at 500 Watt for 7,5 min with yield of
87%.[46]
Figure 2.5: Synthesis of alkylidene malonate and acetoacetate under microwave assistance.
The same reaction was then extended in a small library of compounds
obtained changing aldehyde and acetoacetate (Figure 2.6), in order to
obtain the substrates for a Yonemitsu-type trimolecular condensation that
will be described in the next chapters.
Figure 2.6: Alkylidene acetoacetate obtained through microwave assisted Knöevenagel condensation.
Further studies were made to optimize a microwave assisted protocol
for the synthesis of alkylidene malonamides and acetoacetamides. We
recently reported the synthesis of unsaturated malonamides as scaffolds
for the synthesis of several heterocycles.[47] Starting from these results
we proceeded with the synthesis of α,β-unsaturated acetoacetamides,
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through the employment of Knövenagel condensation between β-ketoamides
and aldehydes.[48] They have been synthetized by a one-pot two-step
protocol based on the preparation of amino-acid-derived-β-keto amides
10 through microwave irradiation: the first step is the acetoacetylation
of aminoacids, followed by Knöevenagel condensation (Figure 2.7). The
Figure 2.7: One-pot two-steps synthesis of α,β-unsaturated acetoacetamides.
optimization was initially performed on each step. The synthesis of β-
ketoamides is carried out by opening of 2,2,6-trimethyl-4H-1,3-dioxin-4-
one (DAA) [49] since simple acetoacetylating agents may afford the con-
current condensation of the amine on the ketone, leading to β-enamino
derivatives. There are two mechanisms proposed for this reaction: the
unimolecular formation of acetylketene concomitant to release of ace-
tone (Figure 2.8, Path A) or a bimolecular pathways with nucleophilic
attack of amine on dioxinone and elimination of acetone (Figure 2.8,
Path B).
Figure 2.8: Possible mechanisms for the reaction of dioxinone with amino esters.
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Figure 2.9: Model reaction between dioxinone and leucine methyl ester.
The first mechanism have been confirmed by kinetic and spectro-
scopic studies, which underline that the decomposition of dioxinone is
a reversible process [50]. We chose as standard reaction that between
leucine methyl ester and DAA (Figure 2.9). Some results are reported in
Table 2.1.
Table 2.1: Optimization of dioxinone ring opening reaction.
Entry Solvent MW Time Catalyst Yield
power (min) (mol%) (%)[a]
1 toluene 250 W 5 10 −
2 1,4-dioxane 250 W 5 10 −
3 tol1, 4-dioxane 250 W 5 10 −
4 chlorobenzene 250 W 5 10 57
5 DMF 250 W 5 10 70
6 tolDMF(3:1) 250 W 5 10 24
7 tolDMF(2:1) 250 W 5 10 44
8 tolDMF(1:1) 250 W 5 10 > 95
9 solvent free 250 W 5 10 0
10 tolDMF(1:1) 250 W 5 0 72
11 tolDMF(1:1) 250 W 10 0 > 95
12 tolDMF(1:1) 80 W 45 10 67
13 tolDMF(1:1) 100 W 20 10 > 95
14 tolDMF(1:1) 300 W 5 10 77
[a] When the conversion was uncomplete, signals due to the dioxinone
protons were observed in the 1H NMR spectrum of the crude reaction
mixture.
In the first screening, the solvent had to be selected, since the amino
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acids are solid compounds. This matter represents a great improvement
over the already reported methods, in which commonly liquid amines
are used. Initially, the reaction was perfomed in presence of Yb(OTf)3,
as catalyst, by MW irradiation at 250 Watt for 5 min. As reported in
Table 2.1 (entry 1-3), the reaction doesn’t work in toluene, dioxane or
mixture of them, as consequence of their low ability to convert electro-
magnetic energy into heat. When chlorobenzene is used (entry 4), the
product is isolated in 57% yield. If DMF is used as solvent (entry 5),
the yield is 70% but the removal of the solvent is quite difficult. For this
reason, 3:1 and 2:1 mixtures of toluene and DMF have been tried (entry
6 and 7) with encouraging results. So, with a 1:1 mixture of the same
solvents (entry 8) the conversion is complete. The reaction in which
the dioxinone is used as solvent (entry 9) doesn’t occur. Moreover, we
observed that when the conversion is not complete dioxinone is always
present in the mixture: this information confirms that the decomposition
to give acetylketene is a reversible process [50]. Further investigation
showed that the presence of catalyst was not necessary even if without it
the reaction time had to be doubled to obtain complete conversion (entry
10 and 11). Different setting conditions of the microwave oven showed
that lowering the power longer time is required (entry 12 and 13), while
stronger irradiation gave an increase in the formation of by-products (en-
try 14). The optimal conditions were then applied to different amino
ester (Figure 2.10): the results are reported in Table 2.2.
Figure 2.10: Reaction of dioxinone and amino ester under the optimized conditions.
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Table 2.2: Reaction of dioxinone with amino esters.
Entry Reagent MW Time Catalyst Yield
power (min) (mol%) (%)[a]
1 Gly-OEt 250 W 5 10 > 95
2 Gly-OEt 250 W 5 0 41
3 Gly-OEt 250 W 10 0 > 95
4 Val-OMe 250 W 5 10 83
5 Val-OMe 250 W 5 0 72
6 Val-OMe 250 W 10 0 > 95
7 Phe-OMe 250 W 10 0 > 95
8 Trp-OEt 250 W 10 0 > 95
9 β-Ala-OEt 250 W 15 0 > 95
10 Glu-OMe 250 W 10 0 86
11 Pro-OMe 250 W 15 0 86
[a] When the conversion was uncomplete, signals due to the dioxinone
protons were observed in the 1H NMR spectrum of the crude reaction
mixture.
Different trials were done with and without catalyst using amino esters
of phenylalanine, glycine, valine and tryptophan. As reported in Table
2.2, when glycine ethyl ester was used, the reaction gives complete con-
version in presence of catalyst (entry 1) while to obtain the same result
without catalyst the irradiation time has to be increased to 10 min (en-
try 2 and 3). The same trend was observed using valine (entry 4-6):
without the catalyst, yield of 72% was reached after 5 min of irradiation
(entry 5), but elonging the reaction time to 10 min complete conversion
was obtained (entry 6). As regards tryptophan ethyl ester (entry 8) and
phenylalanine methyl ester (entry 7) good results comparable with those
previously shown for the same conditions were detected. Considering
the possibility to avoid the employment of catalyst by using longer irra-
diation times, we extended the study using β-alanine methyl ester (entry
9), methyl glutamate (entry 10) and proline methyl ester (entry 11). By
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modulation of the reaction times for each amino ester, good results have
been reported for them too by using the same conditions. Starting from
these results, we proceeded with the optimization of the second step, the
Knöevenagel condensation, in a microwave assisted one-pot two-steps
protocol (Figure 2.11). As previously described, the procedure was first
optimized for leucine methyl ester and then extended to other amino es-
ters and aldehydes as reported in Table 2.3.
Table 2.3: Optimization of one-pot two-steps sequence with leucine methyl ester.
Entry Reagent Aldehyde Base Product Yield ZE
(equiv.)[b] (mol%) (%) ratio
1 Leu-OMe iPrCHO 0 11a 9 9:1
(3)
2 Leu-OMe iPrCHO 0 11a 84 9:1
(6)
3 Leu-OMe iPrCHO 0 11a 90 9:1
(12)
4[a] Leu-OMe iPrCHO 10 11a 92 9:1
(6)
5 Leu-OMe C6H11CHO 0 12a 95 9:1
(1.5)
6 Leu-OMe PhCHO 0 13a 95 95 : 5
(1.5)
[a] The second step was stopped after 30 min.
[b] When conversion was incomplete, signals due to acetoacetamide intermediate were
observed in the 1H NMR spectrum of the crude reaction mixture.
The best results have been obtained by irradiation in the second step
for 45 min, while loger times gave increasing of by-products without
enhancement of yield. When volatile aldehydes have been used, great
excess of them was required (entry 1-3), while as regards high boiling
point aldehydes the amount descreased to 1.5 equivalents (entry 5 and
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Figure 2.11: One-pot two-steps reaction for the synthesis of alkylidene-amides.
6). By addition of piperidine as catalyst in the Knöevenagel condensa-
tion (entry 4), reduction in time of reaction and increasing overall yield
were possible. When this protocol was extended to proline methyl es-
ter, none Knöevenagel product can be detected as consequence of the
reduced reactivity of the methylene group of a tertiary amide and of the
higher rigidity of the molecule [51]. TheZ/E ratios were always in favor
of Z isomer as consequence of the steric hindrance linked to the aldehyde
and the side-chain of the amino ester [46]. This protocol shows how it
is possible to realize the same reaction in bigger scales: in fact, the re-
action with isobutyraldehyde and leucine methyl ester gave quantitative
yield by elongation of the reaction time to 60 min. Moreover, trials to de-
mostrate that the conventional heating is unsuccessful were performed,
since they require long reaction times and bring to formation of several
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by-product.
2.3 Conclusions
By developing efficient protocols for the synthesis of alkylidene or
arylidene malonamides, acetoacetamides, acetoacetate and malonate it
was possible to obtain small libraries of compounds employed as start-
ing materials for the synthesis of more complex structures. Performing
the Knöevenagel condensation with the catalysis of piperidine or Ti(Cl)4,
it is possible to synthesize with good yield but commonly long reac-
tion times different kinds of alkylidene acetoacetates, malonamides and
malonates. The introduction of microwave technology allowed improve-
ments on the previous mentioned conditions: the MW-induced heat-
ing gives a reduction of the reaction times and an enhancement of the
yield due to a bigger reactivity of the polar intermediate of the cata-
lyzed and not catalyzed reactions. In particular, microwave have been
used in a one-pot two-step protocol for the preparation of amino-acid
derived unsaturated acetoacetamides, decreasing the amount of catalyst
needed both for the dioxinone ring opening (concerning the synthesis of
N-amino ester acetoacetamide) and for the Knöevenagel reaction.
2.4 Experimental procedures
2.4.1 General methods
All chemicals were purchased from commercial suppliers and were
used without furhter purification. Microwave-assisted reaction were car-
ried out in Milestone Mycrosynth apparatus, with a dual magnetron sys-
tem with a pyramid-shaped diffuser, 1000 W maximum power output,
and temperature monitor and control by optical fiber up to a vessel tem-
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perature of 250 oC. Flash chromatography was carried out on silica gel
(230-400 mesh). Dowex R©50WX2-200(H) ion exchange resin was used
for purification of free amino acids or free amines. NMR spectra were
recorded with a Varian Mercury Plus 400 or Varian Gemini 200 instru-
ments. Chemical shifts are reported as δ values (ppm), and were cali-
brated using the residual solvent peaks of: CDCl3, set a delta = 7.27 ppm
(1H NMR) or δ = 77.0 ppm (13C NMR); CD3OD, set at δ = 3.31 ppm
(1H NMR) and δ = 49.o ppm (13C NMR); D2O, set at δ = 4.79 ppm (1H
NMR); CD3CN, set at δ = 1.93 ppm (1H NMR) and δ = 117.7 ppm (13C
NMR); (CD3)2CO, set at δ = 2.04 ppm (1H NMR) and δ = 29.8 ppm
(13C NMR). Coupling costants are given in Hz. LC-MS analysis was
carried out with an HP1100 liquid chromatograph coupled to an electro-
spray ionization mass spectormeter (LC-ESI-MS), using a Phenomenex
Gemini C18 - 3µ - 110 Å column, H2O/CH3CN as neutral solvent or
H2O/CH3CN with 0.2% formic acid as acid solvent at 25 oC (positive-
ion mode, mz = 100-500, fragmentor 70 V). Another set of experiments
has been performed on an HP1100 liquid chromatograph coupled with
an electrospray ionization-ion trap mass spectrometer MSD1100 usign
a Phenomenex Zorbax C18 - 3.5µ - 80 Å column, H2O/CH3CN with
0.08% trifluoroacetic acid as acid solvent (positive scan 100-500m/z,
fragmentor 70 eV).
2.4.2 Synthesis and characterization
Synthesis of N-ethyl methyl malonyl amide (1). In a 2-necked
round-bottom flask, equipped to perform reaction under N2, ethylamine
(1.2 eq) and TEA (2 eq) were added in dry DCM (1M). Methyl malonyl
chloride (1 eq) was added dropwise at 0oC and the mixture stirred at
room temperature overnight. The reaction was quenched with water and
the product extracted with DCM. The product was used without further
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purifications (Y%> 99%). 1H NMR (400 MHz, CDCl3) δ 7.02 (bs, 1H),
3.73 (s, 3H), 3.44-3.27 (m, 2H), 3.29 (s, 2H), 1.14 (dt, 3J= 7.2 Hz, 4J=
1.6 Hz, 3H). 13C NMR (400 MHz, CDCl3) δ 168.2, 166.4, 51.1, 36.5,
33.7, 14.9. LC-ESI-MS: 1.5 min, [M + H]+=146, [M + Na]+=178,
[2M +Na]+=313.
General procedure for the synthesis of alkylidene derivatives un-
der basic catalysis at room temperature: (2a,b) and (4). Methylene
active compound (1 eq), piperidine (0.15 eq) and aldehyde (1.7 eq) were
stirred at room temperature for 12h/3days. The crude was poured in
water and extracted with EtOAc. Purification by flash chromatography
(silica gel, 9:1=Cy:EtOAc) allowed to isolate the product as a mixture of
two isomers (Z/E).
Compound (2a): Y%=56%, Z/E=1/4. E-isomer: 1H NMR (400 MHz,
CDCl3) δ 6.91 (d, 3J= 10.4 Hz, 1H), 6.93 (bs, 1H), 3.74 (s, 3H), 3.41-
3.30 (m, 2H), 3.75 (m, 1H), 1.73-1.64 (m, 5H), 1.37-1.07 (m, 5H), 1.17
(t, 3J= 7.2 Hz, 3H); 13C NMR (400 MHz, CDCl3) δ 164.3, 163.7, 155.3,
125.6, 51.3, 38.0, 33.7, 31.3, 25.2, 24.7, 14.0; LC-ESI-MS: 8.9 min,
[M + H]+=240, [M + Na]+=262, [2M + Na]+=501. Z-isomer: 1H
NMR (400 MHz, CDCl3) δ 6.80 (d, 3J= 10.4 Hz, 1H), 6.93 (bs, 1H), 3.74
(s, 3H), 3.41-3.30 (m, 2H), 3.75 (m, 1H), 1.73-1.64 (m, 5H), 1.37-1.07
(m, 5H), 1.17 (t, 3J= 7.2 Hz, 3H); 13C NMR (400 MHz, CDCl3) δ 166.7,
164.1, 155.3, 126.8, 51.5, 38.0, 33.7, 31.3, 25.2, 24.7, 14.0; LC-ESI-MS:
6.6 min, [M +H]+=240, [M +Na]+=262, [2M +Na]+=501.
Compound (2b): Y%=55%, Z/E=1/4. E-isomer: 1H NMR (400 MHz,
CDCl3) δ 6.90 (d, 3J= 10.4 Hz, 1H), 6.88 (bs, 1H), 3.76 (s, 3H), 3.40-3.34
(m, 2H), 3.26 (m, 1H), 1.18 (t, 3J= 7.2 Hz, 3H), 1.06 (d, 3J= 6.8 Hz, 6H).
13C NMR (400 MHz, CDCl3) δ 166.5, 162.1, 160.3, 124.5, 51.2 , 43.5,
29.1, 21.8, 14.9; LC-ESI-MS: 8.8 min [M +H]+=200, [M +K]+=238,
[2M + Na]+=421. Z-isomer: 1H NMR (400 MHz, CDCl3) δ 6.88 (bs,
1H), 6.79 (d, 3J= 10.4 Hz, 1H), 3.76 (s, 3H), 3.40-3.34 (m, 2H), 3.26 (m,
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1H), 1.18 (t, 3J= 7.2 Hz, 3H), 1.06 (d, 3J= 6.8 Hz, 6H); 13C NMR (400
MHz, CDCl3) δ 167.7, 163.3, 160.3, 125.0, 51.3, 43.3, 28.9, 21.8, 14.9;
LC-ESI-MS: 8.0 min [M+H]+=200, [M+K]+=238, [2M+Na]+=421.
Compound (4): Y%=40%, Z/E=1/4. 1H NMR (400 MHz, CDCl3) δ
6.77 (t, J = 8.0 Hz, 1H, E isomer), 6.74 (t, J = 7.6 Hz, 1H, Z isomer),
2.42 (dt, J= 7.6, 7.2 Hz, 2H), 2.29 (s, 3H), 2.23 (dt, J= 2.4, 6.8 Hz, 2H),
1.96 (t, J= 2.4 Hz, 1H), 1.72 (m, 2H), 1.53 (s, 9H); 13C NMR (400 MHz,
CDCl3) δ 194.8, 165.5, 145.1, 138.6, 83.2, 82.1, 69.2, 28.6, 28.0, 27.0,
26.8, 18.0; LC-ESI-MS 9.1 min, [M + Na]+=259, [M + K]+=275,
[2M +Na]+=495.
Protection of 5-hexyn-1-ol with TMS-group (5). To a solution of 5-
hexyn-1-ol (1 eq) in THF (0.5 M), n-butyllithium (1.5 M in hexane; 2 eq)
was added. After 30 min of stirring at -78 oC, the reaction was stirred at
0 oC for 2 h. At -78 oC trimethylsilyl chloride (2.1 eq) was added and the
mixture heated to reflux for 12 h and then warmed at room temperature.
It was treated with 10% HCl and stirred over 30 min. The reaction was
extracted with ethyl eter, washed with brine, dried with sodium sulphate
and evaporated under reduced pressure. The crude was used without
further purification (Y%> 99%). 1H NMR (400 MHz, CDCl3) δ 3.63 (t,
J= 6.0 Hz, 2H), 2.26 (t, J= 6.6 Hz, 2H), 1.65, (m, 4H), 0.14 (s, 9H); 13C
NMR (400 MHz, CDCl3) δ 107.0, 84.7, 62.3, 31.7, 24.7, 19.5.
General procedure for the Swern oxidation: (3) and (6). In glasses
equipped to perform reaction under inert atmosphere, keeping the tem-
perature at -78 oC, a solution of dimethyl sulfoxide (2.3 eq) in DCM (4M)
was added to a solution of oxalyl chloride (1.2 eq) in DCM (0.52M), and
the mixture was stirred for 5 min. The alcohol (1 eq) in DCM (0.9M)
was added dropwise in 5 min and the solution was stirred for 15 min.
TEA dry (5 eq) was added dropwise and the mixture was stirred for 10
min at room temperature. The mixture was extracted with ethyl ether and
washed with water. The organic layer was evaporated and washed agin
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with NH4Cl sat. It was then dried over sodium sulphate and evaporated
under reduced pressure to give the product as a yellow oil, used without
further purifications.
Compound (3): Y%=> 99%, 1H NMR (400 MHz, CDCl3) δ 9.79 (t, J=
1.3 Hz, 1H), 2.59 (dt, J= 1.3, 7.2 Hz, 2H), 2.26 (dt, J= 2.6, 7.2 Hz, 2H),
1.96 (t, J= 2.6 Hz, 1H), 1.84 (m, 2H); 13C NMR (400 MHz, CDCl3) δ
200.1, 82.2, 68.6, 45.2, 20.0, 16.7.
Compound (6): Y%=93%, 1H NMR (400 MHz, CDCl3) δ 9.80 (s, 1H),
2.57 (t, J= 6.7 Hz, 2H), 2.28 (t, J) 6.7 Hz, 2H), 1.85 (m, 2H), 0.12 (s, 9H);
13C NMR (400 MHz, CDCl3) δ 201.8, 105.8, 85.7, 42.6, 20.9, 19.2, 0.0.
Procedure for the syntehsis of alkylidene derivatives by TiCl4
catalysis: (7). A 1 M solution of TiCl4 in DCM (2 eq) was added drop-
wise to THF (0.55M) at 0oC and the mixture was stirred for few minutes.
Then tert-butyl acetoacetate (1 eq) in THF (2.3M) and (6) (11 eq) in THF
(2.3M) were added at 0oC; the mixture was stirred for 75 min. A solu-
tion of pyridine (4 eq) in THF (5.7M) was then added dropwise in 90
min and the mixture stirred overnight. The solution was diluted with
Et2O and washed with water and brine. The organic layer was dried over
Na2SO4 and then evaporated. The crude product was purified by flash
chromatography (silica gel, 98/2 cyclohexane/EtOAc) to obtain the pro-
duct as a 1/4 mixture of Z/E isomers. Y%=83%, 1H NMR (400 MHz,
CDCl3) δ 6.75 (t, J= 8.0 Hz, 1H, E isomer), 6.73 (t, J= 7.6 Hz, 1H, Z iso-
mer), 2.39 (dt, J= 7.6, 7.6 Hz, 2H), 2.28 (s, 3H), 2.24 (m, 2H), 1.68 (m,
2H), 1.53 (s, 9H), 0.12 (s, 9H); 13C NMR (400 MHz, CDCl3) δ 201.0
(E), 194.8 (Z), 165.5 (Z), 163.3 (E), 145.8 (E), 145.4 (Z), 138.4 (Z),
137.9 (E), 105.9 (Z+E), 85.2 (Z+E), 82.1 (Z), 81.7 (E), 28.7 (Z+E), 28.0
(Z), 27.9 (E), 27.8 (E), 27.4 (E), 27.2 (Z), 26.8 (Z), 19.5 (Z), 19.3 (E), 0.0
(Z+E); LC-ESI-MS: 12.5 min, m/z: [M +Na]+=331, [M +K]+=347,
[2M +Na]+=639.
General procedure for the synthesis of alkylidene and arylidene
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malonate or acetoacetate under microwave assistance: (8a,b) and
(9a,f). Dimethyl malonate, ethyl acetoacetate or tert-butyl acetoacetate
(1 eq), aldehyde (1 eq) and piperidine (0.15 equiv) were stirred in the
microwave reactor and irradiatiated at 250 W for 7 min. The mixture
was diluted with EtOAc, washed with water, dried on sodium sulphate
and evaporated under reduced pressure. The crude was purified by flash
chromatography (98/2=cyclohexane:AcOEt, in gradient) and the two Z/E
isomers separated. The yield and Z/E ratio depends on the substrate.
Compound (8a): Y%=80%, E/Z> 95%, 1H NMR (400 MHz, CDCl3)
δ 6.85 (d, J= 10.8 Hz, 1H), 3.80 (s, 3H), 3.76 (s, 3H), 2.60-2.73 (m, 1H),
1.08 (d, J= 6.6 Hz, 6H).
Compound (8b): Y%> 99%, Z/E=4/1. Z isomer: 1H NMR (200 MHz,
CDCl3) δ 6.53 (d, 1H, J= 10.4 Hz), 2.65 (m, 1H), 2.30 (s, 3H), 1.55 (s,
9H), 1.09 (d, 6H, J= 6.45 Hz); LC-ESI-MS 9.5 min, m/z: [M+H]+=235.
E isomer: 1H NMR (200 MHz, CDCl3) δ 6.58 (d, 1H, J= 10.6 Hz), 2.60
(m, 1H), 2.34 (s, 3H), 1.51 (s, 9H), 1.45 (d, 6H, J= 6.6 Hz); LC-ESI-MS
10.2 min, m/z: [M +H]+=235.
Compound (9a): Y%=95%, Z/E=3/1, Z isomer: 1H NMR (200 MHz,
CDCl3) δ 7.58 (s, 1H), 7.28-7.48 (m, 5H), 4.34 (q, J = 7.2 Hz, 2H), 2.43
(s, 3H), 1.28 (t, J = 7.2 Hz); 13C NMR (200 MHz, CDCl3) δ 194.6, 167.7,
141.2, 134.6, 132.9, 130.7, 129.5, 128.8, 61.5, 26.5, 13.8. E isomer: 1H
NMR (200 MHz, CDCl3) δ 7.68 (s, 1H), 7.34-7.39 (m, 5H), 4.30 (q, J
= 7.2 Hz, 2H), 2.36 (s, 3H), 1.34 (t, J = 7.2 Hz); 13C NMR (200 MHz,
CDCl3) δ 203.3, 164.3, 140.4, 134.0, 132.8, 130.3, 129.6, 128.8, 61.5,
31.1, 14.1. Anal. Calcd. For C13H14O3: C, 71.54; H, 6.47. Found: C,
71.59; H, 6.48.
Compound (9b): Y%=87%, Z/E=2.3/1, Z isomer: 1H NMR (200 MHz,
CDCl3) δ 6.60 (d, 1H, J= 10.6 Hz), 4.29 (q, 2H, J= 7.4 Hz), 2.65 (m, 1H),
2.30 (s, 3H), 1.31 (t, 3H, J= 7.4 Hz), 1.07 (d, 6H, J= 6.6 Hz); 13C NMR
(200 MHz, CDCl3) δ 195.4, 166.6, 154.0, 134.9, 61.2, 29.6, 26.8, 21.9
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(2), 14.1; GC-MS: 11.74 min, m/z: 184(2), 138(100), 123(60), 110(15),
96(57), 81(24), 67(32), 55(26). E isomer: 1H NMR (200 MHz, CDCl3)
δ 6.69 (d, 1H, J= 10.6 Hz), 4.24 (q, 2H, J= 7.4 Hz), 2.62 (m, 1H), 2.37
(s, 3H), 1.30 (t, 3H, J= 7.4 Hz), 1.02 (d, 6H, J= 6.6 Hz); 13C NMR
(200 MHz, CDCl3) δ 197.9, 166.5, 154.0, 134.8, 61.1, 29.4, 26.5, 21.8,
21.6, 13.9; GC-MS: 11.45 min, m/z: 184(2), 138(100), 123(55), 110(15),
96(64), 81(26), 67(31), 55(19).
Compound (9c): Y%=78%, Z/E=2.4/1, Z isomer: 1H NMR (200 MHz,
CDCl3) δ 6.63 (d, 1H, J= 9.8 Hz), 4.30 (q, 2H, J=7.0 Hz), 2.37 (m, 1H),
2.31 (s, 3H), 1.60-1.77 (m, 5H), 1.34 (t, 3H, J= 7.0 Hz), 1.21-1.43 (m,
5H); 13C NMR (200 MHz, CDCl3) δ 197.9, 166.6, 152.5, 135.2, 61.0,
39.1, 31.8, 31.7, 26.7, 25.3, 25.1(2), 14.1; GC-MS: 9.3 min, m/z: 225. E
isomer: 1H NMR (200 MHz, CDCl3) δ 6.72 (d, 1H, J= 10.6 Hz), 4.26
(q, 2H, J= 7.0 Hz), 2.42 (m, 1H), 2.38 (s, 3H), 1.66-1.77 (m, 5H), 1.27
(t, 3H, J= 7.0 Hz), 1.14-1.26 (m, 5H); 13C NMR (200 MHz, CDCl3) δ
201.3, 164.7, 152.8, 133.9, 61.0, 38.3, 31.9 (2), 31.3, 25.6, 25.0 (2), 14.1;
GC-MS: 10.0 min, m/z: 225.
Compound (9d): Y%=80%, only Z isomer: 1H NMR (400 MHz, CDCl3)
δ 8.16 (m, 2H), 7.62 (s, 1H), 7.56 (d, 2H, J= 8.4 Hz), 7.50 (d, 2H, J= 8.4
Hz), 4.27 (q, J= 7.2 Hz, 2H), 2.38 (s, 3H), 1.20 (t, J= 7.2 Hz, 3H); 13C
NMR (200 MHz, CDCl3) δ 198.5, 165.2, 147.9, 147.3, 138.9, 132.5
(2C), 130.6, 123.8 (2C), 61.2, 29.8, 14.4.
Compound (9e): Y%=79%, only Z isomer: 1H NMR (400 MHz, CDCl3)
δ 8.62 (s, 1H), 7.63 (d, 2H, J= 8.3 Hz), 7.27 (d, 2H, J= 8.3 Hz), 4.20 (q,
J= 7.1 Hz, 2H), 2.36 (s, 3H), 2.32 (s, 3H), 1.24 (t, J= 7.1 Hz, 3H); 13C
NMR (200 MHz, CDCl3) δ 198.7, 168.9, 165.1, 150.7, 149.1, 130.6,
129.5, 129.4 (2C), 121.7 (2C), 61.3, 28.9, 21.0, 14.2.
Compound (9f): Y%=81%, only Z isomer: 1H NMR (400 MHz, CDCl3)
δ 8.63 (s, 1H), 7.57 (m, 1H), 7.45 (m, 1H), 7.30 (m, 1H), 7.12 (m, 1H),
4.18 (q, J= 7.3 Hz, 2H), 2.45 (s, 3H), 2.32 (s, 3H), 1.27 (t, J= 7.3 Hz,
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3H); 13C NMR (200 MHz, CDCl3) δ 198.6, 169.0, 165.0, 151.1, 149.0,
148.7, 131.2, 129.8, 125.5, 121.1, 120.9, 62.1, 29.7, 20.4, 14.5.
General procedure for the preparation of (3-oxobutanoyl)-L-amino
esters: (10a,h). 2,2,6-trimethyl-4H-1,3-dioxin-4-one (1 eq), triethyl-
amine (1 eq) and amino ester (1 eq) were dissolved in a mixture of
toluene/DMF (1mL + 1mL) in the microwave reactor. The mixture was
irradiated (250W, 5 minutes) and then allowed to cool to room temper-
ature under stirring. The mixture was diluted with EtOAc and washed
with water and brine. The organic layer was dried over Na2SO4 and
evaporated. The crude product was purified by flash chromatography
over silica (cyclohexane/ ethyl acetate 80:20).
Compound (10a): 1H NMR (400 MHz, CDCl3) δ 7.21 (bd, 1H), 4.63
(m , 1H), 3.74 (s, 3H), 3.46 (s, 2H), 2.26 (s, 3H), 1.57 (m, 3H), 0.95
(d, 6H, J= 7.2 Hz); 13C NMR (400 MHz, CDCl3) δ 203.8, 173.0, 165.6,
52.0, 50.6, 49.6, 40.9, 30.5, 24.6, 22.6, 21.6; LC-ESI-MS: 3.89 min, m/z:
[M +H]+=230, [M +Na]+=252, [2M +Na]+=481.
Compound (10b): 1H NMR (400 MHz, CDCl3) δ 7.36 (bt, 1H), 4.19
(d , 2H, J= 5.2 Hz), 4.06 (q, 2H, J= 7.2 Hz), 3.45 (s, 2H), 2.26 (s,
3H), 1.20 (t, 3H, J= 7.2 Hz); 13C NMR (400 MHz, CDCl3) δ 203.4,
175.5, 169.4, 61.0, 49.6, 41.0, 30.0, 13.7. LC-ESI-MS: 3.10 min, m/z:
[M +Na]+=210.
Compound (10c): 1H NMR (400 MHz, CDCl3) δ 7.35 (bd, 1H, J= 9.6
Hz), 4.53 (dd, 1H, J= 4.4, 9.6 Hz), 3.72 (s, 3H), 3.46 (s, 2H), 2.27 (s,
3H), 2.19 (m, 1H), 0.95 (d, 3H, J=7.2 Hz), 0.92 (d, 3H, J= 7.2 Hz);
13C NMR (400 MHz, CDCl3) δ 203.2, 173.4, 167.7, 57.5, 52.1, 49.4,
30.7, 29.8, 20.0, 19.8; LC-ESI-MS: 2.50 min, m/z: [M + H]+=216,
[M +Na]+=238, [2M +Na]+=453.
Compound (10d): 1H NMR (400 MHz, CDCl3) δ 7.15-7.41 (m, 6H),
4.82 (m, 1H), 3.76 (s, 3H), 3.39 (s, 2H), 3.00 (m, 2H), 2.18 (s, 3H);
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13C NMR (400 MHz, CDCl3) δ 203.6, 172.4, 166.2, 134.5, 127.8 (2C),
127.2 (2C), 126.8, 58.7, 52.3, 49.2, 37.5, 30.2; LC-ESI-MS: 4.42 min,
m/z: [M +H]+=264, [M +Na]+=286, [2M +Na]+=549.
Compound (10e): 1H NMR (400 MHz, CDCl3) δ 8.66 (bs, 1H), 7.51
(d, 1H, J= 7.6 Hz), 7.34 (d, 1H, J=8.0 Hz), 7.22 (d, 1H, J=8.4 Hz), 6.93-
7.15 (m, 3H), 4.88 (dt, 1H, J= 8.0, 6.4 Hz), 4.10 (m, 2H), 3.28 (m, 2H),
3.17 (s, 2H), 2.14 (s, 3H), 1.18 (t, 3H, J=7.2 Hz); 13C NMR (400 MHz,
CDCl3) δ 203.9, 172.2, 165.7, 136.1, 127.4„ 123.1, 122.1, 119.5, 118.4,
111.3„ 109.5, 61.3, 53.0, 49.5, 30.6, 29.6, 14.2; LC-ESI-MS: 4.75 min,
m/z: [M +H]+=317, [M +Na]+=339.
Compound (10f): 1H NMR (400 MHz, CDCl3) δ 7.26 (bd, 1H)„ 4.17 (q
, 2H, J= 7.4 Hz), 3.53 (dt, 2H, J= 6.2, 6.8 Hz), 3.40 (s, 2H), 2.55 (t, 2H,
J= 6.2 Hz), 2.27 (s, 3H), 1.28 (t, 3H, J= 7.4 Hz); 13C NMR (400 MHz,
CDCl3) δ 203.0, 172.6, 166.0, 61.0, 49.7, 36.2, 32.8, 31.0, 14.2; LC-ESI-
MS: 1.41 min, m/z: [M+H]+=188, [M+Na]+=210, [2M+Na]+=397.
Compound (10g): 1H NMR (400 MHz, CDCl3) δ 7.21 (bd, 1H), 4.62
(m, 1H), 3.65 (s, 3H), 3.64 (s, 3H), 3.41 (s, 2H), 2.28 (s, 3H), 2.01-2.41
(m, 4H); 13C NMR (400 MHz, CDCl3) δ 203.3, 172.3, 171.7, 162.6,
52.2, 51.5, 50.8, 49.8, 31.2, 27.1, 26.4; LC-ESI-MS: 2.42 min, m/z:
[M +H]+=260, [M +Na]+=282.
Compound (10h): 1H NMR (400 MHz, CDCl3) δ 4.52 (m, 1H), 3.78 (s,
3H), 3.20-3.40 (m, 2H), 2.22 (s, 3H), 1.90-2.05 (m, 4H); 13C NMR (400
MHz, CDCl3) δ 202.9, 172.4, 168.7, 63.8, 52.2, 49.8, 48.6, 29.9, 28.5,
24.6; LC-ESI-MS: 2.38 min, m/z: [M +H]+=214.
General procedure for the preparation of alkylidene acetacetamides
via one-pot two-step: (11a,g), (12a) and (13a). 2,2,6-trimethyl-4H-1,3-
dioxin-4-one (1 eq), amino ester (1 eq) and triethylamine (1 eq) were
added to a mixture of toluene/DMF (1:1, 0.5M) and stirred under mi-
crowave irradiation for 5 min at 250W. After cooling at room tempera-
ture, aldehyde (see Table 2.2) was added and the reaction irradiated again
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for 45 min at 250W. The mixture was diluted with EtOAc and washed
with water and brine. After drying with sodium sulphate, the organic
phase was evaporated and the crude purified by flash chromatography
over silica gel (cyclohexane/ ethyl acetate 80:20).
Compound (11a): 1H NMR (400 MHz, CDCl3) δ 7.11 (bd, 1H, J=
6.4), 6.79 (d, 0.1H, J= 10.4 Hz, E isomer), 6.70 (d, 0.9H, J= 10.0 Hz,
Z isomer), 4.71 (m, 1H), 3.75 (s, 2.7H, Z isomer), 3.74 (s, 0.3H, E iso-
mer), 3.16 (m, 1H), 2.43 (s, 0.3H, E isomer), 2.37 (s, 2.7H, Z isomer),
1.60-1.80 (m, 3H), 1.10 (d, 6H, J=6.6 Hz),0.96 (d, 6H, J=6.0 Hz); 13C
NMR (400 MHz, CDCl3) δ 196.5, 172.4, 165.4, 155.0, 135.5, 51.6, 50.2,
40.3, 28.6, 26.4, 24.3, 22.3, 21.5, 21.4, 21.0; LC-ESI-MS: 6.85 min, m/z:
[M +H]+=283, [M +Na]+=306.
Compound (11b): 1H NMR (400 MHz, CDCl3) δ 7.36 (bt, 1H)„ 6.80
(d, 0.1H, J= 11.2Hz, E isomer), 6.64 (d, 0.9H, J=10.8Hz, Z isomer), 4.17
(q, 2H, J= 6.8 Hz), 4.06 (d, 2H, J= 5.2 Hz, Z isomer), 4.01 (d, 0.2H, J=
4.8Hz, E isomer), 3.12 (m, 1H), 2.32 (s, 0.3H, E isomer), 2.30 (s, 2.7H,
Z isomer), 1.21 (d, 3H, J= 6.6 Hz), 1.19 (d, 3H, J= 6.6 Hz),1.04 (t, 3H,
J= 6.8 Hz); 13C NMR (400 MHz, CDCl3) δ 197.4, 169.4, 165.9, 156.5,
135.5, 61.2, 41.1, 29.0, 26.6, 21.9 (2C), 14.0; LC-ESI-MS: 5.37 min,
m/z: [M +H]+=242, [M +Na]+=264.
Compound (11c): 1H NMR (400 MHz, CDCl3) δ 7.18 (bd, 1H, J= 9.6
Hz), 6.68 (d, 1H, J= 8.8 Hz), 4.61 (dd, 1H, J= 4.8, 9.6 Hz), 3.73 (s,
3H), 3.17 (m, 1H), 2.34 (s, 3H), 2.12 (m, 1H), 1.10 (d, 6H, J= 6.6 Hz),
0.98 (d, 3H, J= 7.2 Hz), 0.93 (d, 3H, J= 7.2 Hz); 13C NMR (400 MHz,
CDCl3) δ 198.4, 172.5, 165.1, 153.8, 134.8, 57.1, 52.0, 30.2, 29.8, 24.2,
21.9, 21.7, 20.0, 19.9; LC-ESI-MS: 7.53 min, m/z: [M + H]+=270,
[M +Na]+=292.
Compound (11d): 1H NMR (400 MHz, CDCl3) δ 7.10-7.34 (m, 5H),
6.98 (bd, 1H, J= 6.8), 6.61 (d, 1H, J= 10.2 Hz), 4.98 (m, 1H), 3.77 (s,
3H), 3.21 (dd, 1H, J= 5.6, 14.0 Hz), 3.11 (dd, 1H, J= 7.2, 14.0 Hz), 2.91
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(m, 1H), 2.35 (s, 3H), 1.02 (d, 3H, J= 6.6 Hz), 0.98 (d, 3H, J=6.6 Hz);
13C NMR (400 MHz, CDCl3) δ 198.8, 171.9, 157.9, 154.1, 136.7, 134.8,
128.4, 127.7, 125.6, 57.3,51.6, 37.2, 30.1, 24.6, 22.2, 21.8; LC-ESI-MS:
7.10 min, m/z: [M +H]+=318, [M +Na]+=340, [2M +Na]+=657.
Compound (11e): 1H NMR (400 MHz, CDCl3) δ 8.45 (bs, 1H), 7.56
(d, 1H, J= 8.0 Hz), 7.32 (d, 1H, J= 8.4 Hz), 7.06-7.17 (m, 3H), 6.96
(bd, 1H, J= 7.6 Hz), 6.57 (d, 1H, J= 10.6 Hz), 5.01 (m, 1H), 4.11 (m,
2H), 3.37 (dd, 1H, J= 5.6, 12.0 Hz), 3.35 (dd, 1H, J= 6.0, 12.0 Hz), 2.87
(m, 1H), 2.24 (s, 3H), 1.19 (t, 3H, J= 6.8 Hz), 0.97 (d, 3H, J= 6.6 Hz),
0.94 (d, 3H, J= 6.6 Hz); 13C NMR (400 MHz, CDCl3) δ 197.2, 172.0,
165.9, 155.9, 136.0, 135.7, 127.1, 123.3, 121.6, 119.0, 118.0, 111.2,
108.9, 61.3, 52.7, 31.2, 29.0, 26.4, 21.7, 18.8, 14.1; LC-ESI-MS: 8.81
min, m/z: [M +H]+=371, [M +Na]+=393, [2M +Na]+=763.
Compound (11f): 1H NMR (400 MHz, CDCl3) δ 7.08 (bt, 1H), 6.77 (d,
0.2H, J= 11.4 Hz, E isomer), 6.72 (d, 0.8H, J= 11.4 Hz, Z isomer), 4.18
(q , 2H, J= 7.4 Hz), 3.57 (dt, 2H, J= 6.2, 6.8 Hz), 2.82 (m, 1H), 2.57 (t,
2H, J= 6.4 Hz), 2.45 (s, 0.6H, E isomer), 2.42 (s, 2.4H, Z isomer), 1.27
(t, 3H, J= 7.4 Hz), 1.09 (d, 3H, J= 6.8 Hz), 1.07 (d, 3H, J= 6.8 Hz); 13C
NMR (400 MHz, CDCl3) δ 197.1, 172.4, 162.6, 155.2, 136.2, 61.1, 36.3,
31.2, 26.3, 21.7(2C), 14.2; LC-ESI-MS: 5.41 min, m/z: [M +H]+=256,
[M +Na]+=278.
Compound (11g): 1H NMR (400 MHz, CDCl3) δ 7.38 (bd, 1H), 6.65
(d, 0.1H, J= 11.2 Hz, E isomer), 6.62 (d, 0.9H, J= 10.8 Hz, Z isomer),
3.76 (s, 3H), 3.75 (s, 3H), 3.03 (m, 1H), 2.38 (s, 3H), 2.01-2.41 (m, 4H),
1.18 (d, 3H, J= 6.6 Hz), 1.06 (d, 3H, J= 6.6 Hz); 13C NMR (400 MHz,
CDCl3) δ 203.4, 172.8, 172.3, 165.9, 149.9, 137.3, 55.3, 51.5, 51.1, 33.4,
26.9, 25.6, 24.5, 19.1, 18.7; LC-ESI-MS: 4.10 min, m/z: [M+H]+=314,
[M +Na]+=336, [2M +Na]+=649.
Compound (12a): 1H NMR (400 MHz, CDCl3) δ 7.02 (bd, 1H, J= 8.2
Hz), 6.79 (d, 0.1H, J= 10.8 Hz, E isomer), 6.70 (d, 0.9H, J= 10.2 Hz,
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Z isomer), 4.72 (m, 1H), 3.72 (s, 2.7H, Z isomer), 3.68 (s, 0.3H, E iso-
mer), 2.84 (m, 1H), 2.41 (s, 0.3H, E isomer), 2.33 (s, 2.7H, Z isomer),
1.56-1.81 (m, 8H), 1.11-1.40 (m, 5H), 0.98 (d, 3H, J= 6.6 Hz), 0.96 (d,
3H, J= 6.6 Hz); 13C NMR (400 MHz, CDCl3) δ 198.1, 173.2, 164.7,
157.1, 136.2, 52.8, 50.8, 40.5, 33.1 (2C), 31.6, 28.9, 26.4, 25.3 (2C),
24.9, 21.7, 21.0; LC-ESI-MS: 8.82 (Z isomer), 10.08 (E isomer) min,
m/z: [M +H]+=324, [M +Na]+=346.
Compound (13a): 1H NMR (400 MHz, CDCl3) δ 7.35 (s, 1H), 7.20-
7.90 (m, 5H), 6.20 (bd, 1H), 4.69 (m, 1H), 3.78 (s, 3H), 2.41 (s, 3H),
1.45-1.80 (m, 3H), 1.00 (d, 3H, J= 6.6 Hz), 0.98 (d, 3H, J= 6.6 Hz); 13C
NMR (400 MHz, CDCl3) δ 195.0, 172.3, 162.8, 162.3, 139.7, 136.1,
129.3, 128.6, 128.2, 128.1, 51.6, 50.6, 40.3, 31.0, 26.6, 22.4, 21.1; LC-
ESI-MS: 7.67 min, m/z: [M + H]+=318, [M + Na]+=340, [2M +
Na]+=657.
2.5 Notes and references
The spectroscopic data and the synthetic procedures have been adapted
from Ref. [38], [45] and [48], with the proper reuse licenses. See Ap-
pendix.
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Chapter3
Reactivity of alkylidene or arylidene derivatives for the
synthesis of isoxazolidinones, isoxazolines and
deydro-β-prolines
3.1 Introduction
The reactivity of the previously reported alkylidene and arylidene
malonates, acetoacetates, malonamides and acetoacetamides is the start-
ing point in the development of more complex structures in order to ex-
plore the possibility of their application in different fields of chemistry
and biochemistry. One of the most widely employed reactivity of these
systems is their versatility in conjugated addition reactions. This kind
of reactions has a not so long story since the first example was reported
in 1883 by Komnenos who studied the reaction between sodium diethyl
malonate and diethyl ethylidenemalonate and further developments of
this topic were presented in 1887 by Michael in the base-catalyzed reac-
tion between sodium malonates and and β-ketoesters to ethylcinnamate.
Starting from the first examples in which, as reported above, the main nu-
cleophiles were stabilized carbanions, several improvements were made
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in order to expand the spectrum of nucleophiles able to be employed for
this purpose. In fact, talking about conjugated addition or 1,4-addition,
it is commonly referred to addition of any kind of nucleophile to an un-
saturated system usually conjugated with an activating group, in partic-
ular an electron-withdrawing group. However, since there is possibil-
ity to choose several nucleophiles, carbon- or heteroatom-based, a dis-
tinction can be made: with "‘Michael addition"’ you can refer to ad-
dition of stabilized carbanion species on α,β-unsaturated substrates, in
the conjugation with an activating group like a carbonyl group; with
"‘heteroconjugate addition"’ you can refer to addition of heteroatom-
based nucleophiles to the same unsaturated systems [52]. Consider-
ing the existance of more than one electrophilic functionalities on α,β-
unsaturated systems conjugated with carbonyl group, it is important to
clarify why the 4-position is so reactive towards carbanion and some
heteroatom-based nucleophiles: the explanation is based on the theory
of frontier molecular orbital (FMO) which shows that the coefficient of
LUMO orbital is larger in the β-position, so soft nucleophiles should at-
tack in this position [53]. In particular for heteronucleophiles, the great
reactivity in a Michael addition is also due to termodinamic and kinetic
factors related to the gain in terms of energy in the product of the reaction
compared to the energies of the two starting materials. In this chapter, we
will focus on the addition to unsaturated systems of C-based nucleophile,
like indole, for the synthesis of C-C bond and of N-based nucleophile,
like hydroxylamines and allyl amines, for the synthesis of C-N bond.
3.1.1 C-C bond formation in MCRs.
As regard the first topic, we studied the conjugated addition of indole
toα,β-unsaturated systems in a multicomponent reaction, the Yonemitsu
trimolecular condensation. Multicomponent reactions (MCRs) are de-
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fined as reactions involving three or more components added together in
the same vassel leading to a final product that contains the most of atoms
of the starting material without the need of purification between different
steps of reaction. Starting with the Streker reaction for the synthesis of α-
aminoacids in 1850 and going through the Biginelli reaction in 1981 for
the synthesis of dihydropyrimidinones, several examples of these reac-
tions have been reported in literature. Usually, MCRs are considered one-
pot reactions since all the reagent are present in the same reactor but it is
possible to make a distintion between domino/cascade or tandem one-pot
reaction (in which all the reagents are introduced in the same moment
and all the reactions depend on the intermediate produced in previous
step) and multicatalytic one-pot reaction (in which the reagents are not
all present in the same moment)[54]. The particular beauty of MCRs is in
the ability to identify simple compounds with high density of reactivity,
which means that there could be the possibility to activate different spe-
cific functionalities in different moments. In this contest, 1,3-dicarbonyl
compounds are very useful since they possess two elecrophilic centers
and four (or five if they have amides) nucleophilic ones, granting great
versatility. The reactivity of 1,3-dicarbonyl compounds in these reac-
tions remained limited until 1990s when they appeared in a Knöevenagel-
hetero-Diels-Alder reaction [55]. Among the different family of MCRs
1,3-dicarbonyl-based reactions, those involving one pronucleophilic re-
active site will be explored [56]. As consequence of the acidity of the
2-position protons, 1,3-dicarbonyl compounds in cyclic or acyclic form
are considered having one pronucleophilic site. One of the first applica-
tion in MCRs is in the three-components Yonemitsu condensation which
uses Meldrum’s acid as 1,3-dicarbonyl compound, an aldehyde and in-
doles in presence of proline as catalyst [57]. Subsequent decarboxyla-
tive ethanolysis of the adduct lead to various ethyl 3-substituted indolyl-
propionate, employed as intermediates for the synthesis of indole-based
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alkaloids (Figure 3.1). The reactivity of Meldrum’s acid is linked to its
Figure 3.1: Yonemitsu trimolecular condensation.
pKa value lower that of most commonly used 1,3-dicarbonyl compounds
(4.97 for dimethyl malonate vs 13.7). Since it is not so cheap reagent,
several examples have been reported in which it is substituted by acyclic
methylene active compounds: as consequence of their lower reactivity in
Yonemitsu reactions, they have been coupled with Lewis acid catalysts.
So in 2008 Renzetti et al. reported a TiCl4 catalyzed reaction of isobu-
tyrraldehyde, indole and dimethyl malonate in dichloromethane in pre-
sence of Et3N as base. In order to expand the scope of the reaction, other
aldehydes, substitute-indoles and other dicarbonyl compounds were used
in the same conditions [36]. The mechanism of this Ti-catalyzed reaction
was explained in 2015 by Renzetti et al.: as partially reported in Chap-
ter 2, they postulate the existance of three steps. Initially (i) TiCl4 gives
a complex together with dicarbonyl compound that evolves through (ii)
the formation of O-titanium enolate after addition of the base. This is
the substrate for the (iii) Michael addition of indole species. This occurs
with two possible mechanisms (path A or B in Figure 3.2). According
to path A, there is nucleophilic addition of indole to adduct obtained
from Knöevenagel condensation Ti-mediated; the deprotonation of the
product of Michael addition by triethylamine restores the aromaticity of
indole e produces an anionic intermediate that after protonation of the
α-carbon and dissociation of Ti gives the final product. According to
path B, the last two steps are inverted. Moreover, the addition of indole
starts with the attack of C3 of indole on Cβ of the Knöevenagel adduct,
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which can happen from two possible bond plane with several orientation
of indole. However, the energetic favoured ones are those in which the
N-H of indole is oriented towards the metal (Figure 3.3) [40]. The same
reaction was then explored changing Ti-catalyst, using TiCl2(OiPr)2 and
obtaining comparable results changing the partners of reaction [37].
Figure 3.2: Mechanism of Michael addition of indole on α,β-unsaturated-Ti-complex.
Since the reported methods require large amount of catalyst with-
out possibility to recover it, other trials have been reported in which
the Ti-catalyst was replaced by earth rare triflate catalysts that allowed
to perform reaction even in water and recovering the catalyst. In 2011
Epifano et al. reported an Yb(OTf)3-catalyzed Yonemitsu reaction that
works under solvent-free conditions with 10mol% of catalyst under so-
nication for 12h [58]. By changing the earth rare metal, not comparable
results have been obtained as consequence of the high oxophilicity of
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Figure 3.3: Possible facial addition of indole.
Yb3+ cation linked to its small ionic radius. Since Indium salts are exten-
sively employed in Friedel-Crafts reaction (and the Michael addition of
indole can be considered a sort of it), Acharya et al. reported Yonemitsu-
condesation catalyzed by InCl3 between indole, formaldehyde and se-
condary amines finding good results in 1,4-dioxane at room temperature
even if long reaction times are required (4-24h) [59]. Other examples
are those in which the catalyst is a mixture of Eu(OTf)3 and proline in
MeOH, but in this case too the reaction times are too long [60]. Con-
sidering that the main drawbacks of this procedures are the long reaction
times, we decided to use the microwave-assisted heating to increase the
rates, reducing at the same time the formation of side-products. So, we
decided to explore the use of microwaves on this reaction to verify the
possibility to avoid the use of stechiometric amount of catalyst and re-
duce the reaction times [45].
3.1.2 C-N bond formation for the synthesis of isoxazolidinones, isoxazo-
lines and isoxazolidines.
Alkylidene malonate and acetoacetate have been largely employed in
the synthesis of isoxazolidin-5-ones, isoxazolidines and isoxazolines
since these cyclic structures are easily inserted in biologically active
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compounds as consequence of their utility as building blocks for the syn-
thesis of β-aminoacids and γ-lactams. One of the most used synthetic
route is based on the heteroconjugated addition of N-hydroxylamine on
α,β-unsaturated esters or ketones with consequent cyclization of the N-
hydroxyl group on ester for the synthesis of isoxazolidin-5-one and on
ketone for the synthesis of isoxazolidine and its derivative isoxazoline.
For example, in 1995 Saito et al. reported the addition of N-α-methyl
benzylhydroxylamine to homochiral esters for the synthesis of isoxazolidin-
5-one (Figure 3.4) [61].
Figure 3.4: Synthesis of isoxazolidin-5-one starting from homochiral esters.
As extention of this work, Bentley et al. reported analogue reac-
tion between unsaturated esters and homochiral lithium N-α-methyl ben-
zylhydroxylamine for the synthesis of isoxazolidin-5-one used for di-
asteroselectivity tandem alkylation reactions for the synthesis of 3,4,4-
trisubstituted derivatives 22 of isoxazolidinone (Figure 3.5). They showed
how is possible to generate in situ the lithium derivatives of N-tertbutyl
hydroxylamine using n-BuLi solution in THF at -78 oC giving the adduct
pruduct 19 with 95:5 diastereomeric ratio. The cyclization was obtained
when the hydroxylamine were O-silylated by the use of TBAF with 80%
of conversion and 95:5 dr of 20. With LiTMP in THF at -78 oC was pos-
sible to introduce the mono-alkylation at C4 of 21, while with LiHMDS
was possible the second alkylation that gives with very good yield the
desidered trisubstitute isoxazolidinone 22 with > 99 : 1 dr [62].
The same approach was used by Juarez-Garcia et al. for the synthesis
of isoxazolidin-5-one as monomers in the synthesis of β3-oligopeptides
[63]. They initially used proline as catalyst for the conjugated addition
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Figure 3.5: Synthesis of isoxazolidin-5-one starting from lithium hydroxylamine.
of N-Cbz-hydroxylamine on α,β-unsaturated aldehydes as reported by
Cordoba in 2007: however they found several difficulties in the removal
of Cbz group by hydrogenolysis without cleavage of N-O bond of the
cycle. So they developed a different strategy by employing substituted
acrylonitriles, D-glucose derived hydroxylamine and aldehyde neat at
85-115 oC for 16h affording the cycloadduct that by treatment with tri-
ethylamine gives the desidered product 27 (Figure 3.6). They applied an
analogue procedure on vinylacetate by using carbonate-base instead of
triethylamine.
Our group recently reported deeply studied protocols for the conju-
gated addition of protected-hydroxylamines on alkylidene and arylidene
malonates, malonamides and acetoacetates. They represent a great im-
provement in this field since none example with electron-withdrawing
group in the α position of unsaturated ketones or esters was reported be-
fore. All these reactions have been performed using N,O-bis(trimethylsilyl)-
hydroxylamine and 3-5mol% of Lewis acid as catalyst, with great ver-
satility of alkylidene or arylidene substrates [64] [65] [47]. As regard
alkylidene and arylidene malonate, the reaction was performed on isobutyl-
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Figure 3.6: Synthesis of N-(D-glucose)-isoxazolidin-5-one.
, n-propyl, isopropyl-, heptyl-, phenyl- dimethylmalonates in presence of
3mol% of Yb(OTf)3 in dichloromethane at -40 oC obtaining the desidered
product with good yield (Figure 3.7).
Figure 3.7: Conjugated addition of diprotected hydroxylamine on alkylidene/arylidene malonate.
On N-(benzyl)-methylmalonamide the reaction gave very good yield
when catalyzed by 5mol% Sc(OTf)3 at -40 oC in DCM while on ethyl
acetoacetate the reaction was catalyzed by 5mol% of Yb(OTf)3 (Figure
3.8). In this last case, the cyclization occurs spontaneously at room tem-
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perature affording the isoxazolidine 33, but this process can be acceler-
ated by adding a small amount of silica gel into the crude reaction.
Figure 3.8: Conjugated addition of diprotected hydroxylamine on alkylidene/arylidene malonamides
and acetoacetate.
In the first two examples, the cyclization of the adduct was obtained
by using TBAF in THF, as reported previously, obtaining the desidered
products isoxazolidin-5-ones 35 and 36 in high yield (Figure 3.9).
Figure 3.9: Cyclization TBAF induced.
The reaction on alkylidene acetoacetate has been used to explain the
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mechanism of the addition (Figure 3.10): after formation of C-N bond,
the intermediate has zwitterionic nature with negative charge delocal-
ized on the enolate moiety and positive one on the nitrogen atom; the
transfer of TMS group from nitrogen atom to the oxygen gives the inter-
mediate 33’ or the proton transfer to α-carbon gives the intermediate 33.
They slowly and spontaneously converted at room temperature through
hemiketalization to a 80:20 mixture of the two C-5 stereoisomers of 3,4-
trans-hydroxyisoxazolidines 34 [66].
Figure 3.10: Mechanism of addition of hydroxylamine on alkylidene acetoacetate and cyclization.
3.1.3 C-N bond and subsequent C-C bond formation for the synthesis of
3,4-dehydro-β-pirrole.
With the expression "‘priviliged structures"’ we commonly refer to
all those structures having structural features able to induce easy bind-
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ing with a proper receptor as consequence of the spatial disposition of
their side chains. Among the natural compounds that can guarantee this
behaviour there is proline ring and its derivatives: it can reduce the al-
lowed rotation giving more rigidity to the structure in which it is inserted.
For this reason, in peptidometic approaches the research of proline ana-
logues represents an interesting matter. In the family of proline analogues
β-proline and 3,4-dehydroproline received great attention.[67] The com-
bination of these two structures was part of the focus of this study for the
development of a protocol for the synthesis of 3,4-dehydro-β-pirrole by
using the reactivity of alkylidene malonamides and acetoacetates. If the
benefits of the β-analogue of proline linked to the possiblity to overcome
the problem of bioavailability of natural amino acids are well known, it is
important to understand why 3,4-dehydro proline is so usefull to explain
the fusion of the two mentioned structures (Figure 3.11).
Figure 3.11: β-proline and 3,4.deydroproline.
In fact, it is known that 3,4-dehydroproline can increase the biolo-
gical activity of the structure containing it (compared to the same struc-
tures containing proline) since the double bond between Cβ and Cγ is
involved in further binding interactions with the target enhancing the
binding affinity; furthermore, it gives bigger restricted conformational
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flexybility compared to proline. In the past years, the methods used for
the synthesis of this structure and its substituted analogues goes from
dehydratation of 4-hydroxyproline to enyne methatesis through silver(I)-
catalyzed cyclization of amino acids derived allenes [68]. However,
ring closing metathesis (RCM) has been largely employed for this pur-
pose, with the Sharpless asymmetric epoxidation, Pd-catalyzed kinetic
dinamic asymmetric trasformation of vinyl epoxides, Ir-catalyzed allylic
ammination and regioselective Ru-catalyzed allylic ammination. Studies
on this last method started in 90’s when Grubbs et al. reported several
examples of ring closing methatesis of diene mediated by ruthenium car-
bene 37 for the synthesis of O- and N- unsaturated heterocycles [69]. It
was an implementation of a previous work in which they studied the same
reactions catalyzed by molybdenum catalyst 38 [70]: they postulated that
the ruthenium catalyst 37 was less sensitive to atmospheric oxygen and
more tolerant toward a larger spectrum of functionalities compared to the
molybdenum one 38 (Figure 3.12). We employed the same chemistry for
the synthesis of 3,4-deydro-β-proline.
Figure 3.12: Ruthenium and molybdenum catalysts for ring-closing methatesis.
The starting materials for this reaction are N,N’-allylic dienes. Seve-
ral examples have been reported of allylic ammination on allylic carbon-
ate for the synthesis of these syntons: Evans et al. reported allylic ammi-
nation ruthenium-catalyzed with lithium anion of N-p-toluensulphonyl
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allylamine on racemic allyl carbonates variuosly substituted obtaining
the desidered products in good yields and excellent regiochemistry, with
the aim to obtain the product of 1,2-substitution [71]. This approach al-
lowed the synthesis of 2-substituted pyrrole 41 or 2,5-disubstituted pyr-
role 43, if one of the allylic moieties was functionalized (Figure 3.13).
Figure 3.13: Allylic ammination of racemic allyl carbonate with Li-N-p-toluensulphonyl allylamine.
Regio- and stereoselective P(OPh)3/Ir-catalyzed allylic amination of
allylic ester were reported in 2001 by Takeuchi et al. They found that
careful study of the central metal of the catalyst and proper choice of its
ligand can influence the results in terms of regio-, stereo- and enantios-
electivity. Then, the solvent can influence the same aspects by stabiliza-
tion of δ-allyl metal intermediate or transition state of the reaction. They
postulated that primary amines on allylic carbonates gave monoallyla-
tion with SN2’ mechanism (ratio of SN2’product/SN2product >77/23
changing ligand/metal ratio and reaction time), overcoming the problem
related to diallylation promoted by palladium-catalyst in the Tsuji-Trost
reaction (Figure 3.14) [72]. This work was implemented by Hartwig et
al. in 2004 and by Helmchen et al. in 2008 with the introduction of
a chiral ligand on Ir-catalyst allowing enantioselective allylic amination
[73][74].
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Figure 3.14: Allylic ammination of allyl carbonate Ir-catalyzed.
Another approach in this topic is the stereospecific substitution of
optically active allyl carbonates by amine nucleophiles [75]. With re-
action setup similar to those reported above (chiral ligand/Ir-catalyst), it
is possible the enantioselective alcohol displacement with an SN2’ me-
chanism. Obviously, the enantiomerically pure allyl carbonate can be
easly obtained starting from the enantiomeric pure corresponding alco-
hol. For our purpose, that is to say the introduction in β-position of
3,4-dehydro proline of a carboxylic funtionalities, the allyl alcohol de-
rives from alkylidene malonamides or acetoacetates treated with Luche-
reduction conditions for the selective reduction of ketones in presence of
esters and unsaturation. The resolution of the racemic mixture of substi-
tuted alcohols can be treated following a protocol already reported that
involves the employment of enzymes [46].
3.2 Results and discussions
3.2.1 Conjugated addition of indole on alkylidene malonate and acetoac-
etate
In order to develop a library of compounds to verify the versatility of
the procedure, we started with the optimization of conjugated addition of
indole on compound 8a (Figure 3.15). As reported above this reaction on
alkylidene malonate as been deeply studied, in particular in Lewis acid-
catalyzed reactions; but none example of microwave assisted procedure
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has been reported. For this reason, the reaction was optimized by chang-
ing the irradiation power, the catalyst, the solvent and the reaction times,
as reported in Table 3.1.
Table 3.1: Optimization of conjugated addition of indole on alkylidene malonate 8a and acetoacetate 8b.
Entrya Reagent Solvent Lewis acid Yieldb(%)
46 47 48
1 8a Toluene Yb(OTf)3 28 36 −
2 8a DMF Yb(OTf)3 41 21 15
3 8a CH3CN Yb(OTf)3 6 29 −
4 8a DMF Cu(OTf)3 51 21 7
5 8a DMF Zn(OTf)3 18 − 5
6 8a DMF Sc(OTf)3 57 − 16
7 8b DMF Yb(OTf)3 19 9 55
8 8b DMF Cu(OTf)3 − 12 75
9 8b DMF Zn(OTf)3 − 9 38
10 8b DMF Sc(OTf)3 41 7 44
11 8b DMF − − 18 −
[a] 250 W for 20 min.
[b] Yield calculated by integration of 1H NMR and HPLC peaks. The
remaining amount is unreacted starting material.
Figure 3.15: Conjugated addition of indole on alkylidene malonate and acetoacetate.
As regard alkylidene malonate 8a, the first catalyst was Yb(OTf)3
already used for this purpose: so, we proceeded by changing solvent.
When toluene and acetonitrile were used the product 47 is the main pro-
duct (entry 1 and 3), while in DMF (entry 2) 46a is obtained with 41%
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yield. The product 47 probably derives from 46 and it can be explained
with loss of methylene fragment and addition of a second molecule of
indole (Figure 3.16). Then, we proceeded by changing the metal salt:
Figure 3.16: Mechanism for the formation of 47.
with Cu-catalyst compound 46 was isolated in 51% yield (entry 4) to-
gether with the product of decarboxylation 48. When Zn-catalyst was
used, very small amount of product was obtained (entry 5), while with
Sc-catalyst the product was obtained with good yield (57%) and with
small amount of 48 as only co-product (entry 6). The same approach
has been used with alkylidene acetoacetate 8b: this substrate has been
less studied since the product of addition has two stereocenters and the
keeping of stereodefinition is quite difficult as consequence of the acidity
of acetoacetic proton. The irradiation at 250 W for 20 min gave mainly
the two co-product 47 and 48 with Yb, Cu and Zn catalyst previously
reported (entry 7-9). Only Sc(OTf)3 gave more or less equal amount of
46 and 48 with traces of 47 (entry 10). Working without catalyst, only
47 can be isolated (entry 11).
With the optimized condition of this step in our hand, and reminding the
optimization of the Knöevenagel condensation reported in Chapter 2, we
proceeded performing the one-pot two-steps reaction, without purifica-
tion of intermediates. As usual, the optimization was realized initially for
dimethyl malonate. We proceeded in two ways: the first was the adding
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Table 3.2: Optimization of one-pot two-steps protocol.
Entry Reagent Second stepa Solvent Lewis acid Yieldb(%)
46 47 48
1 A 250 W DMF Sc(OTf)3 33 16 16
20 min
2 A 250 W DMF Yb(OTf)3 45 25 8
20 min
3 A rt-4h CH3CN Yb(OTf)3 30 3 9
4c B 250 W DMF Sc(OTf)3 − 5 12
20 min
5 B rt-4h DMF Yb(OTf)3 − 6 77
6 B rt-4h DMF Sc(OTf)3 − 6 85
7 B rt-4h CH3CN Yb(OTf)3 67 − 5
(51/49)
8 B rt-4h CH3CN Sc(OTf)3 75 7 16
(63/37)
9 B rt-4h CH3CN Cu(OTf)3 47 16 12
(50/50)
10 B rt-4h CH3CN Zn(OTf)3 23 8 43
(51/49)
11 B 0oC-17h CH3CN Sc(OTf)3 71 7 16
(70/30)
12 B 0oC-17h CH3CN Yb(OTf)3 66 8 12
(60/40)
13 B -20oC-4h CH3CN Yb(OTf)3 29 2 34
(75/25)
[a] First step at 250 W for 7 min.[b] Yield calculated by integration of 1H NMR and
HPLC peaks. The remaining amount is unreacted starting material.[c] Products of
decarboxylation or decomposition were mainly observed.
of indole to the mixture of aldehyde, dimethyl malonate and piperidine,
without adding solvent or catalyst irradiating at 250 W for 10 min, but
only small amount of 47 was detected; then, we added indole in presence
of Yb(OTf)3 and in the same irradiating conditions only intermediate 8a
was recovered. So, we tried adding all the reagents together: the re-
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sults are reported in Table 3.2. After the first step setup at 250 W for 7
min, the second step in DMF was irradiated at 250 W for 20 min giving
yields of 46 from 33% to 45% with large amount of 47, using Sc(OTf)3
or Yb(OTf)3 (entry 1-2); changing solvent by using acetonitrile and per-
forming the reaction at room temperature comparable results with those
reported for MW-assisted reactions in DMF were recordered (entry 3).
Then, we proceeded the study on ethyl acetoacetate. In this case too,
the second step was studied first by the assistance of microwaves, but
the reaction didn’t give any useful result (entry 4). At room temperature
with screening of solvents and catalyst, we found that acetonitrile was
the best solvent, because in all the trials in which it was employed, it
was possible detect satisfactory amount of product 46. The best results
were obtained with Sc(OTf)3 with yield of 75% (entry 8) and Yb(OTf)3
with yield of 65% (entry 7). By lowering the temperature, enhancement
of diastereomeric ratio was recordered (entry 11-13). The (2S*,3S*) ste-
reochemistry was assigned in comparison with literature [36] [37], but
however the acidity of α-proton induces a fast equilibration of the mix-
ture under mild basic condition due to the piperidine. The optimized
conditions were applied to the reaction with substituted indoles, whose
results are reported in Table 3.3.
The presence of electronwithdrawing or donating group doesn’t seem to
affect the reactivity. In most of the cases, large amount of bis-indole can
be detected; for the reaction with isobutanal, good yields and reduced
amount of side products were recordered (entry 5-7). The reaction with
2-OH-benzaldehyde was deeply studied since it is known that the product
of the Knöevenagel condensation of this aldehyde with 1,3-dicarbonyl
compounds lead to 3-carboxycoumarin derivatives through spontaneous
cyclization of intermediates. Considering the rilevance that the indole
substituent gives from a biochemical point of view, the attempt was to
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Table 3.3: One-pot two-steps protocol with substituted indoles and aromatic aldehyde.
Entry R1 R2 R3 Product Yield Yield
46a(%) 47a(%)
1 Ph H H 46c 36 27
2 Ph F H 46d 39 30
3 Ph Me H 46e 32 29
4 Ph H Me 46f 23 33
5 i-Pr F H 46g 55 <5
6 i-Pr Me H 46h 50 18
7 i-Pr H Me 46i 61 18
8 Cyclohexyl H H 46j 45 <5
9 4-NO2-Ph H H 46k 55 22
10 4-AcO-Ph H H 46l 40 26
11 3-AcO-Ph H H 46m 53 13
[a] Yields were calculated by integration of 1H NMR and HPLC peaks.
The products are 60/40 mixture of diastereoisomers.
The remaning amount is unreacted alkylidene acetoacetate.
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realize the Yonemitsu trimolecular condensation between indole, 2-OH-
benzaldehyde and ethyl acetoacetate or diethyl malonate (Figure 3.17).
The results of the optimization are reported in Table 3.4. The reaction
Figure 3.17: Yonemitsu trimolecular condensation for the synthesis of coumarin derivatives.
proceeds slowly at room temperature for them both the 1,3-dicarbony
compounds, in fact the main product is the intermediate resulting from
the cyclization of the Knöevenagel condensation product (entry 1 and
6). By using microwave irradiation the best results for each methylene
active substrates have been obtained with 90 min of irradiation at 250 W:
as regards diethyl malonate, 45% of product was isolated together with
55% of intermediate (entry 3); for ethyl acetoacetate, a maximum of 27%
of product was isolated (entry 8).
3.2.2 1,4-addition of N,O-bis(trimethylsilyl)hydroxyl amine for the synthe-
sis of isoxazolidinones and isoxazolines
The reaction conditions for the addition of N,O-bis(trimethylsylil)
hydroxylamine were optimized on the base of our previous experience
and they can be divided depending on the N,O-heterocycle that we want
to obtain. As regard the synthesis of isoxazolidine and isoxazoline (Fig-
ure 3.18), we proceeded by adding to alkylidene acetoacetate 4 and 7
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Table 3.4: Optimization of Yonemitsu trimolecular condensation between 2-OH-benzaldehyde, indole
and 1,3-dicarbonyl compound.
Entry Reagent Cat(%)-indole(%) Conditions Time (min) Yield (%)
49 int
1 A 10%-1 eq rt 240 5 95
2 A 10%-1 eq MW-250 W 50 40 60
3 A 10%-1 eq MW-250 W 90 45 55
4 A 50%-1 eq MW-250 W 50 10 90
5[a] A 10%-2 eq MW-250 W 50 15 45
6 B 10%-1 eq rt 240 5 95
7 B 10%-1 eq MW-250 W 20 25 75
8 B 10%-1 eq MW-250 W 90 27 73
[a] Product of decarboxylation was detected.
the above-mentioned hydroxylamine in presence of a catalytic amount
of Yb(OTf)3 as Lewis acid. This procedure allows to avoid the forma-
tion of oxime byproduct as a result of the undesired 1,2-addition reac-
tion. The TMS group on N-atom was spontaneously removed during
the usual work-up condition inducing the rapid conversion of the inter-
mediate trans-5-hydroxyisoxazolidine-4-carboxylate, as single epimer,
through intramolecular hemiketalisation, leading to compounds 50 and
51. The mechanism of the cyclization and the explanation of the stre-
odefinition of the reaction can be obtained on the base of previous studies
on analogue systems having different substitution on C3 and different
carboxylate group on C4 (Figure 3.19). Starting from the consideration
that from the conjugated addition experimentally is possible to obtain
the (3,4)-trans isomer mainly, with two configuration (R,R) or (S,S), the
effect of cyclization on stereodefinition depends on it (the number asso-
ciated to each atom can be found in Figure 3.18). In this situation, H(13)
and H(14) should interact with O(3) and O(5) respectively; rotation of
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Figure 3.18: Synthesis of isoxazolidines and isoxazolines.
C(9)-N(11) bond allows the cyclization of O(12) on C(2) on Re face; the
same happens in the Si face as consequence of the rotation of C(9)-C(4)
bond. Through the cyclization a third stereocenter is defined in C5 and it
can have (R) or (S) configuration.
This intermediate was used without further purifications in order to
stabilize the ring structure since when the N-atom is unprotected is more
suitable of ring opening. So, the isoxazolidine ring 50 and 51 were im-
mediately employed for the acylation with methylmalonyl chloride in
DCM in presence of triethylamine to obtain the N-acylated isoxazoli-
dine 52 and 53 with yields of 51% and 50% respectively, in two steps.
The dehydratation of compounds 52 and 53 with MsCl afforded the final
N-(methylmalonyl)-isoxazolin-4-carboxylates 54 and 55 with yields of
51% and 87% respectively. In addition, removal of the protective group
on terminal alkyne of intermediate 55 gave the same product 54 with 53%
yield. The addition of N,O-bis(trimethylsilyl)hydroxylamine on alkyli-
dene malonamides 2a-b was used for the synthesis of isoxazolidin-5-
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Figure 3.19: Mechanism of intramolecular cyclization for the synthesis of isoxazolidine.
ones 56a,b (Figure 3.20): as described before, we performed the reaction
in DCM in presence of a catalyst that in this case is Sc(OTf)3 added in
catalytic amount after lowering the temperature at -40oC, to avoid the
formation of byproducts like the corresponding oxime and to avoid pro-
duct of retroaldolic reaction. In this condition the diastereomeric ratio is
>95/5 in favour of the anti-product. The same reaction can be performed
without catalyst and at 0o but with longer reaction times and lower di-
astereomeric ratio. To induce the intramolecular cyclization, we tried to
work-up the product of addition but it rapidly degradates on both silica
gel and alumina. So, we proceeded by adding TBAF directly in the ves-
sel after disappearance of alkylidene malonamides (after 1.5 h). It gave a
tetrabutylammonium hydroxylamino salt that is the real substrate of cy-
clization, leading in 15 min to isoxazolidinones 56a,b with yield of 66%
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and 63% respectively.
Figure 3.20: Synthesis of isoxazolidin-5-one.
3.2.3 Luche reduction and SN2’ addition for the synthesis of 3,4-dehydro-
β-prolines
Alkylidene acetoacetamides and acetoacetates were employed for the
synthesis of 3,4-dehydro-β-prolines [76]. For this purpose, compounds
11a and 8a,b were subjected to chemoselective Luche reduction using
CeCl3/ NaBH4 in a mixture of THF/MeOH obtaining the corrispond-
ing allyl alcohol 57 and 58a,b with yields of 80% and 92% respec-
tively. Since the reduction induce the formation of a stereocenter, we pro-
ceeded through an enzymatic resolution to resolve the two enantiomers
of compound 58a,b, employed separately for our purposes, while for
compound 57 we used the racemic mixture since the purpose of the
study on this substrate was focused on its utility as synthon for further
transformations: as regard the allyl alcohol 58a,b, the enzymatic reso-
lution was achieved by using Pseoudomanas cepacia lipase on the pro-
ducts of acetylation of 58a,b with vinyl acetate, affording the acetylated
compound (R)-59a,b and the alcohol (S)-58a,b in good yield and high
enantiomeric excess even if long reaction times are required. The Pseu-
domonas cepacia lipase (EC 3.1.1.3) is widely used in organic chemistry
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for the resolution of racemic secondary alcohols but also for transes-
terifications and hydrolysis. The acetylation catalyzed by this enzyme
was possible by adding vinyl acetate to a solution of 58a,b in diethyl
ether. The enzyme catalyzed the reaction of only one of the two enan-
tiomers, so we were able, after filtering off the enzyme, to recover a
1:1 mixture of acetate and alcohol (detected by 1H NMR signals), sepa-
rated by flash chromatography. The acetate (R)-59a,b was hydrolized to
the corresponding alcohol (R)-58a,b by K2CO3 in MeOH. The stereo-
selectivity of the enzyme depends of the relative size of the substituents
(small and large) of the alcohol and, according to the Kazlauskas’s rule
[77], (S)-configuration reacts faster than the (R) one: we obtained the
(S)-enantiomer of the allyl alcohol and the (R)-enantiomer of the corre-
sponding acetate (Figure 3.21). In both the studies, the compounds 57
and (R)-58a,b/(S)-58a,b were converted in the corresponding carbon-
ate 60 and (R)-61a,b/(S)-61a,b by using di-tert(butyl)-dicarbonate and
DMAP in THF (70%) or methyl chloroformiate and LiHMDA in THF
(75-78%). In the first case, the allylic amination was achieved with al-
lylamine or 4-methoxy-benzylamine in presence of [Ir(COD)Cl]2 with
P(OPh)3 as additional ligand obtaining the product 62a,b in usatisfac-
tory yields (23% and 32% respectively) as 70:30 Z/E mixture. Proba-
bly, the retrodonation in the unsaturated amide is the reason of the low
reactivity. For this reason, we introduced an electron-withdrawing tert-
butyl carbamate on the nitrogen of the amide obtaining 64 in good yield.
Repeating the SN2’ reaction in the same conditions reported above but
using 4-amino-benzylamine we were able to isolate the desidered pro-
duct 65 in 52% yield (Figure 3.22). In the second case, the two enan-
tiomers of 61a,b were subjected to SN2’ reaction with allylamine in the
usual conditions and the crudes were used without further purifications
in the next step: (R)-63a,b/(S)-63a,b were N-protected with (i)Fmoc-
group 66b or functionalized with acilating agents like (ii)methyl mal-
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Figure 3.21: Synthesis and resolution of the allyl alchol.
onyl chloride 67a,b or (iii)1-isocianato-2-methylbenzene 68b in order to
perform the ring closing methatesis reaction (Figure 3.23): in fact, ex-
periments on the deprotected analogues gave unsatisfactory results. So,
the diallylamines 66b, 67a,b and 68b were the substrates for the ring
closing metathesis catalyzed by Grubbs-Hoveyda II generation catalyst
in methyl-tertbutyl ether obtaining the products 69b, 70a,b and 71b with
yields of (i)79-81%, (ii)80-95% and (iii)60-65%, respectively. Finally,
the tert-butyl ester on C3 was hydrolize by using TFA for further func-
tionalizations (Figure 3.24).
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Figure 3.22: Allylic ammination.
3.3 Conclusions
Alkylidene and arylidene acetoacetates, malonates, malonamides and
acetoacetamides act as versatile building blocks for the synthesis of seve-
ral heterocycles, that can be incorporated in biologically relevant struc-
tures, or for the development of protocols for the conjugated addition
of C-based nucleophiles. As consequence of their high reactivity as
Michael acceptors and in order to achieve satisfactory results in the con-
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Figure 3.23: Acylation of diallylamines.
densation of indoles with alkylidene or arylidene malonates or acetoac-
etates and aldehydes, it was possible to develop a smart protocol in which
the reactivity of the Michael acceptors is the key element of Yonemitsu-
type trimolecular condensation in presence of Lewis acids as catalysts,
by using microwave irradiation. The conditions were optimized for both
malonates and acetoacetates and they work very well with substituted
aldehydes and indoles. The trick of this procedure is the use of catalytic
amount of Lewis acid, together with the significant reduction in reac-
tion times in comparison to the same procedure performed without the
assistance of microwaves. The protocol can be applied to the synthesis
of coumarin derivatives in order to prepare indole-coumarin compounds
with potential biological applications, whose synthesis was not reported
with other strategies. The advantages of a one-pot two-steps protocol,
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Figure 3.24: Ring closing metathesis.
like the Yonemitsu condensations is, can be mantained also by chang-
ing the nucleophiles, choosing N-based ones like hydroxylamines and
primary amines. The firsts can be employed for the synthesis of isox-
azolidine, isoxazoline and isoxazolidin-5-one largely employed as pep-
tidomimetic structures for the synthesis of bioactive molecules. The ad-
dition of hydroxylamine is catalyzed by different Lewis acids, depending
on the alkylidene compound, and proceeds with good yield. Through in-
tramolecular cyclization, the adduct gives spontaneously the proper ring
which can be functionalized. The primary amines are used as nucleophi-
les for the allylic ammination of allyl alcohol obtained through reduc-
tion of alkylidene acetoacetates or malonamides. With this approach, it
is possible to generate enantiopure adduct as consequence of the enzy-
matic resolution performed on the starting allyl alcohol: the amine reacts
keeping the initial configuration. The diallyl amine obtained from the the
conjugated addition is the starting material for the ring closing metathe-
sis that allows the cyclization to obtain 3,4-deydro-β-proline ring. A
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protocol to obtain entantiopure rings was developed, based on the use of
Grubbs-Hoveyda II generation catalyst.
3.4 Experimental procedures
3.4.1 General methods
All chemicals were purchased from commercial suppliers and were
used without furhter purification. Microwave-assisted reaction were car-
ried out in Milestone Mycrosynth apparatus, with a dual magnetron sys-
tem with a pyramid-shaped diffuser, 1000 W maximum power output,
and temperature monitor and control by optical fiber up to a vessel tem-
perature of 250 oC. Flash chromatography was carried out on silica gel
(230-400 mesh). Dowex R©50WX2-200(H) ion exchange resin was used
for purification of free amino acids or free amines. NMR spectra were
recorded with a Varian Mercury Plus 400 or Varian Gemini 200 instru-
ments. Chemical shifts are reported as δ values (ppm), and were cali-
brated using the residual solvent peaks of: CDCl3, set a delta = 7.27 ppm
(1H NMR) or δ = 77.0 ppm (13C NMR); CD3OD, set at δ = 3.31 ppm
(1H NMR) and δ = 49.o ppm (13C NMR); D2O, set at δ = 4.79 ppm (1H
NMR); CD3CN, set at δ = 1.93 ppm (1H NMR) and δ = 117.7 ppm (13C
NMR); (CD3)2CO, set at δ = 2.04 ppm (1H NMR) and δ = 29.8 ppm
(13C NMR). Coupling costants are given in Hz. LC-MS analysis was
carried out with an HP1100 liquid chromatograph coupled to an electro-
spray ionization mass spectormeter (LC-ESI-MS), using a Phenomenex
Gemini C18 - 3µ - 110 Å column, H2O/CH3CN as neutral solvent or
H2O/CH3CN with 0.2% formic acid as acid solvent at 25 oC (positive-
ion mode, mz = 100-500, fragmentor 70 V). Another set of experiments
has been performed on an HP1100 liquid chromatograph coupled with
an electrospray ionization-ion trap mass spectrometer MSD1100 usign
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a Phenomenex Zorbax C18 - 3.5µ - 80 Å column, H2O/CH3CN with
0.08% trifluoroacetic acid as acid solvent (positive scan 100-500m/z,
fragmentor 70 eV).
3.4.2 Synthesis and characterization
General procedure for the one-pot two steps trimolecular con-
densation with the assistance of MW in the second step. Ethyl ace-
toacetate or dimethyl malonate (1 eq), aldehyde (1 eq) and piperidine (15
mol%) were added in the microwave reactor and irradiated at 250 W for
7 min. After cooling the mixture at room temperature, DMF (1M), indole
(1 eq) and lewis acid (10 mol%) were added and the solution irradiated at
250 W for 20 min. The mixture was allowed to reach room temperature
and then it was diluited with water and washed with EtOAc. After drying
the organic layer over Na2SO4, the solvent was evaporated and the crude
purified by flash chromatography on silica gel (cyclohexane/ethyl acetate
90/10).
General procedure for the one-pot two steps trimolecular con-
densation performing the second step at room temperature. Ethyl
acetoacetate or dimethyl malonate (1 eq), aldehyde (1 eq) and piperidine
(15 mol%) were added in the microwave reactor and irradiated at 250
W for 7 min. After cooling the mixture at room temperature, the proper
solvent (1M), indole (1 eq) and lewis acid (10 mol%) were added and the
mixture stirred at rt for 4h. After disappearance of the starting material,
the reaction was diluited with water and washed with EtOAc. After dry-
ing the organic layer over Na2SO4, the solvent was evaporated and the
crude purified by flash chromatography on silica gel (cyclohexane/ethyl
acetate 90/10).
Compound (46a): 1H NMR (400 MHz, CDCl3) δ 8.08 (s, 1H), 7.68
(dd, J= 7.8, 1.5 Hz, 1H), 7.38-7.29 (m, 1H), 7.14-7.07 (m, 2H), 7.04
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(d, J= 2.5 Hz, 1H), 4.00 (d, J= 11.0 Hz, 1H), 3.83 (dd, J= 11.0, 4.9
Hz, 1H), 3.75 (s, 3H), 3.36 (s, 3H), 2.17e1.97 (m, 1H), 0.88 (d, J= 6.7
Hz, 6H); 13C NMR (400 MHz, CDCl3) δ 169.3, 168.7, 135.6, 128.4,
122.6, 121.8, 119.6, 119.3, 113.0, 110.8, 56.3, 52.6, 52.2, 42.1, 30.6,
21.9, 17.9; LC-ESI-MS: 10.41 min, [M +H]+=304, [M +Na]+=326,
[2M +Na]+=629; IR (film) cm 1 3405, 3057, 2957, 2874, 1732, 1619,
1542, 1457, 742; Rf=0.44 (7/3 EtOAc/cyclohexane as eluent); Anal.
Calcd for C17H21NO4 (303.1): C, 67.31; H, 6.98; N, 4.62. Found: C,
67.50; H, 6.99; N, 4.62.
Compound (46b): 1H NMR (400 MHz, CDCl3) 6/4 mixture of isomers
δ 8.19 (s, 0.4H, minor), 8.14 (s, 0.6H, major), 7.75-7.56 (m, 1H), 7.33
(dd, J= 8.0, 3.8 Hz, 1H), 7.21-7.04 (m, 2H), 6.99 (d, J= 2.5 Hz, 0.6H),
6.89 (d, J= 2.0 Hz, 0.4H), 4.02 (d, J= 11.5 Hz, 0.6H), 3.95 (d, J= 12.1
Hz, 0.4H), 3.86 (dd, J= 11.5, 4.1 Hz, 0.6H), 3.86 (dd, J= 12.1, 4.1 Hz,
0.4H), 2.32 (s, 3H), 2.03-2.10 (m, 0.6H), 2.02-1.95 (m, 0.4H), 1.90 (s,
3H), 1.50 (s, 9H), 0.99-0.75 (m, 6H); 13C NMR (400 MHz, CDCl3) δ
203.9, 203.2, 168.5,167.5, 135.5, 135.4,128.9,128.4,123.3,122.9,121.9,
121.7,119.9,119.6,119.3,119.2, 113.3, 112.4, 111.0, 110.7, 82.0, 81.3,
66.3, 66.0, 41.9, 41.4, 30.6, 30.4, 29.0, 27.9, 27.4, 27.1, 22.2, 22.1,
17.5, 17.2; LC-ESI-MS: 10.54 min (major), 11.05 min (minor), [M +
Na]+=352; IR (film) cm 1, 3336, 3186, 2926, 2853, 1728, 1697, 1461,
1376, 733; Rf=0.56 (7/3 EtOAc/cyclohexane as eluent). Anal. Calcd for
C18H23NO3 (329.2): C, 72.92; H, 8.26; N, 4.25. Found: C, 72.43; H,
8.24; N, 4.24.
Compound (47): 1H NMR (400 MHz, CDCl3) δ 7.77 (s, 2H), 7.67 (d,
J= 8.2 Hz, 2H), 7.25 (dd, J= 8.0, 1.0 Hz, 2H), 7.21-7.03 (m, 4H), 6.99
(d, J= 2.4 Hz, 2H), 4.27 (d, J= 8.4 Hz, 1H), 2.76-2.54 (m, 1H), 1.03 (d,
J= 6.6 Hz, 6H); 13C NMR (400 MHz, CDCl3) δ 137.0, 136.1, 123.6,
121.5, 119.2, 118.7, 110.9, 110.8, 58.9, 41.0, 21.8; LC-ESI-MS: 10.91
min, [M + H]+=289, [M + Na]+=311; IR (Nujol) cm 1 3422, 3020,
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1596, 1454, 1376, 744, 704. Rf= 0.62 (7/3 EtOAc/cyclohexane as elu-
ent); Anal. Calcd for C20H20N2 (288.2): C, 83.30; H, 6.99; N, 9.71.
Found: C, 83.23; H, 6.97; N, 9.73.
Compound (48a): 1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.65
(dd, J= 8.0, 1.3 Hz, 1H), 7.35 (dd, J= 8.2, 1.0 Hz, 1H), 7.14-7.20 (m,
2H), 6.99 (d, J= 2.4 Hz, 1H), 3.53 (s, 3H), 3.42-3.29 (m, 1H), 2.83 (dd,
J= 15.0, 5.7 Hz, 1H), 2.71 (dd, J= 15.0, 9.6 Hz, 1H), 2.20-1.97 (m, 1H),
0.94 (d, J= 6.7 Hz, 3H), 0.92 (d, J= 6.7 Hz, 3H); 13C NMR (400 MHz,
CDCl3) δ 170.6, 136.1, 127.5, 121.7, 120.9, 119.2, 119.0, 117.9, 110.9,
49.6, 40.1, 32.6, 30.3, 20.5, 20.1; LC-ESI-MS: 9.36 min, [M+H]+=246,
[M + Na]+=268; IR (film) cm 1 3314, 3078, 2944, 2861, 1698, 1462,
1358, 753; Rf= 0.62 (7/3 EtOAc/cyclohexane as eluent); Anal. Calcd
for C15H19NO2 (245.1): C, 73.44; H, 7.81; N, 5.71. Found: C, 73.61;
H, 7.82; N, 5.70.
Compound (48b): 1H NMR (400 MHz, CDCl3) δ 8.01 (s, 1H), 7.66 (dd,
J= 8.1, 1.3 Hz, 1H), 7.44-7.29 (d, 2H, J= 7.2 Hz), 7.24-7.03 (m, 1H), 6.95
(d, J= 2.4 Hz, 1H), 3.35 (dt, J= 8.0, 6.6 Hz, 1H), 2.95 (dd, J= 15.0, 8.0
Hz, 1H), 2.77 (dd, J= 15.0, 6.6 Hz, 1H), 2.18-2.02 (m, 1H), 1.99 (s, 3H),
0.94 (d, J= 6.7 Hz, 3H), 0.89 (d, J= 6.7 Hz, 3H); 13C NMR (400 MHz,
CDCl3) δ 209.4, 136.3, 127.2, 121.9, 121.7, 119.3, 119.0, 117.3, 111.2,
47.0, 39.3, 32.7, 30.1, 20.5, 20.3; LC-ESI-MS: 8.71 min, [M+H]+=230,
[M + Na]+=252, [M + K]+=268; IR (film) cm 1 3283, 3055, 2959,
2870, 1694, 1456, 1360, 744. Rf= 0.66 (7/3 EtOAc/cyclohexane as elu-
ent). Anal. Calcd for C15H19NO (229.1): C, 78.56; H, 8.35; N, 6.11.
Found: C, 78.36; H, 8.34; N, 6.13.
Compound (46c): major isomer: 1H NMR (400 MHz, CDCl3) δ 8.03
(br s, NH), 7.55 (d, 1H, J= 5.0 Hz), 7.35-7.02 (m, 9H), 5.06 (d, 1H, J=
8.0 Hz), 4.39 (d, 1H, J= 8.0 Hz), 3.96 (q, 2H, J= 7.2 Hz), 2.16 (s, 3H),
1.01 (t, 3H J= 7.2 Hz); 13C NMR (400 MHz, CDCl3) δ 203.1, 168.1,
141.3, 136.2, 128.3, 128.0, 126.7, 126.4, 122.4, 121.4, 119.4, 111.2,
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66.6, 61.4, 43.0, 30.3, 13.7; LC-ESI-MS: 9.8 min, [M + Na]+=358,
[2M +Na]+=693. Minor isomer: 1H NMR (400 MHz, CDCl3): δ 8.00
(br s, NH), 7.55 (d, 1H, J= 5.0 Hz), 7.35e7.02 (m, 9H), 5.09 (d, 1H, J= 8.0
Hz), 4.51 (d, 1H, J= 8.0 Hz), 3.98 (q, 2H, J= 7.2 Hz), 2.03 (s, 3H), 0.99
(t, 3H, J= 7.2 Hz); 13C NMR (400 MHz, CDCl3) δ 202.2, 168.0, 141.3,
136.1, 128.6, 128.1, 126.7, 126.6, 122.2, 120.7, 119.6, 117.2, 111.0,
65.8, 61.6, 42.6, 30.9, 13.6; LC-ESI-MS: 9.6 min, [M + Na]+=358,
[2M +Na]+=693. IR (film) cm 1 3397, 3060, 2931, 2872, 1737, 1715,
1456, 1367, 742. Rf= 0.37 (7/3 EtOAc/cyclohexane as eluent). Anal.
Calcd for C21H21NO3 (335.1): C, 75.20; H, 6.31; N, 4.18. Found: C,
75.15; H, 6.29; N, 4.20.
Compound (46d): major isomer: 1H NMR (400 MHz, CDCl3) δ 8.00
(br s, NH), 7.39-7.11 (m, 7H), 6.99 (d, 1H, J= 2.0 Hz), 6.85-6.95 (m,
1H), 6.68 (s, 1H), 4.96 (d, 1H, J= 12.0 Hz), 4.37 (d, 1H, J= 12.0 Hz),
3.95 (q, 2H, J= 7.2 Hz), 2.20 (s, 3H), 0.98 (t, 3H, J= 7.2 Hz); 13C NMR
(400 MHz, CDCl3) δ 202.1, 167.9, 157.8 (d, JC−F= 214 Hz), 140.9,
132.7, 128.4 (d, JC−F= 10 Hz), 128.0, 127.3, 126.9, 123.0, 119.3, 111.7,
110.4 (d, JC−F= 9 Hz), 104.6 (d, JC−F= 23 Hz), 66.3, 61.5, 29.6, 28.4,
13.9; LC-ESI-MS: 9.7 min, [M + Na]+=376, [2M + Na]+=729. Mi-
nor isomer: 1H NMR (400 MHz, CDCl3) δ 7.97 (br s, NH), 7.39-7.11
(m, 7H), 6.98 (d, 1H, J= 2.0 Hz), 6.68 (s, 1H), 6.8-6.95 (m, 1H), 5.00
(d, 1H, J= 11.6 Hz), 4.48 (d, 1H, J= 11.6 Hz), 3.97 (q, 2H, J= 7.2 Hz),
2.20 (s, 3H), 0.98 (t, 3H, J= 7.2 Hz); 13C NMR (400 MHz, CDCl3) δ
202.9, 168.0, 157.5 (d, JC−F= 214 Hz), 143.3, 133.2, 128.5 (d, JC−F=
10 Hz), 127.9, 127.2, 126.4, 122.5, 119.3, 111.6, 110.1 (d, JC−F= 8
Hz), 104.8 (d, JC−F= 23 Hz), 65.6, 61.5, 30.4, 28.4, 13.7; LC-ESI-MS:
9.9 min, [M + Na]+=376, [2M + Na]+=729. IR (film) cm 1 3389,
2963, 2929, 2866, 1739, 1711, 1459, 1282, 1202, 799. Rf= 0.34 (7/3
EtOAc/cyclohexane as eluent). Anal. Calcd for C21H20FNO3 (353.1):
C, 71.37; H, 5.70; N, 3.96. Found: C, 71.22; H, 5.71; N, 3.97.
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Compound (46e): major isomer: 1H NMR (400 MHz, CDCl3) δ 7.95
(br s, NH), 7.37-6.95 (m, 9H), 5.04 (d, 1H, J= 12.0 Hz), 4.36 (d, 1H,
J= 12.0 Hz), 3.96-4.00 (m, 2H), 2.40 (s, 3H), 2.05 (s, 3H), 0.98 (t,
3H, J= 7.2 Hz); 13C NMR (400 MHz, CDCl3) δ 202.3, 168.2, 141.4,
134.5, 128.7, 128.2, 127.9, 127.8, 126.6, 124.0, 121.4, 118.7, 115.7,
110.6, 66.0, 61.4, 30.3, 28.0, 21.6, 13.6; LC-ESI-MS: 10.4 min, [M +
Na]+=372, [2M + Na]+=721. Minor isomer: 1H NMR (400 MHz,
CDCl3) δ 8.00 (br s, NH), 7.37-6.95 (m, 9H), 5.07 (d, 1H, J= 11.8 Hz),
4.49 (d, 1H, J= 11.8 Hz), 3.96e4.00 (m, 2H), 2.40 (s, 3H), 2.05 (s, 3H),
1.01 (t, 3H, J= 7.2 Hz); 13C NMR (400 MHz, CDCl3) δ 203.1, 168.0,
141.4, 134.5, 128.9, 128.5, 127.9, 127.8, 126.8, 124.1, 121.5, 118.9,
116.7, 110.7, 66.8, 61.2, 30.4, 28.2, 21.4, 13.8; LC-ESI-MS: 10.2 min,
[M +Na]+=372, [2M +Na]+=721. IR (film) cm 1 3397, 3089, 2924,
2854, 1740, 1712, 1456, 1366, 701. RfÂ 140.41 (7/3 EtOAc/cyclohexane
as eluent). Anal. Calcd for C22H23NO3 (349.4): C, 75.62; H, 6.63; N,
4.01. Found: C, 75.64; H, 6.60; N, 4.02.
Compound (46f): major isomer: 1H NMR (400 MHz, CDCl3) δ 7.69-
7.11 (m, H), 7.00 (m, 1H), 6.94 (s, 1H), 5.07 (d, 1H, J= 11.0 Hz), 4.39
(d, 1H, J= 11.0 Hz), 3.98-4.05 (m, 2H), 3.70 (s, 3H), 2.06 (s, 3H),
0.98 (t, 3H, J= 7.2 Hz); 13C NMR (400 MHz, CDCl3) δ 202.0, 167.9,
141.2, 136.9, 130.6, 128.0, 127.7, 126.6, 125.5, 121.7, 119.1, 118.9,
115.6, 109.0, 65.9, 61.3, 42.6, 30.1, 13.8; LC-ESI-MS: 11.2 min, [M +
Na]+=372. Minor isomer: 1H NMR (400 MHz, CDCl3): δ 7.69-7.11
(m, 8H), 7.00 (m, 1H), 6.94 (s, 1H), 5.10 (d, 1H, J= 11.2 Hz), 4.50 (d, 1H,
J= 11.2 Hz), 3.98-4.05 (m, 2H), 3.70 (s, 3H), 2.18 (s, 3H), 1.00 (t, 3H,
J= 7.2 Hz); 13C NMR (400 MHz, CDCl3) δ 202.9, 168.0, 141.6, 136.9,
129.5, 128.2, 127.9, 126.8, 126.0, 121.9, 119.3, 118.9, 114.7, 109.1,
66.6, 61.3, 43.0, 30.8, 13.7; LC-ESI-MS: 10.7 min, [M + Na]+=372.
IR (film) cm 1 3058, 2980, 2927, 1714, 1698, 1540, 1471, 741. Rf=
0.53 (7/3 EtOAc/cyclohexane as eluent). Anal. Calcd for C22H23NO3
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(349.2): C, 75.62; H, 6.63; N, 4.01. Found: C, 75.49; H, 6.62; N, 4.03.
Compound (46g): major isomer: 1H NMR (400 MHz, CDCl3) δ 8.32
(br s, NH), 7.29 (dd, 1H, JH−H= 1 Hz, JH−F= 9.6 Hz), 7.21 (dd, 1H,
JH−H= 9.2 Hz, JH−F= 4.4 Hz), 6.89 (d, 1H, J= 2.4 Hz), 6.87 (dd,
1H, JH−H= 9.2 Hz, JH−F= 2.4 Hz), 4.12-4.30 (m, 2H), 4.02 (d, 1H,
J= 12.0 Hz), 3.77 (m, 1H), 2.03 (m, 1H), 1.94 (s, 3H), 1.31 (t, 3H,
J= 7.2 Hz), 0.85 (d, 6H, J= 6.6 Hz); 13C NMR (400 MHz, CDCl3) δ
203.3, 169.1, 157.9 (d, JC−F= 233 Hz), 132.1, 129.0 (d, JC−F= 10 Hz),
125.1, 113.4, 111.6, 110.6 (d, JC−F=12 Hz), 104.5 (d, JC−F= 18 Hz),
64.7, 61.5, 42.0, 30.6, 27.2, 21.9, 17.7, 14.0; LC-ESI-MS: 10.1 min,
[M + Na]+=342, [2M + Na]+=661. Minor isomer: 1H NMR (400
MHz, CDCl3) δ 8.20 (1H, br s), 7.29 (dd, 1H, JH−H= 1 Hz, JH−F=
9.6 Hz), 7.21 (dd, 1H, JH−H= 9.2 Hz, JH−F= 4.4 Hz), 7.02 (d, 1H,
J= 2.8 Hz), 6.87 (dd, 1H, JH−H= 9.2 Hz, JH−F= 2.4 Hz), 4.12-4.30
(m, 2H), 4.10 (d, 1H, J= 10.8 Hz), 3.77 (m, 1H); 2.31 (s, 3H), 1.98 (m,
1H), 0.83 (d, 6H, J= 6.6 Hz), 0.77 (t, 3H, J= 7.2 Hz). 13C NMR (400
MHz, CDCl3) δ 202.8, 168.5, 158.0 (d, JC−F= 233 Hz), 132.0, 128.7 (d,
JC−F= 10 Hz), 124.6, 113.3, 112.4, 110.1 (d, JC−F= 12 Hz), 103.4 (d,
JC−F= 18 Hz), 64.8, 61.0, 41.7, 30.9, 29.1, 22.0, 17.2, 13.4. LC-ESI-
MS: 9.8 min, [M +Na]+=342, [2M +Na]+=661. IR (film) cm 1 3376,
2987, 2929, 2857, 1736, 1704, 1454, 1274, 1211, 788. Rf= 0.48 (7/3
EtOAc/cyclohexane as eluent). Anal. Calcd for C18H22FNO3 (319.1):
C, 67.69; H, 6.94; N, 4.39. Found: C, 67.71; H, 6.90; N, 4.38.
Compound (46h): major isomer: 1H NMR (400 MHz, CDCl3) δ 7.97
(br s, NH), 7.45 (s, 1H), 7.23-6.86 (m, 3H), 4.25 (q, 2H, J= 7.2 Hz), 4.10
(d, 1H, J= 11.0 Hz), 3.83 (dd, 1H, J= 2.8, 11.0 Hz), 2.47 (s, 3H), 2.31 (s,
3H), 1.90e2.14 (m, 1H), 1.31 (t, 3H, J= 7.2 Hz), 0.88 (d, 6H, J= 6.6 Hz);
13C NMR (400 MHz, CDCl3) δ 203.6, 169.4, 134.6, 128.8, 128.3, 123.6,
121.9, 119.2, 112.5, 110.6, 65.0, 61.0, 41.6, 31.0, 29.2, 21.9, 17.8, 17.3,
13.5. LC-ESI-MS: 10.5 min, [M +Na]+=338. Minor isomer: 1H NMR
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(400 MHz, CDCl3): δ 8.02 (br s, NH), 7.45 (s, 1H), 7.23-6.86 (m, 3H),
4.02 (d, 1H, J= 12.0 Hz), 3.86 (dd, 1H, J= 4.0, 12.0 Hz), 3.80 (q, 2H, J=
7.6 Hz), 2.43 (s, 3H), 1.90-2.14 (m, 1H), 1.92 (s, 3H), 1.02 (d, 3H, J=
6.6 Hz), 0.88 (d, 6H, J= 6.6 Hz), 0.81 (t, 3H, J= 7.6 Hz); 13C NMR (400
MHz, CDCl3) δ 203.3, 168.6, 134.0, 128.7, 128.1, 123.3, 121.8, 119.0,
111.5, 110.4, 64.9, 61.4, 41.8, 30.8, 29.0, 21.5, 17.6, 17.1, 14.1. LC-
ESI-MS: 10.8 min, [M +Na]+=338. IR (film) cm 1 3404, 2960, 2924,
2871, 1735, 1707, 1464, 1367, 795. Rf= 0.53 (7/3 EtOAc/cyclohexane
as eluent). Anal. Calcd for C19H25NO3 (315.2): C, 72.35; H, 7.99; N,
4.44. Found: C, 72.42; H, 7.96; N, 4.45.
Compound (46i): major isomer: 1H NMR (400 MHz, CDCl3) δ 7.65
(d, 1H, J= 8.0 Hz), 7.25-7.08 (m, 3H), 6.74 (s, 1H), 4.23 (q, 2H, J= 7.2
Hz), 4.09 (d, 1H, J= 10.8 Hz), 3.81 (dd, 1H, J= 4.4, 10.8 Hz), 3.70 (s,
3H), 1.96-2.04 (m, 1H), 1.91 (s, 3H), 1.28 (t, 3H, J= 7.2 Hz), 0.84 (d,
3H, J= 6.6 Hz), 0.83 (d, 3H, J= 6.6 Hz); 13C NMR (400 MHz, CDCl3)
δ 203.3, 169.5, 128.7, 127.5, 121.5, 119.7, 119.0, 110.4, 109.1, 64.8,
61.4, 41.7, 32.8, 30.6, 29.0, 22.1, 17.7, 14.1; LC-ESI-MS: 10.8 min,
[M +Na]+=338. Minor isomer: 1H NMR (400 MHz, CDCl3): δ: 7.65
(d, 1H, J= 8.0 Hz), 7.25-7.08 (m, 3H), 6.88 (s, 1H), 4.20 (q, 2H, J= 7.2
Hz), 4.01 (d, 1H, J= 12.0 Hz), 3.86 (dd, 1H, J= 4.0, 12.0 Hz), 3.71 (s,
3H), 2.28 (s, 3H), 1.96-2.04 (m, 1H), 0.84 (d, 3H, J= 6.6 Hz), 0.83 (d,
3H, J= 6.6 Hz), 0.73 (t, 3H, J= 7.2 Hz). 13C NMR (400 MHz, CDCl3)
δ 203.2, 168.5, 136.4, 129.0, 121.2, 119.3, 118.8, 111.4, 108.8, 65.0,
60.8, 42.0, 32.7, 30.4, 27.6, 22.0, 17.2, 13.4. LC-ESI-MS: 10.5 min,
[M + Na]+=338. IR (film) cm 1 3055, 2961, 2933, 2876, 1710, 1614,
1467, 1356, 739. RfÂ 140.62 (7/3 EtOAc/cyclohexane as eluent). Anal.
Calcd for C19H25NO3 (315.2): C, 72.35; H, 7.99; N, 4.44. Found: C,
72.60; H, 7.98; N, 4.43.
Compound (46j): mixture of isomers: 1H NMR (400 MHz, CDCl3): δ
8.14 (br s, 0.7H, major), 8.09 (br s, 0.3H, minor), 7.72 (d, J= 7.6 Hz,
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0.3H, minor) 7.67 (d, J= 8.0 Hz, 0.7H, major), 7.34 (br d, J= 8.0 Hz,
1H), 7.21-7.09 (m, 2H), 7.03 (d, J= 2.5 Hz, 0.3H, minor), 6.90 (d, J=
2.4 Hz, 0.7H, major), 4.34-4.16 (m, 2H), 4.18 (d, J= 10.8 Hz, 0.3H, mi-
nor), 4.11 (d, J= 11.6 Hz, 0.7H, major), 3.86 (dd, J= 11.6, 3.5 Hz, 0.7H),
3.83 (dd, J= 10.8, 5.2 Hz, 0.3H), 2.30 (s, 0.9H, minor), 2.18 (s, 2.1H,
major), 1.82-1.50 (m, 7H), 1.39 (t, J= 7.2 Hz, 0.9H, minor) 1.31 (t, J=
7.2 Hz, 2.1H, major), 1.05-1.30 (m, 2H); 13C NMR (400 MHz, CDCl3)
δ 203.8, 203.3, 169.3, 168.6, 135.6, 135.5, 128.1, 128.0, 123.3, 122.9,
121.8, 121.6, 121.4, 121.3, 119.5, 119.4, 119.2, 119.1, 113.6, 112.7,
111.0, 110.8, 64.3, 64.0, 61.4, 41.1, 40.9, 32.4, 32.3, 26.5, 26.4, 26.2,
26.1, 26.0, 25.9, 14.1, 13.3; LC-ESI-MS: 11.32 min (minor), 11.63 (ma-
jor) [M + Na]+=364. IR (film) cm 1 3439, 2972, 2921, 2851, 1731,
1705, 1487, 1367, 754. Rf=0.61 (7/3 EtOAc/cyclohexane as eluent).
Anal. Calcd for C21H27NO3 (341.5): C, 73.87; H, 7.97; N, 4.10. Found:
C, 73.89; H, 7.94; N, 4.12.
Compound (46k): major isomer 1H NMR (400 MHz, CDCl3): δ 8.47
(br s, NH), 8.00-8.10 (m, 2H), 7.45-7.00 (m, 8H), 5.20 (d, 1H, J= 12.0
Hz), 4.45 (d, 1H, J= 12.0 Hz), 3.95-4.08 (m, 2H), 2.18 (s, 3H), 1.07 (t,
3H, J= 7.2 Hz); 13C NMR (400 MHz, CDCl3) δ 201.7, 167.6, 149.3,
146.5, 136.2, 126.2, 123.7, 122.7, 121.8, 119.9, 118.5, 114.6, 111.3,
65.3, 61.8, 42.2, 30.9, 13.8; LC-ESI-MS: 9.7 min, [M + water]+=398,
[M+Na]+=403. Minor isomer: 1H NMR (400 MHz, CDCl3): δ 8.42 (br
s, NH), 8.00-8.10 (m, 2H), 7.45-7.00 (m, 8H), 5.23 (d, 1H, J= 12.0 Hz),
4.55 (d, 1H, J= 12.0 Hz), 3.95-4.08 (m, 2H), 2.16 (s, 3H), 0.99 (t, 3H,
J= 7.2 Hz); 13C NMR (400 MHz, CDCl3) δ 201.0, 167.4, 149.5, 146.6,
136.3, 129.0, 125.9, 123.6, 122.5, 121.2, 119.7, 118.7, 115.4, 111.5,
65.4, 61.7, 41.8, 30.2, 13.6; LC-ESI-MS: 9.6 min, [M + water]+=398,
[M + Na]+=403. IR (film) cm 1 3405, 3111, 2981, 2856, 1738, 1714,
1519, 1420, 744. RfÂ 140.20 (7/3 EtOAc/cyclohexane as eluent). Anal.
Calcd for C21H20N2O5 (380.1): C, 66.31; H, 5.30; N, 7.36. Found: C,
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66.10; H, 5.29; N, 7.37.
Compound (46l): major isomer: 1H NMR (400 MHz, CDCl3) δ 7.98 (br
s, NH), 7.52-6.93 (m, 9H), 5.09 (d, 1H, J= 12.0 Hz), 4.45 (d, 1H, J= 12.0
Hz), 3.95-4.05 (m, 2H), 2.22 (s, 3H), 2.05 (s, 3H), 1.04 (t, 3H, J= 7.2
Hz); 13C NMR (400 MHz, CDCl3) δ 203.0, 169.3, 168.0, 149.3, 138.9,
136.7, 136.1, 129.0, 127.0, 126.2, 122.5, 121.7, 119.9, 111.2, 65.8, 61.6,
41.8, 30.4, 28.2, 21.0, 13.8. LC-ESI-MS: 9.0 min, [M + water]+=411,
[M+Na]+=416. Minor isomer: 1H NMR (400 MHz, CDCl3) δ 8.04 (br
s, NH), 7.52-6.93 (m, 9H), 5.05 (d, 1H, J= 12.0 Hz), 4.32 (d, 1H, J= 12.0
Hz), 3.95-4.05 (m, 2H), 2.13 (s, 3H), 2.03 (s, 3H), 0.94 (t, 3H, J= 7.2
Hz); 13C NMR (400 MHz, CDCl3) δ 202.1, 169.3, 167.9, 154.0, 138.8,
136.7, 136.2, 129.7, 127.0, 126.4, 123.5, 121.5, 119.7, 111.0, 66.6, 61.5,
42.3, 30.5, 29.6, 21.1, 13.7. LC-ESI-MS: 9.0 min, [M + water]+=411,
[M + Na]+=416. IR (film) cm 1 3407, 2980, 2927, 2871, 1740, 1738,
1710,1506, 1368,1201, 743. Rf= 0.24 (7/3 EtOAc/cyclohexane as elu-
ent). Anal. Calcd for C23H23NO5 (393.4): C, 70.21; H, 5.89; N, 3.56.
Found: C, 70.24; H, 5.91; N, 3.55.
Compound (46m): major isomer: 1H NMR (400 MHz, CDCl3) δ 8.10
(br s, NH), 7.55-6.91 (m, 8H), 6.79 (br s, 1H), 5.11 (d, 1H, J= 12.2
Hz), 4.36 (d, 1H, J= 12.2 Hz), 4.01-3.97 (m, 2H), 2.26 (s, 3H), 2.06 (s,
3H), 1.03 (t, 3H, J= 7.2 Hz); 13C NMR (400 MHz, CDCl3) δ 203.0,
169.4, 167.9, 150.6, 143.1, 136.1, 129.4, 126.2, 125.4, 122.3, 121.6,
121.1, 119.8, 119.6, 118.8, 115.6, 111.1, 66.2, 61.6, 42.5, 30.6, 21.0,
13.6. LC-ESI-MS: 9.0 min, [M + water]+=411, [M + Na]+=416.
Minor isomer: 1H NMR (400 MHz, CDCl3) δ 8.06 (br s, NH), 7.55-
6.91 (m, 8H), 6.67 (br s, 1H), 5.08 (d, 1H, J= 12.4 Hz), 4.49 (d, 1H,
J= 12.4 Hz), 4.01-3.97 (m, 2H), 2.25 (s, 3H), 2.08 (s, 3H), 0.98 (t, 3H,
JÂ 147.2 Hz);
13C NMR (400 MHz, CDCl3) δ 202.3, 169.3, 167.8, 150.5,
143.1, 136.1, 129.1, 126.3, 125.7, 122.1, 121.6, 121.0, 119.8, 119.4,
119.1, 111.2, 65.5, 61.5, 42.2, 28.4, 20.9, 14.0. LC-ESI-MS: 8.9 min,
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[M + water]+=411, [M + Na]+=416. IR (film) cm 1 3400, 2982,
2926, 2854, 1741, 1738, 1725, 1486, 1368, 1206, 744. Rf= 0.22 (7/3
EtOAc/cyclohexane as eluent). Anal. Calcd for C23H23NO5 (393.4): C,
70.21; H, 5.89; N, 3.56. Found: C, 70.23; H, 5.87; N, 3.53.
Compound (49a): 1H NMR (400 MHz, CDCl3) δ 8.16 (br s, NH), 7.65-
7.02 (m, 8H), 6.81 (d, 1H, J= 3.6 Hz), 5.01 (d, 1H, J= 7.2 Hz), 4.38 (q,
2H, J= 7.2 Hz), 4.18 (d, 1H, J= 7.2 Hz), 1.38 (t, 3H, J= 7.2 Hz); 13C NMR
(400 MHz, CDCl3) δ 166.9, 164.6, 150.6, 148.5, 136.6, 134.2, 129.4,
124.7, 124.6, 123.8, 123.4, 121.9, 117.6, 116.4, 116.3, 111.8, 61.6, 52.9,
36.4, 13.9. LC-ESI-MS: 9.7 min, [M + H]+=336, [M + Na]+=358.
IR (film) cm 1 3357, 3060, 2982, 2931, 2851, 1768, 1715, 1486, 1375,
1244, 1201, 761. Rf= 0.35 (7/3 EtOAc/cyclohexane as eluent). Anal.
Calcd for C20H17NO4 (335.1): C, 71.63; H, 5.11; N, 4.18. Found: C,
71.65; H, 5.14; N, 4.20.
Compound (49a): 1H NMR (400 MHz, CDCl3) δ 8.18 (br s, NH),
7.44-7.04 (m, 8H), 6.82 (d, 1H, J= 3.6 Hz), 5.02 (d, 1H, J= 7.2 Hz),
4.26 (d, 1H, J= 7.2 Hz), 2.20 (s, 3H); 13C NMR (400 MHz, CDCl3)
δ 201.1, 169.5, 165.7, 150.5, 137.0, 136.7, 36.5, 128.8, 128.0, 125.1,
123.4, 122.5, 121.4, 119.9, 118.5, 116.7, 111.8, 59.1, 35.2, 29.7; LC-
ESI-MS: 8.8 min, [M + H]+=306, [2M + Na]+=633. IR (film) cm 1
3405, 3058, 2924, 2854, 1752, 1718, 1486, 1339, 745. Rf= 0.34 (7/3
EtOAc/cyclohexane as eluent). Anal. Calcd for C19H15NO3 (305.3): C,
74.74; H, 4.95; N, 4.59. Found: C, 74.76; H, 4.97; N, 4.61.
General procedure for the synthesis of isoxazolidine ring: (50)
and (51). Under inert atmosphere, 4 or 7 (1 eq) and Yb(OTf)3 (0.5 eq)
were added in DCM (0.5M) and the mixture stirred for 10 min at room
temperature. N,O-bis(trimethylsilyl) hydroxylamine (2 eq) was added
at 0oC and the reaction stirred for additional 30 min. The solution was
diluted with dichloromethane and washed with water. After drying the
79
CHAPTER 3. REACTIVITY OF ALKYLIDENE OR ARYLIDENE DERIVATIVES FOR THE
SYNTHESIS OF ISOXAZOLIDINONES, ISOXAZOLINES AND DEYDRO-β-PROLINES
organic layer onto Na2SO4, the solvent was epavorated and the crude
employed without further purifications in the next step.
General procedure for the acylation of isoxazolidine ring: (52)
and (53). Under inert atmosphere, triethylamine (1.5 eq) and methyl
malonyl chloride (1.5 eq) were added at 0oC to a solution of (50) or (51)
(1 eq) in DCM (0.5M). The mixture was stirred at room temperature for
2.5 h. After this period, the reaction was diluted with dichloromethane
and washed with water. After drying the organic layer onto Na2SO4, the
solvent was epavorated and the crude was purified by flash chromatogra-
phy on silica gel (80/20 cyclohexane/EtOAc).
Compound (52): Yield 51% (over two steps); 1H NMR (400 MHz,
CDCl3) δ 4.65 (dt, J= 6.8, 7.4 Hz, 1H), 3.72 (s, 3H), 3.59 (d, J= 15.5
Hz, 1H), 3.53 (d, J= 15.6 Hz, 1H), 2.86 (d, J= 7.4 Hz, 1H), 2.28-2.19
(m, 2H), 1.92 (t, J= 2.4 Hz, 1H), 1.83-1.74 (m, 2H), 1.63 (s, 3H), 1.64-
1.52 (m, 2H), 1.46 (s, 9H); 13C NMR (400 MHz, CDCl3) δ 169.3, 168.4,
167.5, 105.3, 83.7, 82.6, 68.7, 61.6, 59.1, 52.3, 40.7, 33.9, 27.8, 24.6,
22.8, 17.8. LC-ESI-MS: 8.3 min, [M + H]+=370, [M + Na]+=392,
[2M +Na]+=761.
Compound (53): Yield 50% (over two steps); 1H NMR (400 MHz,
CDCl3) δ 4.64 (dt, J= 6.8, 7.2 Hz, 1H), 3.67 (s, 3H), 3.50 (s, 2H),
2.82 (d, J= 7.2 Hz, 1H), 2.21 (dt, J= 6.8, 6.0 Hz, 2H), 1.72 (m, 2H),
1.62 (s, 3H), 1.59-1.47 (m, 2H), 1.42 (s, 9H), 0.07 (s, 9H); 13C NMR
(400 MHz, CDCl3) δ 169.2, 168.5, 167.6, 106.7, 105.4, 84.8, 82.6, 61.7,
59.2, 52.4, 40.8, 34.0, 27.9, 24.8, 22.9, 19.4, 0.1. LC-ESI-MS: 11.3 min,
[M +H]+=442, [M +Na]+=464, [2M +Na]+=905.
General procedure for th synthesis of isoxazoline: (54) and (55).
Under inert atmosphere, triethylamine (2 eq) and methanesulfonyl chlo-
ride (2 eq) were added to a solution of (52) and (53) (1 eq) in DCM
(0.25M) at 0oC and the mixture stirred at rt for 24h. After this period,
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the reaction was diluted with dichloromethane and washed with water.
The organic layer dried on Na2SO4 and the solvent evaported. The crude
was purified by flash chromatography onto silica gel (80/20 cyclohex-
ane/EtOAc). Yield of (54) 51%; yield of (55) 87%.
Removal of protective group for the synthesis of (54). To a solution of
(55) (2 eq) in THF (0.5M), tetrabutylammonium fluoride trihydrate (1.9
eq) was added and the mixture stirred overnight at room temperature.
After adding 5 ml of H2O, THF was removed and the solution diluted
with 10 ml of DCM. The organic layer was washed with water, dried
over Na2SO4 and evaporated. The crude product was purified by flash
chromatography on silica gel (80/20 cyclohexane/EtOAc). Yield of (54)
53%.
Compound (54): 1H NMR (400 MHz, CDCl3) δ 5.30 (m, 1H), 3.72
(s, 3H), 3.58 (d, J= 15.9 Hz, 1H), 3.46 (d, J= 15.9 Hz, 1H), 2.29-2.14
(m, 2H), 2.20 (s, 3H), 1.99 (m, 1H), 1.92 (t, J= 2.4 Hz, 1H), 1.76 (m,
1H), 1.64-1.53 (m, 2H), 1.48 (s, 9H); 13C NMR (400 MHz, CDCl3)
δ 166.8, 162.0, 161.0, 105.8, 83.8, 80.9, 68.4, 62.8, 52.2, 40.4, 32.4,
28.0, 26.7, 23.6, 17.8, 11.1. LC-ESI-MS: 10.1 min, [M + H]+=352,
[M +Na]+=374, [2M +Na]+=725.
Compound (55): 1H NMR (400 MHz, CDCl3) δ 5.30 (m, 1H), 3.72 (s,
3H), 3.58 (d, J= 15.9 Hz, 1H), 3.46 (d, J= 15.9 Hz, 1H), 2.24 (dt, J= 3.2,
7.2 Hz, 2H), 2.20 (s, 3H), 1.92 (m, 1H), 1.71 (m, 1H), 1.64-1.53 (m, 2H),
1.48 (s, 9H), 0.12 (s, 9H); 13C NMR (400 MHz, CDCl3) δ 167.0, 167.9,
162.2, 161.1, 106.9, 106.0, 84.6, 81.1, 63.1, 52.4, 40.6, 32.8, 28.2, 23.9,
19.5, 11.3, 0.1; LC-ESI-MS: 13.2 min, [M+H]+=424, [M+Na]+=446,
[M +K]+=462.
Synthesis of isoxazolidin-5-one: (56a,b). Under inert atmosphere,
(2a,b) (1 eq) and Sc(OTf)3 (15 mol%) were stirred in DCM (0.2M) at
room temperature for 15 min. N,O-bis(trimethylsilyl) hydroxylamine
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(1.5 eq) was added at -40oC and the mixture stirred for 1.5h. After this
period, tetrabutylammonium fluoride (2 eq) was added and the mixture
stirred at room temperature for 15 min. The solution was diluted with
dichloromethane and washed with water. After drying the organic layer
onto Na2SO4, the solvent was epavorated and the crude was purified by
flash chromatography on silica gel (8:2->7:3 Cy:EtOAc).
Compound (56a): yield 66%; 1H NMR (400 MHz, CDCl3) δ 6.27 (bs,
1H), 3.97 (dd, 3J= 6.4 Hz, 3J= 5.6 Hz, 1H), 3.38-3.27 (m, 2H), 3.31
(d, 3J= 5.2 Hz, 1H), 1.84-1.55 (m, 6H), 1.27-1.02 (m, 5H), 1.16 (t, 3J=
7.2 Hz, 3H); 13C NMR (400 MHz, CDCl3) δ 165.5, 163.5, 66.9, 51.9,
40.1, 34.7, 28.9, 26.5, 25.7, 25.4, 25.3, 13.9; LC-ESI-MS: 13.2 min,
[M +H]+=241, [M +Na]+=263, [M +K]+=279.
Compound (56b): yield 63%; 1H NMR (400 MHz, CDCl3) δ 6.34 (bs,
1H), 3.94(dd, 3J= 6.4 Hz, 3J= 6.4 Hz, 1H), 1.91 (m, 1H), 1.16 (t, 3J=
7.2 Hz, 3H), 0.99 (d, 3J= 6.8 Hz, 3H), 0.97 (d, 3J= 6.8 Hz, 3H); 13C
NMR (400 MHz, CDCl3) δ 165.9, 163.9, 66.5, 51.4, 35.1, 30.8, 18.9
18.0, 14.4; LC-ESI-MS: 13.2 min, [M + H]+=201, [M + Na]+=223,
[M +K]+=239.
General procedure for Luche reduction of alkylidene malonamide
and acetoacetate: (57) and (58a,b). To a solution of compound (11a) or
(8a,b) (1 eq) in THF/MeOH 9:1 (0.25M) at room temperature, CeCl3.7H2O
(1.1 ) and NaBH4 (1.1 eq) were added and the reaction quenched after
disappearence of the starting ketone. After addition of water and re-
moval of THF and MeOH under reduced pressure, the residue was di-
luted with ethyl acetate and washed with water. The organic layer was
dried over Na2SO4 and solvent was removed under reduced pressure.
Racemic alcohol (57) or (58a,b) was isolated by flash chromatography
on silica gel (cyclohexane/ethyl acetate 85/15 as eluant). Compound
(57): (60:40 mixture of inseparable diastereoisomers): 1H NMR (400
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MHz, CDCl3) δ 7.06 (d, 0.4H, J= 8.0 Hz), 7.00 (d, 0.6H, J= 8.4 Hz),
5.33 (d, 1H, J= 10.1Hz), 4.43 (m, 1H), 4.17 (q, 1H, J =6.4 Hz), 3.99 (bs,
1H), 3.53 (s, 3H), 2.40-2.80 (m, 1H), 1.18-1.55 (m, 3H), 1.16 (d, 1.2H,
J= 6.4 Hz), 1.11 (d, 1.8H, J= 6.4 Hz), 0.69-0.82 (m, 12H); 13C NMR
(400 MHz, CDCl3) δ 172.9, 168.3, 141.2, 136.1, 70.0, 51.6, 50.1, 40.5,
27.5, 24.4, 22.4, 22.3, 21.3, 21.1; LC-ESI-MS: 6.67 min (major), 7.91
(minor), [M +H]+=286, [M +Na]+=308.
Enzymatic resolution of allyl alcohol: (58a,b). Racemic (58a,b)
was dissolved in diethyl ether and vinyl acetate (5 eq) and Pseudomonas
cepacia lipase (35 mg/ml) were added. The mixture was refluxed for
30h and then filtered off to recover the enxyme. After drying the organic
layer onto Na2SO4, the solvent was epavorated and the crude purified
by flash chromatography on silica gel (95/5 cyclohexane/ethyl acetate)
to isolate (S)-(58a,b) and the acetate (R)-58a,b. It was hydrolized by
using K2CO3 (1 eq) in MeOH, stirring the mixture for 30 min. The re-
action was quenched with acid water and extracted with ethyl acetate.
The crude (R)-58a,b was used without further purifications. Compound
(58b): yield (S)-58b 94%, yield (R)-58b 90%. E-isomer: 1H NMR (400
MHz, CDCl3) δ 6.37(d, 3J= 10.4 Hz, 1H), 3.03 (m, 1H), 1.51 (s, 9H),
1.32 (d, 3J= 6.6 Hz, 3H), 0.99 (d, 3J= 8 Hz, 6H); 13C NMR (400 MHz,
CDCl3) δ 166.8, 147.3, 131.9, 81.0, 58.6, 29.1, 28.3, 22.6, 22.4. Z-
isomer: 1H NMR (400 MHz, CDCl3) δ 5.75 (d, 3J= 10 Hz, 1H), 4.36
(q, 3J= 6.4 Hz, 1H), 3.03 (m, 1H), 1.51 (s, 9H), 1.32 (d, 3J= 6.6 Hz,
3H), 0.99 (d, 3J= 8 Hz, 6H); 13C NMR (400 MHz, CDCl3) δ 167.2,
146.7, 130.1, 81.1, 58.8, 28.2, 27.7, 22.6, 22.4. LC-ESI-MS: 1.6 min,
[M + H]+=215, [M + Na]+=227, [2M + Na]+=451. S-enantiomer
[α]D= -26, R-enantiomer [α]D= +38 (c 1 in CHCl3).
Compound (58a): yield (S)-58b 45%, yield (R)-58b 60%. E-isomer:
1H NMR (400 MHz, CDCl3) δ 6.50 (d, 1H, J= 9.8 Hz), 4.70 (q, 1H,
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J = 6.6 Hz), 2.34 (m, 1H), 1.50 (s, 9H), 1.44-1.73 (m, 5H), 1.39 (d,
3H, J= 6.6 Hz), 1.11-1.25 (m, 5H); 13C NMR (400 MHz, CDCl3) δ
167.7, 147.8, 132.1, 81.0, 60.6, 37.0, 32.1(2), 25.7, 25.4 (2), 23.9, 22.7;
GC-MS: 16.81 min, m/z: 226(2), 211(100), 179(18), 165(68), 143(55),
129(38), 119(35), 105(19), 91(32), 81(70), 67(45), 55(43). Z-isomer: 1H
NMR (400 MHz, CDCl3) δ 5.88 (d, 1H, J= 10.0 Hz), 4.41 (q, 1H, J= 6.6
Hz), 4.24 (q, 2H, J= 7.0 Hz), 2.75 (m, 1H), 2.30 (br s, 1H), 1.60-1.73 (m,
5H), 1.25 (d, 3H, J= 6.6 Hz), 1.25 (t, 3H, J= 7.0 Hz), 1.01-1.36 (m, 5H);
13C NMR (400 MHz, CDCl"3) δ 167.7, 145.6, 133.4, 81.1, 60.2, 37.9,
32.5, 32.4, 25.9, 25.7, 25.4, 22.5, 22.4; GC-MS: 16.40 min, m/z: 226(2),
208(38), 179(33), 162(100), 147(28), 133(51), 119(37), 107(20), 99(29),
91(36), 81(87), 67(38), 55(34).
Procedure for the synthesis of allylic tertbutylcarbonate: (60).
To a solution of the allylic alcohol 57 (1 eq) in THF, ditertbutyl dicar-
bonate (2.5 eq), DMAP (0.2 eq) and TEA (1.2 eq) were added and the
mixture was stirred for 2h at room temperature. After the addition of
water and the removal of THF, ethyl acetate was added and the organic
layer extracted and dried over Na2SO4. The crude was purified by flash
chromatography on silica gel (cyclohexane/ethyl acetate 85/15 as eluant).
Compound (60): yield 70% (60:40 mixture of inseparable diastereoiso-
mers). 1H NMR (400 MHz, CDCl3) δ 6.66 (d, 0.6H, J=8.2 Hz), 6.55
(d, 0.4H, J= 8.0 Hz), 5.63 (d, 0.4H, J= 10.0 Hz), 5.63 (d, 0.6H, J= 10.1
Hz), 5.16 (q, 1H, J= 7.2 Hz), 4.65 (m, 1H), 3.99 (bs, 1H), 3.75 (s, 3H),
2.68-2.85 (m, 1H), 1.55-1.75 (m, 3H), 1.49 (s, 9H), 1.43 (d, 3H, J= 7.2
Hz), 0.96-1.03 (m, 12H); 13C NMR (400 MHz, CDCl3) δ 173.0, 167.5,
152.6, 141.9 (142.5), 134.3 (135.0), 82.1, 74.4, 52.0, 50.7, 41.0, 28.1
(3C), 27.6, 24.8, 22.7, 22.5, 21.6, 19.4 (20.1); LC-ESI-MS: 8.2 min,
[M +H]+=386, [M +Na]+=408.
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Procedure for the synthesis of allylic methylcarbonate: (61a,b).
Under inert atmosphere, each enantiomer of (58a,b) (1 eq) was dissolved
at -78oC in THF and then LiHMDA (1.5 eq) was added. The mixture
was stirred for 30 min and then methyl chloroformiate (2 eq) was added
dropwise. The mixture was stirred for 1.5h at -78oC. The reaction was
diluted with ethyl acetate and washed with water. The crude was purified
by flash chromatography on silica gel (95:5=Cy:EtOAc).
Compound (61b): yield of (S)-61b: 75%; yield of (R)-61b: 78%. E-
isomer: 1H NMR (400 MHz, CDCl3) δ 5.81 (dd, 3J= 9.6 Hz, 4J= 1.2
Hz, 1H), 5.44 (q, 3J= 6.4 Hz, 1H), 3.77 (s, 3H), 3.15 (m, 1H), 1.51 (s,
9H), 1.40 (d, 3J= 6.8 Hz, 3H), 0.99 (d, 3J= 6.8 Hz, 6H); 13C NMR (400
MHz, CDCl3) δ 165.6, 155.0, 146.7, 131.3, 81.2, 74.0, 54.5, 28.1, 26.2,
22.5, 19.8; LC-ESI-MS: 11.8 min, [M + H]+=273, [M + Na]+=295.
Z-isomer: 1H NMR (400 MHz, CDCl3) δ 5.76 (d, 3J= 9.6 Hz, 1H), 4.36
(q, 3J= 6.4 Hz, 1H), 3.77 (s, 3H), 3.00 (m, 1H), 1.48 (s, 9H), 1.32 (d,
3J= 6.4 Hz, 3H), 0.99 (d, 3J= 6.8 Hz, 6H); 13C NMR (400 MHz, CDCl3)
δ 165.6, 155.0, 146.7, 131.3, 81.2, 74.0, 54.5, 28.1, 26.2, 22.5, 19.8;
LC-ESI-MS: 8.9 min, [M +H]+=273, [M +Na]+=295. S-enantiomer
[α]D= -30.0, R-enantiomer [α]D= +28.9 (c 1 in CHCl3).
Compound (61a): E-isomer: 1H NMR (200 MHz, CDCl3) δ 5.88 (d,
1H, J= 10.0 Hz), 5.60 (q, 1H, J= 6.6 Hz), 2.80 (m, 1H), 2.02 (s, 3H),
1.55-1.77 (m, 5H), 1.33 (d, 3H, J= 6.6 Hz), 0.89-1.25 (m, 5H); 13C
NMR (400 MHz, CDCl3) δ 170.1, 166.4, 146.7, 130.8, 81.2, 60.2, 37.8,
32.6, 32.4, 26.0, 25.5(2), 22.7, 21.2(2), 19.9; GC-MS 17.40 min, m/z:
268(2), 225(18), 208(55), 179(63), 162(100), 151(10), 143(95), 133(57),
119(35), 105(33), 91(41), 81(84), 67(38), 55(31). [α]D25= +27:2 (c 1.0,
CHCl3).
Procedure for the synthesis of N-Boc-derivative: (64). To a so-
lution of the 60 (1 eq) in THF, ditertbutyl dicarbonate (2.5 eq), DMAP
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(0.2 eq) and TEA (1.2 eq) were added and the solution was refluxed for
1h. After cooling the mixture and quenching it with water, THF was re-
moved and the residue was diluted with ethyl acetate and washed with
water. The organic layer was dried over Na2SO4 and solvent was re-
moved. Compound (64) was isolated by flash chromatography on silica
gel (cyclohexane/ethyl acetate 85/15 as eluant). Compound (64): yield
60% (60:40 mixture of inseparable diastereoisomers): 1H NMR (400
MHz, CDCl3) δ 6.60 (bm, 1H), 5.70 (d, 0.4H, J= 10.0 Hz), 5.68 (d,
0.6H, J= 10.2 Hz), 5.18 (m, 1H), 4.68 (m, 1H), 3.71 (s, 3H), 2.53 (m,
1H), 1.55-1.75 (m, 3H), 1.49 (s, 9H), 1.42 (s, 9H), 1.45 (d, 3H, J= 7.2
Hz), 0.98-1.15 (m, 12H); 13C NMR (200 MHz, CDCl3) δ 171.3, 169.7,
152.9, 150.9, 142.5, 135.3 (135.4), 84.0, 81.9, 72.9, 52.0, 51.9, 38.8,
27.8 (3C), 27.6 (3C), 26.8, 25.2, 22.7, 23.3, 22.0, 21.9, 19.3 (19.5); LC-
ESI-MS: 15.1 min, [M +H]+=486, [M +Na]+=508.
General procedure for allylic amination: (62a,b), (63a,b) and
(65). Under inert atmosphere, to a solution of [Ir(COD)(Cl)]2 (5 mol%)
and phosphorous ligand (20 mol%) in EtOH, carbonate 60, 61a,b or 64
(1 eq) and amine (5 eq) were added at r.t. The solution was stirred under
reflux. After removal of the solvent and the excess of amine, the residue
was diluted with ethyl acetate and washed with water, then dried over
Na2SO4. The crude was purified by flash chromatography on silica gel
(cyclohexane/ethyl acetate 85:15 as eluant).
Compound (62a): (major Z isomer) 1H NMR (400 MHz, CDCl3) δ 9.52
(bd, 1H), 7.12 (q, 1H, J= 6.8 Hz), 6.09 (m, 1H), 5.36 (bd, 1H, J= 17.2
Hz), 5.31 (bd, 1H, J= 10.0 Hz), 4.79 (m, 1H), 3.89 (s, 3H), 3.61 (d, 1H,
J= 8.0 Hz), 3.24 (dd, 1H, J= 12.4, 6.4 Hz), 2.89 (dd, 1H, J=12.4, 8.6
Hz), 2.17 (d, 3H, J= 6.8), 1.79 (m, 1H), 1.42-1.46 (m, 3H), 0.99-1.24
(m, 12H); 13C NMR (200 MHz, CDCl3) δ 173.1, 168.9, 137.4, 136.0,
134.8, 119.4, 58.4, 49.7, 38.1, 33.6, 27.0, 22.5, 22.4, 20.2, 19.3, 17.7;
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LC-ESI-MS: 8.98 min (major), 7.17 (minor), [M +H]+=325.
Compound (62b): (major Z isomer) 1H NMR (400 MHz, CDCl3) δ 9.98
(bd, 1H, J= 7.6 Hz), 7.14 (d, 2H, J=8.0 Hz), 6.97 (m, 1H), 6.87 (d, 2H,
J=8.4 Hz), 4.47 (m, 1H), 3.81 (s, 3H), 3.81 (s, 3H), 3.79 (s, 3H), 3.71-
3.88 (m, 1H), 3.39-3.51(m, 1H), 3.44 (d, 1H, J=6.8 Hz), 1.75 (d, 3H,
J=7.2 Hz), 1.65 (m, 1H), 1.23-1.30 (m, 3H), 0.79-1.03 (m, 12H); 13C
NMR (200 MHz, CDCl3) δ 172.3, 167.7, 159.0, 142.1, 137.0, 131.6,
129.0, 114.1, 60.8, 55.2, 50.7, 41.4, 37.5, 25.0, 22.8, 21.9, 20.4, 20.2,
14.1; LC-ESI-MS: 8.3 min, [M +H]+=405.
Compound (63b): 1H NMR (400 MHz, CDCl3) δ 6.89 (q, 3J= 7.2 Hz,
1H), 5.86 (m, 1H), 5.15 (dd, 3J=17.2 Hz, 2J=2 Hz, 1H), 5.03 (dd, 3J=10.4
Hz, 2J=1.6 Hz, 1H) 3.22 (dd, 3J=14 Hz, 3J=5.2 Hz, 1H), 3.08 (d, 3J=9.2
Hz, 1H), 2.96 (dd, 2J=14 Hz, 3J=6.8 Hz, 1H), 1.92 (m, 1H), 1.75 (d,
3J=7.2 Hz, 3H), 1.46 (s, 9H), 1.07 (d, 3J=6.4 Hz, 3H), 0.74 (d, 3J=6.4
Hz, 3H); 13C NMR (200 MHz, CDCl3) δ 166.7, 138.4, 136.5, 134.3,
115.0, 80.1, 61.4, 49.7, 32.0, 28.1, 21.0, 20.1, 13.9; LC-ESI-MS: 15.0
min, [M +H]+=254; S-enantiomer [α]D= +19.5, R-enantiomer [α]D=
-20.6 (c 1 in CHCl3).
Compound (65): 1H NMR (400 MHz, CDCl3) δ 7.70 (bd, 1H, J= 8.6
Hz), 7.14 (d, 2H, J=8.0 Hz), 6.68 (m, 1H), 6.64 (d, 2H, J=8.0), 5.39 (m,
1H), 4.29 (m, 1H), 3.69 (s, 3H), 3.61 (bs, 2H), 2.51 (m, 1H), 1.99 (m,
4H), 1.67-1.88 (m, 2H), 1.46 (s, 9H), 0.92-1.03 (m, 12H); 13C NMR (200
MHz, CDCl3) δ 171.5, 163.4, 151.3, 145.0, 134.6, 130.5, 130.4, 129.2,
129.1, 114.8, 83.7, 72.9, 62.0, 51.9, 50.0, 38.7, 28.3 (3C), 27.7, 24.9,
23.2, 23.1, 21.9, 21.8, 19.4; LC-ESI-MS: 10.3 min, [M + H]+=490,
[M +Na]+=512.
Procedure for introduction of Fmoc-group on nitrogen: (66). Com-
pound 61 (1 eq), Fmoc-Cl (1 eq) and a NaHCO3 (4 eq) solution in water
(2.5 ml) were added to dioxane (1,4 ml) and the mixture was stirred at
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room temperature overnight. The reaction was quenched with water and
the crude extracted with EtOAc and purified by flash chromatography
(silica gel, 95:5=Cy:EtOAc). Yield of (S)-66: 90%. Yield of (R)-66:
89%. Isomer a: 1H NMR (400 MHz, CDCl3) δ 7.73 (d, 3J= 7.2 Hz, 2H),
7.57 (dd, 3J= 7.6 Hz, 3J= 7.6 Hz, 2H), 7.36 (dd, 3J=8.4 Hz, 3J=8.4 Hz,
2H), 7.30-7.24 (m, 2H), 6.83 (q, 3J= 7.2 Hz, 1H), 5.57 (m, 1H), 4.82
(m, 2H), 4.52 (m, 3H), 4.20 (m, 1H), 3.90 (m, 2H), 2.62 (m, 1H), 1.87
(d, 3J= 7.2 Hz, 3H), 1.45 (s, 9H), 0.82 (d, 3J= 6.4 Hz, 3H), 0.76 (d, 3J=
6.4 Hz, 3H); 13C NMR (200 MHz, CDCl3) δ 166.7, 156.8, 143.3, 142.9,
135.1, 134.6, 129.0, 127.5, 126.9, 124.9, 124.4, 118.8, 80.4, 66.8, 59.5,
47.5, 45.5, 28.0, 26.8, 20.0, 19.7, 14.5. Isomer b: 1H NMR (400 MHz,
CDCl3): δ 7.73 (d, 3J= 7.2 Hz, 2H), 7.57 (dd, 3J= 7.6 Hz, 3J= 7.6 Hz,
2H), 7.36 (dd, 3J= 8.4 Hz, 3J= 8.4 Hz, 2H), 7.30-7.24 (m, 2H), 6.62 (q,
3J= 7.2 Hz, 1H), 5.57 (m, 1H), 4.82 (m, 2H), 4.52 (m, 3H), 4.20 (m,
1H), 3.90 (m, 2H), 2.45 (m, 1H), 1.87 (d, 3J= 7.2 Hz, 3H), 1.45 (s, 9H),
0.82 (d, 3J= 6.4 Hz, 3H), 0.76 (d, 3J= 6.4 Hz, 3H); 13C NMR (200 MHz,
CDCl3) δ 166.7, 156.8, 144.2, 142.7, 135.3, 133.5, 127.3, 126.9, 124.9,
124.4, 119.8, 80.3, 66.8, 66.1, 47.4, 45.8, 28.0, 27.3, 19.8, 19.2, 14.5.
LC-ESI-MS: 19.0 min, 21.5 min [M +H]+=476, [M +Na]+=498. S-
enantiomer [α]D= +6.38, R-enantiomer [α]D= -2.71 (c 1 in CHCl3).
Procedure for the synthesis of N-malonamido derivative: (67a,b).
Methyl malonyl chloride (1.5 eq) and triethylamine (1.5 mmol, 1.5 equiv.)
were added at room temperature to a stirred solution of 61a,b (1 eq) in dry
DCM (5 mL). After stirring for 3 h, the reaction mixture was diluted with
DCM and washed with water. The organic layer was dried over Na2SO4
and the solvent was removed. Purification of the crude residue (Z/E ratio
4/1) by flash chromatography on silica gel (eluant cyclohexane/EtOAc
9:1) afforded enantiopure compounds (Z)-61a,b and (E)-61a,b. The de-
sired product was obtained in yields up to 95%.
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Compound (67a): Z-isomer: 1H NMR (400 MHz, CDCl3) δ 6.85 (q,
J= 6.8 Hz, 1H), 5.66 (m, 1H), 5.38 (d, J= 11.2 Hz, 1H), 4.85-5.10 (m,
2H), 4.39 (m, 1H), 3.94 (m, 1H), 3.65 (s, 3H), 3.48 (d, J= 15.2 Hz, 1H),
3.35 (d, J= 15.2 Hz, 1H), 2.38 (m, 1H), 1.92 (d, J = 7.4 Hz, 3H), 1.50-
1.65 (m, 5H), 1.45 (s, 9H), 1.02-1.21 (m, 5H); 13C NMR (100 MHz,
CDCl3) δ 168.4, 167.0, 166.7, 144.0, 135.0, 132.6, 15.8, 80.4, 55.7,
52.1, 46.9, 36.9, 30.2, 29.8, 28.0, 26.3, 25.8, 14.7; LC-ESI-MS: 10.3
min, [M +H]+=394; HPLC analysis (Chiralpak IA), rt 8.6 min for (R)-
Z-67a, 9.2 min for (S)-Z-67a; (S)-Z-67a [α]D= +20.4 (c 1 in CHCl3),
(R)-Z-67a [α]D= -16.5 (c 1 in CHCl3). E-isomer: 1H NMR (400 MHz,
CDCl3) δ 6.05 (q, J= 6.8 Hz, 1H), 5.64 (m, 1H), 5.32 (d, J= 11.2 Hz, 1H),
4.85-5.10 (m, 2H), 4.37 (m, 1H), 3.90 (m, 1H), 3.68 (s, 3H), 3.44 (d, J=
15.2 Hz, 1H), 3.33 (d, J= 15.2 Hz, 1H), 2.05 (m, 1H), 1.91 (d, J = 7.2 Hz,
3H), 1.50-1.65 (m, 5H), 1.46 (s, 9H), 1.02-1.21 (m, 5H); 13C NMR (100
MHz, CDCl3) δ 168.3, 167.1, 166.7, 144.0, 134.1, 132.3, 116.4, 81.1,
53.4, 45.7, 36.9, 30.2, 29.9, 28.1, 26.2, 25.8, 14.1; LC-ESI-MS: 9.7 min,
[M +H]+=394.
Compound (67b): Z-isomer: 1H NMR (400 MHz, CDCl3) δ 6.91 (q,
J= 7.2 Hz, 1H), 5.70 (m, 1H), 5.33 (d, J= 11.6 Hz, 1H), 5.13 (d, J= 10.4
Hz, 1H), 5.04 (d, J= 17.2 Hz, 1H), 4.44 (dd, J= 18.2 Hz, 2.4 Hz, 1H),
3.94 (dd, J= 18.2 Hz, 5.2 Hz, 1H), 3.74 (s, 3H), 3.53 (d, J= 15.4 Hz, 1H),
3.38 (d, J = 15.4 Hz, 1H), 2.67 (m, 1H), 1.95 (d, J = 7.4 Hz, 3H), 1.45
(s, 9H), 0.92 (d, J= 6.6 Hz, 3H), 0.81(d, J = 6.6 Hz, 3H); 13C NMR (75
MHz, CDCl3) δ 168.4, 167.0, 166.6, 143.9, 135.0, 132.9, 115.7, 80.4,
57.0, 52.1, 46.8, 41.2, 28.0, 27.8, 19.7, 14.6; LC-ESI-MS: 10.7 min,
[M + Na]+=376, [2M + Na]+=729; HPLC analysis (Chiralpak IC),
rt 33.24 min for (R)-Z-67b, 36.62 min for (S)-Z-67b; (S)-Z-67b [α]D=
-30.8 (c 1 in CHCl3), (R)-Z-67b [α]D= +26.7 (c 1 in CHCl3); E-isomer:
1H NMR (400 MHz, CDCl3) δ 6.18 (q, J= 7.2 Hz, 1H), 5.70 (m, 1H),
5.15 (d, J= 10.0 Hz, 1H), 5.13 (d, J = 10.4 Hz, 1H), 5.04 (d, J= 17.2
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Hz, 1H), 4.23 (dd, J= 18.2, 2.0 Hz, 1H), 4.02 (dd, J= 18.2, 5.0 Hz, 1H),
3.76 (s, 3H), 3.54 (d, J= 15.4 Hz, 1H), 3.44 (d, J = 15.4 Hz, 1H), 2.67
(m, 1H), 1.92 (d, J= 7.4 Hz, 3H), 1.43 (s, 9H), 0.96 (d, J= 6.6 Hz, 3H),
0.94 (d, J= 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 168.4, 167.1,
166.6, 142.7, 135.0, 133.1, 115.0, 80.2, 57.3, 52.1, 46.9, 41.0, 29.2, 27.8,
19.8, 14.3; LC-ESI-MS: 10.1 min, [M +Na]+=376, [2M +Na]+=729;
HPLC analysis (Chiralpak IC), rt 48.40 min for (R)-E-67b, 59.28 min for
(S)-E-67b.
Procedure for the synthesis of N-(1-isocyanate-2-methylbenzene)-
derivative: (68). To a solution of 61b (1 eq) in dry DCM (0.4M), 1-
isocyanato-2-methylbenzene (1 eq) was added at rt and the mixture was
stirred for 6h. After removing the solvent, the crude was purified by flash
chromatography on silica gel (cyclohexane/ethyl acetate 80:20). Z iso-
mer: 1H NMR (400 MHz, CDCl3) δ 7.68 (d, J= 7.6 Hz, 1H), 7.14 (m,
2H), 6.94 (m, 1H), 6.91 (q, J=7.6 Hz, 1H, Z isomer), 6.60 (bs, 1H), 5.87
(m, 1H), 5.27 (m, 2H), 5.21 (bd, J = 9.2 Hz, 1H), 4.50 (bd, J = 18.0 Hz,
1H), 4.00 (dd, J = 18.0, 6.0 Hz, 1H), 2.68 (m, 1H), 2.18 (s, 3H), 1.98 (d,
J = 7.6 Hz, 3H), 1.49 (s, 9H), 1.00 (d, J = 6.6 Hz, 3H),0.85 (d, J= 6.6
Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 167.1, 156.4, 142.6, 137.7,
136.3, 133.9, 130.2, 128.1, 126.5, 123.2, 122.3, 116.6, 80.5, 63.0, 58.1,
46.5, 27.9, 20.0, 19.8, 18.4,14.7; LC-ESI-MS: 14.3 min, [M+H]+=387,
[2M+Na]+=795; (S)-Z-68 [α]D= -12.9 (c 2 in CHCl3), (R)-Z-68 [α]D=
+13.1 (c 4.8 in CHCl3). E isomer: 1H NMR (400 MHz, CDCl3) δ 7.68
(d, J= 7.6 Hz, 1H), 7.14 (m, 2H), 6.94 (m, 1H), 6.11 (q, J =7.6 Hz, 1H, E
isomer), 6.60 (bs, 1H), 5.87 (m, 1H), 5.27 (m, 2H), 5.21 (bd, J = 9.2 Hz,
1H), 4.50 (bd, J = 18.0 Hz, 1H), 4.00 (dd, J = 18.0, 6.0 Hz, 1H), 2.68 (m,
1H), 2.18 (s, 3H), 1.98 (d, J = 7.6 Hz, 3H), 1.49 (s, 9H), 1.00 (d, J = 6.6
Hz, 3H), 0.85 (d, J= 6.6 Hz, 3H); LC-ESI-MS: 13.8 min, [M+H]+=387,
[2M +Na]+=795.
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General procedure for ring closing methatesis for the synthesis of
3,4-dehydro-β-pirrole: (69), (70a,b) and (71). To a solution of enan-
tiopure (66) or (67a,b) or (68) (1 eq) in MTBE (0.2M), Hoveyda-Grubbs
II generation catalyst (3 mol%) was added and the mixture was stirred
at reflux for 3 h. The reaction was then cooled to room temperature and
quenched by addition of ethyl vinyl ether. The solvent was removed and
the crude residue was purified by flash chromatography on silica gel (cy-
clohexane/EtOAc 95:5).
Compound (69): yield of (S)-69 81%, yield of (R)-69 79%. Isomer a:
1H NMR (400 MHz, CDCl3) δ 7.75 (d, 3J= 6.8 Hz, 2H), 7.62-7.53 (m,
2H), 7.38 (dd, 3J= 7.6 Hz, 3J= 6.8 Hz, 2H), 7.31 (dd, 3J= 7.6 Hz, 3J= 7.2
Hz, 2H), 6.64 (m, 1H), 4.87 (m, 1H), 4.56 (d, 3J= 5.6 Hz, 2H), 4.55-4.22
(m, 3H), 2.30 (m, 1H), 1.48 (s, 9H), 0.93 (d, 3J=6.8 Hz, 3H), 0.86 (d,
3J=6.8 Hz, 3H); 13C NMR (400 MHz, CDCl3) δ 162.5, 155.0, 144.0,
143.8, 136.8, 136.0, 127.6, 124.9, 124.7, 119.9, 81.3, 68.8, 67.0, 54.2,
47.3, 32.5, 28.0, 19.0, 18.2. Isomer b: 1H NMR (400 MHz, CDCl3) δ
7.75 (d, 3J= 6.8 Hz, 2H), 7.62-7.53 (m, 2H), 7.38 (dd, 3J= 7.6 Hz, 3J=
6.8 Hz, 2H), 7.31 (dd, 3J= 7.6 Hz, 3J= 7.2 Hz, 2H), 6.64 (m, 1H), 4.87
(m, 1H), 4.56 (d, 3J= 5.6 Hz, 2H), 4.55-4.22 (m, 3H), 1.89 (m, 1H), 1.48
(s, 9H), 0.73 (d, 3J= 6.8 Hz, 3H), 0.65 (d, 3J= 6.8 Hz, 3H); 13C NMR
(400 MHz, CDCl3) δ 162.5, 154.8, 144.0, 143,8, 136.2, 135.6, 127.0,
124.9, 124.6, 119.9, 81.1, 68.4, 66.7, 53.9, 47.3, 32.2, 28.0, 17.8, 17.6.
LC-ESI-MS: 15.6 min, [M +H]+=434. (S)-Z-69 [α]D= -17.7, (R)-Z-69
[α]D= +26.5 (c 1 in CHCl3)
Compound (70a): 70/30 trans/cis amide ratio. Trans conformer: 1H
NMR (400 MHz, CDCl3) δ 6.64 (bm, 1H), 4.99 (bm, 1H), 4.28 (dd,
J 16.2, 1.8 Hz, 1H), 4.19 (ddd, J= 16.2, 1.6 4.4 Hz, 1H), 3.68 (s, 3H),
3.34 (s, 2H), 1.95 (m, 1H), 1.54-1.71 (m, 5H), 1.41 (s, 9H), 0.88-1.18
(m, 5H); 13C NMR (100 MHz, CDCl3) δ 167.6, 164.1, 162.3, 137.2,
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133.8, 81.2, 67.3, 54.5, 52.2, 42.0, 41.9, 29.2, 28.5, 27.8, 26.2. Cis
conformer: 1H NMR (400 MHz, CDCl3) δ 6.76 (bm, 1H), 4.64 (bm,
1H), 4.53 (dd, J= 18.8, 2.8 Hz, 1H), 4.01 (ddd, J= 18.8, 1.6, 4.0 Hz,
1H), 3.69 (s, 3H), 3.44 (d, J= 15.2 Hz, 1H), 3.41 (d, J= 15.2 Hz, 1H),
1.95 (m, 1H), 1.54-1.71 (m, 5H), 1.41 (s, 9H), 0.88-1.18 (m, 5H); 13C
NMR (100 MHz, CDCl3) δ 167.6, 165.1, 162.3, 136.2, 135.6, 81.4,
67.9, 54.2, 53.7, 44.7, 40.7, 29.0, 28.3, 26.4, 26.1. LC-ESI-MS: 9.74
min, [M + H]+=352, [M + Na]+=374, [2M + Na]+=725. (S)-70a
[α]D= -39.7, (R)-70a [α]D= +37.6 (c 1 in CHCl3)
Compound (70b): 70/30 trans/cis amide ratio. Trans conformer: 1H
NMR (400 MHz, CDCl3) δ 6.64 (bm, 1H), 5.12 (m, 1H), 4.35 (dd, J=
16.6, 2.4 Hz, 1H), 4.27 (ddd, J= 16.6, 2.0, 4.4 Hz, 1H), 3.75 (s, 3H),
3.41 (s, 2H), 2.41 (m, 1H), 1.50 (s, 9H), 0.92 (d, J= 7.0 Hz, 3H), 0.91 (d,
J= 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 167.7, 164.3, 162.5,
136.7, 134.1, 81.6, 68.0, 54.6, 52.5, 42.2, 31.8, 28.0, 18.4, 18.3. Cis
conformer: 1H NMR (400 MHz, CDCl3) δ 6.76 (bm, 1H), 4.77 (m,
1H), 4.60 (dd, J= 18.8, 2.8 Hz, 1H), 4.08 (ddd, J= 18.8, 1.6, 3.0 Hz,
1H), 3.76 (s, 3H), 3.51 (d, J= 15.0 Hz, 1H), 3.45 (d, J= 15.0 Hz, 1H),
2.14 (m, 1H), 1.51 (s, 9H), 0.96 (d, J = 6.6 Hz, 3H), 0.92 (d, J= 6.6 Hz,
3H); 13C NMR (100 MHz, CDCl3) δ 167.5, 164.8, 162.5, 137.3, 134.9,
81.5, 68.4, 53.8, 52.5,40.8, 34.5, 28.0, 18.7, 17.5. LC-ESI-MS: 8.25 min,
[M + H]+=312, [M + Na]+=334, [2M + Na]+=645. (S)-70b [α]D=
+34.9, (R)-70b [α]D= -28.7 (c 1 in CHCl3).
Compound (71): 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 7.2, 1H),
7.17 (m, 2H), 6.99 (dt, J= 7.6, 1.2 Hz, 1H), 6.71 (m, 1H), 5.60 (bs, 1H),
4.95 (bm, 1H), 4.50 (dd, J= 15.2, 1.6 Hz, 1H), 4.17 (ddd, J = 15.2, 5.2,
1.6 Hz, 1H), 2.33 (m, 1H), 2.25 (s, 3H), 1.49 (s, 9H), 1.00 (d, J= 7.2 Hz,
3H), 0.92 (d, J = 7.2 Hz, 3H); 13C NMR (50 MHz, CDCl3) δ 162.5,
154.5, 136.8, 135.7, 130.3, 128.4, 126.7, 123.9, 122.6, 119.8, 81.3, 68.1,
54.2, 32.8, 28.0, 19.2, 17.9, 17.7; LC-ESI-MS: 10.5 min, [M+H]+=345,
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[2M + Na]+=711. (S)-71 [α]D= -6.0 (c 0.5 in CHCl3), (R)-71 [α]D=
+6.8 (c 1 in CHCl3).
General procedure for the hydrolysis of tert-butyl ester: (72),
(73a,b) and (74). Ester 69, 70a,b or 71 (1 eq) was dissolved in DCM
(0.1M) and TFA (15 eq) was added at 0 Â◦C. The mixture was stirred
at room temperature overnight and then evaporated under vacuum. The
product was used without further purifications.
Compound (72): yield of (S)-72 99%, yield of (R)-72 99%. Isomer a:
1H NMR (400 MHz, CDCl3) δ 7.76 (d, 3J= 7.6 Hz, 2H), 7.76-7.56 (m,
2H), 7.39 (dd, 3J= 7.2 Hz, 3J= 7.2 Hz, 2H), 7.32 (dd, 3J= 6.8 Hz, 3J=
6.8 Hz, 2H), 6.92 (m, 1H), 4.66 (d, 3J= 5.2 Hz, 1H), 4.56 (m, 1H), 4.43
(m, 1H), 4.33-4.20 (m, 2H), 4.09 (dd, 2J= 18.8 Hz, 3J= 4.8 Hz, 1H), 2.30
(m, 1H), 0.94 (d, 3J= 6.8 Hz, 3H), 0.84 (d, 3J= 6.8 Hz, 3H); 13C NMR
(400 MHz, CDCl3) δ 168.7, 156.1, 143.3, 141.4, 140.8, 133.2, 127.8,
127.1, 124.7, 120.0, 68.2, 67.8, 54.5, 47.1, 32.1, 18.9, 17.7. Isomer b:
1H NMR (400 MHz, CDCl3) δ 7.76 (d, 3J= 7.6 Hz, 2H), 7.76-7.56 (m,
2H), 7.39 (dd, 3J= 7.2 Hz, 3J= 7.2 Hz, 2H), 7.32 (dd, 3J= 6.8 Hz, 3J= 6.8
Hz, 2H), 6.92 (m, 1H), 4.66 (d, 3J= 5.2 Hz, 1H), 4.56 (m, 1H), 4.43 (m,
1H), 4.33-4.20 (m, 2H), 4.09 (dd, 2J= 18.8 Hz, 3J= 4.8 Hz, 1H), 1.87 (m,
1H), 0.70 (d, 3J= 6.8 Hz, 3H), 0.62 (d, 3J= 6.8 Hz, 3H). 13C NMR (400
MHz, CDCl3) δ 168.7, 156.1, 143.1, 141.3, 140.5, 133.2, 127.8, 127.1,
124.6, 120.0, 68.2, 67.7, 54.2, 47.1, 32.1, 18.9, 17.7. LC(acid)-ESI-MS:
10.0 min, [M + H]+=378. (S)-72 [α]D= -22.22, (R)-72 [α]D= +22.46
(c 1 in CHCl3).
Compound (73a): (70:30 trans/cis amide ratio). Trans conformer: 1H
NMR (400 MHz, CD3OD) δ 6.80 (m, 1H), 5.05 (m, 1H), 4.52 (bdd, J=
20.0 Hz, 8.8Hz, 1H), 4.35 (bdd, J= 20.0 Hz, 4.4 Hz, 1H), 3.73 (s, 3H),
3.45 (s, 2H), 1.40-1.55 (m,6H), 0.80-0.91 (m, 5H); 13C NMR (100 MHz,
CD3OD) δ 167.6, 167.5, 166.5, 137.9, 134.7, 68.0, 55.3, 52.9, 42.2,
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41.4, 29.7, 28.7, 26.3. Cis conformer: 1H NMR (400 MHz, CD3OD)
δ 6.90 (m, 1H), 4.93 (m, 1H), 4.65 (bd, J= 14.0 Hz, 1H), 4.10 (bd, J=
14.0 Hz, 1H), 3.73 (s, 3H), 3.47 (s, 2H), 1.40-1.55 (m,6H), 0.80-0.91
(m, 5H); 13C NMR (100 MHz, CD3OD) δ 167.6, 167.5, 167.3, 140.5,
133.3, 68.4, 54.6, 53.0, 44.6, 40.3, 29.7, 27.5, 26.1. LC-ESI-MS: 8.7
min, [M +H]+=296. (S)-73a [α]D= +33.9, (R)-73a [α]D= -30.3(c 1 in
MeOH).
Compound (73b): (70:30 trans/cis amide ratio). Trans conformer: 1H
NMR (400 MHz, CD3OD) δ 6.8 (m, 1H), 5.05 (bs, 1H), 4.52 (dd, J=
18.5 Hz, 8.8Hz, 1H), 4.35 (dd, J= 18.5 Hz, 4.4 Hz, 1H), 3.73 (s, 3H),
3.42 (s, 2H), 2.35 (m, 1H), 0.92 (d, J= 7.2 Hz, 3H), 0.90 (d, J= 7.2 Hz,
3H); 13C NMR (100 MHz, CD3OD) δ 171.2, 164.8, 162.4, 135.9, 134.3,
68.8, 53.2, 52.7, 42.2, 31.4, 18.5, 17.8. Cis conformer: 1H NMR (400
MHz, CD3OD) δ 6.90 (m, 1H), 4.93 (bs, 1H), 4.68 (dd, J= 14.0, 2.8 Hz,
1H), 4.10 (bd, J= 14.0 Hz, 1H), 3.72 (s, 3H), 3.48 (d, J= 15.0 Hz, 1H),
3.42(d, J= 15.0 Hz, 1H), 2.22 (m, 1H), 0.98 (d, J= 7.2 Hz, 3H), 0.92 (d,
J= 7.2 Hz, 3H); 13C NMR (100 MHz, CD3OD) δ 171.3, 164.8, 162.4,
137.2, 134.1, 68.1, 53.9, 52.5, 41.6, 34.1, 18.9,17.2. LC-ESI-MS: 5.2
min, [M +H]+=256, [M +Na]+=278. (S)-73b [α]D= +19.5, (R)-73b
[α]D= -26.1 (c 1 in MeOH).
3.5 Notes and references
The spectroscopic data and the synthetic procedures have been adapted
from Ref.[38], [45], [48] and [76], with the proper licenses. See Ap-
pendix.
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Applications of isoxazolidin-5-ones and
dehydro-β-prolines in the synthesis of Linezolid-like
antibiotics and evaluation of the complex balance with
MAO-inhibitory properties.
4.1 Introduction
Among the different tools in the hands of moderne medicine, antibi-
otics are surely the most useful chemotherapeutic ones. The effectiveness
of any kind of chemotherapeutic is due to the complex balance that exists
between the biological efficacy and the developement of tolerance or re-
sistance, in the worst case, during the first uses of that drug. This happens
for antifungal and antiviral treatments but also for anticancer, antidiabete
and antibiotic agents. As regards antimicrobial agents, the diffusion of
resistance is the focus of many public health programs since the diffusion
of bacterias and the development of their straight is a complex matter dif-
ficult to contain. In fact, it is not only a problem for patients already in-
fected and affected by cronic pathologies: they require continuous treat-
ments that can justify the necessity to change the proper drug during the
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life in order to maximize the efficacy. It is also a problem that involves
all the community as consequence of the high possibility of diffusion
of bacterial strains in nosocomial and hospitals, of course in contests of
every day life too [78]. The benefits related to the introduction, in the
beginnig 20th century, of antibiotics were later accompanied to the ap-
perance of several examples of resistance related to more than 400 types
of genic modifications on more than 20000 potential resistance genes,
even if only limited number of them has been really observed [79]. With
the term antibiotic you can refer to all those compounds able to inhibit
or kill bacterias through spercific interaction with a target: for this rea-
son natural and synthetic compounds with this application can be defined
antibiotics. Without any doubt, the discovery of antibiotics can be consi-
dered an unparagonable relevant healt-related event of the last 150 years,
not only for their strictly applications. In fact, there are many examples
of antibiotics employed for other biological purposes like antiviral and
anticancer treatment. Sometimes, the parallel effect is bigger than the
antibiotic one, so they are used as drugs for cardiovascular diseases and
immunosuppressive agents [80]. On the base of these considerations, the
research of new antibiotics selectively active against resistant bacteria is
a deeply studied field of medicinal chemistry.
4.1.1 Antibiotic resistance
Bacteria are probably the oldest living species of the earth and for
this reason, in all this time, they have been attacked with a lot of sub-
stances with the aim to kill them. So they became able to develop re-
sistance mechanisms that explain the behaviour of the most widely em-
ployed antibiotics of the last 50 years. Of course, the increasingly re-
sistance of actual antibiotics became a bigger problem if it is consi-
dered together with the apperance of multidrug resistance forms. The
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multidrug-resistant ESKAPE organisms (Enterococcus spp., Staphylo-
coccus aureus, Klebsiella spp., Acinetobacter baumannii, Pseudomonas
aeruginosa, Enterobacter spp.), also known as "‘nosocomial bacteria"’
or "‘superbugs"’, are causes of chronic infections like menigitis, respira-
tory tract infections, urogenital tract diseases and skin infections. If the
role of antibiotic is to block or shut down a particular function of bacte-
rial cells, the resistance mechanism occurs through a proper strategy to
prevent the fitting of the drug to a target. Between the most clinically
relevant mechanism of resistance three of them received particular at-
tention, since they are related to the use of very common antibiotics:
the first regards the inactivation of a drug through destruction of the
pharmacophore, as it happens for β-lactamic antibiotics destroyed under
the action of β-lactamase; the second concerns target modifications, like
for the mutation of 30S ribosomal protein RpsL when stremptomycin is
used; the third regards changes in penetration or efflux of the drug, like
it happens for Linezolid through a specific multidrug pump [81] (Fig-
ure 4.1). While in the 70s the major problem came from Gram-negative
bacteria, starting from 80s Gram-positive bacteria became the protago-
nists, with Methicillin-resistant Staphylococci, Penicillin-resistant Pneu-
mococci and Vancomycin-resistant Enterococci [82]; so, several classes
of antibiotic agents have been introduced in the last years. As regard
bacteria resistant to Vancomycin, Teicoplanin, new antibiotic belonging
to the family of glycopeptide like Vancomycin, was introduced for infec-
tions due to Gram-positive bacteria. Another approach was the chemical
modifications of the two components of Streptogramin (quinupristin and
dalfopristin) to generate the new Pristinamycin approved for the infec-
tions induced by vancomycin-resistant Enterococcus faecium. Dapto-
mycin, antibiotic of the family of lipopetide, was used since 2003 for
skin infections of Gram-positive bacteria resistant to Vancomycin, Me-
thicillin and Linezolid [83]. Among the most recent classes of antibi-
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Figure 4.1: Antibiotic resistance mechanisms.
otics, oxazolidinones are largely employed against "‘smartly"’ modified
Gram-positive bacteria.
4.1.2 Oxazolidinones: at the edge of antibiotic activity and anti-depressive
role.
Linezolid, commercially available with name Zyvox R©, became the
reference compound of the family of oxazolidinones since its approval
by FDA in 2000. It is active against Vancomycin-resistant Enterococci
(VRE), Methicillin-resistant Staphylococcus aureus (MRSA) and Penicillin-
resistant Staphylococcus pneumoniae (PNSSP) [84][85]. Its structure
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was introduced together with that of Eperezolid (Figure 4.2) that has
almost the same preclinical parameters of Linezolid including solubil-
ity, antimicrobial potency and multiple dose toxicity studies. However,
Linezolid showed better oral bio-availability. Although these similari-
ties and their similar behavior in clinical phase I, at phase II, Linezolid
was selected since it was effective with less doses per day. Like other
Figure 4.2: Antibiotic resistance mechanisms.
oxazolidinone antibiotics precursors of Linezolid, its mechanism of ac-
tion regards the binding to peptidyltransferase center (PTC), correspond-
ing to 50S subunit of prokaryotic ribosome, to avoid the formation of a
complex between 30S subunit, formylmethionyl-tRNA and mRNA inhi-
bition factors, that is the base for the assembly of an initiation complex
for protein synthesis (Figure 4.3). Since it blocks the formation of new
virulent factors in a preliminary stage, its mechanism is completely diffe-
rent from those of other inhibitors of protein synthesis [86][87][88]. The
structure of Linezolid is made up by four chemical moieties that are the
reason for a correct interaction with the binding site (Figure 4.4). Ring-
A, that means the oxazolidinone ring, is the pharmacophore and interacts
with specific residues of the PTC pocket through van der Waals inter-
actions. The acetamide NH on the tail is involved in an hydrogen bond
with the phosphate group on a residue in the upper part of the pocket.
Ring B, the aromatic one, is in the middle of two pi-stacking and gives
99
CHAPTER 4. APPLICATIONS OF ISOXAZOLIDIN-5-ONES AND DEHYDRO-β-PROLINES IN
THE SYNTHESIS OF LINEZOLID-LIKE ANTIBIOTICS AND EVALUATION OF THE COMPLEX
BALANCE WITH MAO-INHIBITORY PROPERTIES.
Figure 4.3: Linezolid mechanism of action.
a T-shaped interaction while the C2 fluorine points out of the pocket,
contributing in a coordination with a putative magnesium ion that ap-
pears out of the pocket when the binding site is occupied with a ligand
in a particular configuration, like that assumed by Linezolid. The mor-
pholine Ring-C is not directly involved in particular interactions but it
is important for the stabilization of pharmacokinetic aspects [89][90].
Despite all these favorable features, there are several cases of resistance
Figure 4.4: Structure of Linezolid divided in relevant moieties.
to Linezolid in patients affected by bacterial infections treated with this
drug, but also in people never treated with this therapy, as consequence of
horizontal diffusion of strong bacterial strains in nosocomial units [91].
Considering their efficacy and the possibility to introduce modifications
to reduce unwanted resistance, oxazolidinones were deeply studied in
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structure-activity relationship (SAR) to identify good bioisoster of each
part of the molecule. The studies were focused mainly on Ring-A and
they showed that bioisosteric modifications should keep an sp2 center
linked to Ring-B, an oxygen atom properly located and stereodefined
C5 linked to acylaminomethyl chain [92]. These requirements are in
agreement with the results obtained when oxazolidinone was substituted
by dihydrofuran-2-one a, tetrahydrofuran-2-one b, pyrrolidin-2-one c,
3-phenylisoxazoline d, 3-phenylisoxazolidinone e and 1,2,4-oxadiazole
f. Microbiological tests, reported as Minimum Inhibitory Concentration
(MIC) tests, show that the removal of one or more of the abovemen-
tioned requirements gives gradual reduction of antibiotic activity (Figure
4.5) [93][94][95][96]. Changes in Ring-B don’t affect significantly the
Figure 4.5: Bioisosteres of Ring-A.
activity, but changes in Ring-C have been widely studied and they regard
mainly four conceptual framework: the fusion of Ring-B and C, intro-
duction of a spacer between Ring-B and Ring-C, appendage of stabiliz-
ing moieties on Rign-C and introduction of new Ring-C [95][96][97].
In particular, reminding that the principal metabolites of Linezolid are
produced during the lactone or lactame pathway and they regard the oxi-
dation of morpholine ring [98][99][100], the morpholine has been substi-
tuted by piperazine and its derivatives, as reported for Eperezolid and its
analogues. Since Linezolid derivatives have C5 aminomethyl functiona-
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lized tail (as amide, urea and thiourea), the resulting structures are similar
to another class of chemotherapeutics inhibitors of monoamino oxidase
(MAOs): Blefoxatone and Toloxatone (Figure 4.6) are active against
them both the human isoforms of MAO (indicated as MAO-A and MAO-
B). These enzymes are responsible for the metabolism of monoamino
neurotrasmitters [101], so inhibition of them results in an increased level
of neurotransmitters like serotonin, norepinephrine and dopamine and
consequent reduction of depressive pathologies and Parkinson deseases
associated to low levels of these neurotransmitters. They oxidize amines
Figure 4.6: Structures of Blefoxatone and Toloxatone.
to imines through reduction of FAD cofactor of MAO, then reoxidized
(Figure 4.7). If the ligand present close to FAD is a MAO-inhibitor, the
reduction of FAD goes through an anionic semiquinone intermediate to
the fully reduced form and no reoxidation of FAD is observed; if the
ligand is not an inhibitor, only the fully reduced form can be detected
[102]. Linezolid shows reversible MAO-A and MAO-B inhibition [103].
Modifications in the tail carrying "‘reverse amide"’ were introduced in
Linezolid analogues and reduced MAO activity and myelotoxicity were
observed: these side effects normally appear with long treatments with
Linezolid [104]. SAR studies revealed that the lipophilicity of oxazolidi-
nones can influence the binding properties since the aromatic ring linked
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Figure 4.7: General mechanism of action of FAD cofactor.
to nitrogen (or oxygen or sulphur) finds a long and deep hydrophobic
cavity in which two tyrosines are aligned with their amine near to N5 of
flavin which activate the catalysis [105].
4.2 Results and discussions
With these information in our hand, we designed and synthetized
anologues of Linezolid evaluating at the same time the antibiotic pro-
perties and the effects as inhibitors of MAOs. So we proceeded step
by step, changing initially the Ring-A by introducing a racemic isoster
of oxazolidinone, isoxazolidin-5-one, or 3,4-dehydro-β-proline, whose
synthesis was partially described in Chapter 3. With the first, we kept
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two of the required features previously described, that is to say the sp2
center linked to aromatic ring and the oxygen atom, while the second
ring is a bolder choice since only the sp2 center is kept. In them both the
cases, we introduced (i) substitutions in CαN to evaluate if they influence
the biological data and (ii) reverse N-ethyl amide in CβN. The Ring-B
was linked to the nitrogen through peptidic bond, keeping the fluorine in
the usual position, while Ring-C in some cases was substituted by piper-
azine or functionalized piperazine. The synthesis, biological evaluation
and computational studies on the library will be described in more details
as follow.
4.2.1 Molecular design and synthesis
The Ring-A was substituted with isoxazolidin-5-one 56a,b and 3,4-
dehydro-β-proline (R)-72b/(S)-72b, whose synthesis was already shown.
The desidered cyclic synthons were further functionalized to obtain the
proper modifications. In particular 72b enantiomers were coupled with
ethyl amine e deprotected from the Fmoc-protecting group to obtain the
designed isosteres of Ring-A (R)-76b and (S)-76b , in which the origi-
nal tail of Linezolid has been substituted with an analogue reverse amide
(Figure 4.8). To optimize the synthesis we proceeded with a convergent
Figure 4.8: Synthesis of functionalized 3,4-dehydro-β-pirrole ring.
approach, preparing on one hand the couple Ring-A & Tail and on the
other the couple Ring-B & Ring-C. While for the first, linear synthesis
should have been chosen, for the second we proceeded by divergent syn-
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thesis. The starting material was 3,4-difluorobenzoic acid protected as
methyl ester by using SOCl2 and methanol to obtain 77 with 63% yield:
the fluorine-aromatic block represents the Ring-B that will be functio-
nalized with Ring-C through the second fluorine atom in position 4. Via
Figure 4.9: Synthesis of Ring-B & Ring-C couple.
nucleophilic substitution we introduced, by K2HPO4 in DMSO, morpho-
line or piperazine obtaining intermediate 78 and 80 with yield of 89-99%.
Furthermore, the N-piperazine was functionalized with Boc-group in one
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case, obtaining 81 in quantitative yield, and with N-Boc-Gly in the other,
by using COMU and DIPEA obtaining 83 in quantitative yield. The three
methyl esters 78, 81 and 83 were hydrolized at room temperature with
LiOH.H2O in a 2:1 mixture of THF:H2O, with yields between 67% and
99% (Figure 4.9). Once the two blocks were synthesized, they were cou-
Figure 4.10: Synthesis of isoxazolidin-5-one and 3,4-dehydro-β-pirrole derivatives.
pled converting in situ the acids 79, 82 and 84 in the corresponding chlo-
ride with thionyl chloride and pyridine: after removing the protective
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group with trifluoroacetic acid the final products 85a,b, 87b, (S)-88b,
(R)-88b, (S)-90b, (R)-90b, (S)-92b and (R)-92b were obtained (Figure
4.10). Their stability in DMSO was studied by 24h monitoring by HPLC
but no by-products were observed.
4.2.2 Evaluation of antibiotic activity and MAO inhibition
The antibiotic activity has been evaluated on MRSA and MSSA strains
but a preliminary screening on commercial bacterial strains showed un-
satisfactory results. Only four selected compounds were further explored
and, for this reason, were tested on clinical strains of S. aureus from pa-
tients affected by cystic fibrosis. The activities have been reported as
MIC values (Table 4.1) and showed modest antibiotic activity only for
compound 85a (MIC=32-64 µg/ml).
Table 4.1: Antimicrobial activities of tested compounds.
MIC MIC-range MIC50 MIC90
(µ/ml) (µ/ml) (µ/ml)
Strains S. aureus E. faecalis 12 S. aureus isolates
ATCC 29213 ATCC 29212
Compound
85a >128 >128 32->128 64 >128
85b >128 >128 >128 >128 >128
(R)-88b >128 >128 >128 >128 >128
(S)-88b >128 >128 >128 >128 >128
Linezolid 4 2 1-4 2 2
Considering the weak antibiotic activity compared to that of Linezolid
(LZD), they were tested in their potential MAO inhibitory activity to-
gether to their citotoxicity. For in vitro tests, HepG2 cells from human
hepatocytoma were chosen since this efficient proliferative cell line ex-
press the both MAO-A and MAO-B [106][107]. Cell viability tests were
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performed to define the dose of compound that should be employed to
determine the effects on MAO activity of HepG2: increasing concen-
tration, from 10 to 100 µg/ml, of 85a, 85b, (R)-88b and (S)-88b were
administrated to the cells for 24h. If none compound induce mortality at
10 µg/ml concentration, with a ten-times increasing concentration a de-
crease in cell viability of 10% with 85a, 85b and (R)-88b and 20% with
(S)-88b were observed. Compounds 85a, 85b and (S)-88b showed sig-
nificative inhibitory effect of 25% at 10 µg/ml, so increasing the the drug
concentration of ten times 45% of inhibitory effect was reached. On the
contrary, the same concentration of Linezolid induces weak enzymatic
inhibition (15%), as reported in literature [99].
4.2.3 SAR studies
The substitution with the two isosteres isoxazolidin-5-one and 3,4-
dehydro-β-proline led to a loss of antibacterial activity. By prediction of
log PKow (see section 4.5) is possible to rationalize the biological trend
observed. All the compounds containing the isoxazolidinone ring have
hydrophilic behaviour in contrast with those containing 3,4-dehydro-β-
pirrole ring that have more lipophilic nature. As regard the first family of
compounds, while diisopropyl group does not affect the hydrophilicity of
the molecules, the cyclohexyl group gives enhancement of lipophilicity,
confermed by higher log PKow values. For the second family of com-
pouds, the modulation of the lipophilicity depends on the substitution on
Ring-C: going from morpholine to Gly-piperazine through piperazine,
the log PKow values go toward those associated to a more hydrophilic
character. Furthermore, as reported in Table 4.2 compound 85a has log
PKow value near to that of Linezolid, confirming that changes in hy-
drophilicity/lipophilicity detected in the other compounds affect signifi-
cantly the interaction with the binding site.
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Figure 4.11: A) Cell viability of 85a, 85b, (R)-88b, (S)-88b and Linezolid in HepG2 cells. B) MAO
activity of 85a, 85b, (R)-88b, (S)-88b and Linezolid in HepG2 cells.
4.2.4 Docking experiments
To understand the binding poses of the new compounds, docking stu-
dies were performed into the active site of human monoamine oxidase
isoforms A (MAO-A) and B (MAO-B). Their crystal structures were re-
treived from the Protein Data Bank (PDB codes: 2Z5X [108][109] and
2V5Z [110][111], respectively) and processed using Schrödinger Pro-
tein Preparation Wizard [112]. A library of compounds was built includ-
ing the four possible stereoisomers of 85a and 85b ((R,R)-85a,b, (R,S)-
85a,b, (S,R)-85a,b and (S,S)-85a,b), the two enantiomers (R)-88b and
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Table 4.2: Prediction of log PKow .
Compound log PKow
85a 1.10
85b -0.26
87b∗ -0.50
(S)-88b 1.72
(S)-90b 1.48
(S)-92b 0.10
Linezolid 1.26
∗log PKow calculated for the
neutral form.
(S)-88b and (S)-Linezolid as reference compound. The optimization of
the library was performed with AutoDock Vina [113] by molecular me-
chanic and docking. The free energy of binding calculated for MAO-A
are lower for all the compounds with respect to (S)-Linezolid and only
(R,R)-85a,b, (R)-88b and (S)-88b showed negative values (Table 4.3).
Table 4.3: Docking scores on MAO-Aa for (R,R)-85a,b, 88b and Linezolid.
Compound Free energy binding
(kcal/mol)
S-Linezolid -6.2
S-88b b -2.0
RR-85a -1.7
RR-85b -0.3
R-88b b -0.2
(S)-88b and (S)-Linezolid direct the morpholine ring toward the MAO-
A aromatic cage (made up by FAD, TYR-407 and TYR-444), but only
(S)-88b penetrates deeply in the binding site to accomadate the bulky
isopropyl group in the space occupied by oxazolidinone for (S)-Linezolid
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(Figure 4.12). The tail amide gives only one hydrogen bond with VAL-
210 as regard (S)-Linezolid, as well the central C=O of (S)-88b with
THR-336.
Figure 4.12: Best docking pose of (S)-Linezolid (cyan carbon atoms) superimposed to the best docking
pose of (S)-88b (orange carbon atoms) in the active site of MAO-A. Residues of the binding site are
represented with green carbon atoms and FAD as CPK.
Similar binding pose was found for (R)-88b, that fits in the deeper
part of the cage as consequence of two possible spatial disposition of
isopropyl group (Figure 4.13). In the same way, the tail amide gives only
an hydrogen bond with PHE-208. The compounds (R,R)-85a,b show
two superimposable docking poses, completely different to one of (S)-
Linezolid (Figure 4.14). In fact, the aromatic cage of MAO-A is occupied
by N-ethyl amide tail of the two compounds, while the morpholine ring is
at the cavity entrance, interacting with VAL-93, LEU-97 and THR-211.
Better result were obtained by docking compounds 85a,b and 88b
into MAO-B, as shown by the free energy values reported in Table 4.4.
All compounds show a second isoenergetic binding pose that differs
only for the relative disposition of Ring-B; with the exception of (R,R)-
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Figure 4.13: Best docking pose of (S)-88b (orange carbon atoms) superimposed to the best docking
pose of (R)-88b (purple carbon atoms) in the active site of MAO-A. Residues of the binding site are
represented with green carbon atoms and FAD as CPK.
85a two distinct binding poses with very similar energies were located:
the first (A) has the morpholine ring oriented toward the aromatic cage
formed by TYR-398 and TYR-435, the second (B) has the tail oriented
toward the same space.
Table 4.4: Docking scores on MAO-B for (R,R)-85a,b, 88b and Linezolid.
Compound Free energy binding
(kcal/mol)
S-Linezolid -7.4 (A), -7.6 (B)
S-88b b -4.1 (A), -3.6 (B)
RR-85b -7.2 (A), -6.8 (B)
SR-85b -6.5 (A), -6.7 (B)
RR-85a -4.5 (A)
R-88b -8.4 (A), -8.9 (B)
The morpholine ring and the aromatic one of the best poses of (R)-88b
and Linezolid are almost superimposed and located in the region between
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Figure 4.14: Best docking pose of (R,R)-85b (orange carbon atoms) superimposed to the best docking
pose of (R,R)-85a (purple carbon atoms) in the active site of MAO-A. Residues of the binding site are
represented with green carbon atoms and FAD as CPK.
the entrance of the cavity and the substrate cavity defined by ILE-199;
the aromatic cage contains, instead, the tail amide with residues TYR-
398 and TYR-435 (Figure 4.15).
The docking pose is stabilized by four hydrogen bond for (R)-88b: (i)
between NH of the tail and GLN-206, (ii) between the C=O of the tail and
TYR-435 and CYS-172, (iii) between the central C=O and TYR-326. As
regard Linezolid, two stabilizing hydrogen bonds were found, between
NH of the tail and TYR-398 and between C=O of oxazolidinone and ILE-
198. The enantiomer (S)-88b has different orientation with respect to its
enantiomer R, since it orients the morpholine ring toward the aromatic
cage of MAO-B and the amide tail toward the entrance of cavity (Figure
4.16). The central amide C=O is involved in the single hydrogen bond
with ILE-199.
As regard the binding poses of (R,R)-85b and (S,R)-85b, they dif-
fer only for the configuration of isopropyl substituted carbon (Figure
4.17 and 4.18). For (R,R)-85b, in pose A, three hydrogen bonds involve
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Figure 4.15: Best docking pose of (S)-Linezolid (pose B, cyan carbon atoms) superimposed to the best
docking pose of (R)-88b (pose B, orange carbon atoms) in the active site of MAO-B. Residues of the
binding site are represented with green carbon atoms and FAD as CPK.
the isoxazolidinone carbonyl and the tail amide C=O with, respectively,
TYR-326 and ILE-199 and with PRO-102. For pose B, the three H-
bonds are formed with tail NH, tail amide C=O and central amide C=O
with, respectively, GLN-206, LEU-171 and TYR-326. (S,R)-85b gives
two H-bond interaction only in pose A, involving central amide C=O and
TYR-326 and the isoxazolidinone carbonyl with PHE-168 (Figure 4.18).
Finally, for (R,R)-85a only one docking pose was found and it was su-
perimposed with that of (R,R)-85b: they are perfectly superimposed with
the cyclohexyl placed between LEU-167, ILE-316 and LEU-164 (Figure
4.19). Furthermore, it gives the same network of hydrogen bonds of
(R,R)-85b.
This results suggest a good selectivity of the new compounds for
MAO-B.
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Figure 4.16: Best docking pose of (R)-88b (pose B, orange carbon atoms) superimposed to the best
docking pose of (S)-88b (pose B, purple carbon atoms) in the active site of MAO-B. Residues of the
binding site are represented with green carbon atoms and FAD as CPK.
4.3 Conclusions
In the research of new oxazolidinone based compounds is important
to keep in mind the balance between antibiotic activity and MAO inhi-
bition. We reported the synthesis of oxazolidinone antibiotic analogues
based on isoxazolidin-5-one and 3,4-dehydro-β-proline as bioisosteres
of oxazolidinone. The library, that showed weak antibiotic activity against
S. aureus strains confirming the hypothesis that structural modifications
on the molecule backbone of oxazolidinone Linezolid affected the antibi-
otic activity, was tested to evaluate the effect as inhibitor of monoamino
oxidase: we surprisingly found good results, confirmed by docking ex-
periments.
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Figure 4.17: Best docking poses of (R,R)-85b (pose A, orange carbon atoms; pose B, purple carbon
atoms) superimposed in the active site of MAO-B. Residues of the binding site are represented with
green carbon atoms and FAD as CPK.
Figure 4.18: Best docking poses of (S,R)-85b (pose B, orange carbon atoms; pose A, purple carbon
atoms) superimposed in the active site of MAO-B. Residues of the binding site are represented with
green carbon atoms and FAD as CPK.
4.4 Experimental procedures
4.4.1 General methods
All chemicals were purchased from commercial suppliers and were
used without furhter purification. Microwave-assisted reaction were car-
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Figure 4.19: Best docking poses of (R,R)-85a (orange carbon atoms) superimposed to the best docking
pose of (R,R)-85b (pose A, purple carbon atoms) in the active site of MAO-B. Residues of the binding
site are represented with green carbon atoms and FAD as CPK.
ried out in Milestone Mycrosynth apparatus, with a dual magnetron sys-
tem with a pyramid-shaped diffuser, 1000 W maximum power output,
and temperature monitor and control by optical fiber up to a vessel tem-
perature of 250 oC. Flash chromatography was carried out on silica gel
(230-400 mesh). Dowex R©50WX2-200(H) ion exchange resin was used
for purification of free amino acids or free amines. NMR spectra were
recorded with a Varian Mercury Plus 400 or Varian Gemini 200 instru-
ments. Chemical shifts are reported as δ values (ppm), and were cali-
brated using the residual solvent peaks of: CDCl3, set a delta = 7.27 ppm
(1H NMR) or δ = 77.0 ppm (13C NMR); CD3OD, set at δ = 3.31 ppm
(1H NMR) and δ = 49.o ppm (13C NMR); D2O, set at δ = 4.79 ppm (1H
NMR); CD3CN, set at δ = 1.93 ppm (1H NMR) and δ = 117.7 ppm (13C
NMR); (CD3)2CO, set at δ = 2.04 ppm (1H NMR) and δ = 29.8 ppm
(13C NMR). Coupling costants are given in Hz. LC-MS analysis was
carried out with an HP1100 liquid chromatograph coupled to an electro-
spray ionization mass spectormeter (LC-ESI-MS), using a Phenomenex
Gemini C18 - 3µ - 110 Å column, H2O/CH3CN as neutral solvent or
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H2O/CH3CN with 0.2% formic acid as acid solvent at 25 oC (positive-
ion mode, mz = 100-500, fragmentor 70 V). Another set of experiments
has been performed on an HP1100 liquid chromatograph coupled with
an electrospray ionization-ion trap mass spectrometer MSD1100 usign
a Phenomenex Zorbax C18 - 3.5µ - 80 Å column, H2O/CH3CN with
0.08% trifluoroacetic acid as acid solvent (positive scan 100-500m/z,
fragmentor 70 eV).
4.4.2 Synthesis and characterization
Synthesis of two enantiomers of N-ethyl amide derivative of 3,4-
dehydro-β-proline: (75b). Under inert atmosphere, 72b (R or S) (1 eq),
TEA (1.5 eq) and HBTU (1.5 eq) were dissolved in dry DCM (13.5 ml)
and ethylamine (2 eq) was added. The mixture was stirred overnight
at room temperature. The reaction was diluted with DCM and washe
with water. Purification by flash chromatography (silica gel, 6:4 Â14
Cy:EtOAc) allowed to isolate the product. Yield of (S)-75b: 98%. Yield
of (R)-72b: 96%. Isomer a: 1H NMR (400 MHz, CDCl3) δ 7.75 (d, 3J=
7.2 Hz, 2H), 7.58 (d, 3J= 7.2 Hz, 2H), 7.47 (bs, 1H), 7.38 (dd, 3J= 7.2
Hz, 3J= 7.2 Hz, 2H), 7.30 (dd, 3J= 7.2 Hz, 3J= 7.2 Hz, 2H), 6.24 (m,
1H), 5.67 (m, 1H), 4.59 (d, 3J= 5.2 Hz, 1H), 4.48-4.21 (m, 3H), 4.05 (m,
1H), 3.34 (q, 3J= 7.2 Hz, 2H), 2.31 (m, 1H), 1.16 (t, 3J= 7.2 Hz, 3H),
0.70 (d, 3J= 6.8 Hz, 3H), 0.60 (d, 3J= 6.8 Hz, 3H); 13C NMR (400 MHz,
CDCl3) δ 171.0, 154.8, 143.8, 141.3, 138.7, 138.5, 128.8, 127.6, 124.8,
124.5, 68.8, 66.9, 54.2, 47.3, 34.3, 31.8, 20.9, 14.5; LC-ESI-MS: 11.4
min, [M +H]+=405. Isomer b: 1H NMR (400 MHz, CDCl3) δ 7.75 (d,
3J= 7.2 Hz, 2H), 7.58 (d, 3J= 7.2 Hz, 2H), 7.47 (bs, 1H), 7.38 (dd, 3J=
7.2 Hz, 3J= 7.2 Hz, 2H), 7.30 (dd, 3J= 7.2 Hz, 3J= 7.2 Hz, 2H), 6.24 (m,
1H), 5.67 (m, 1H), 4.59 (d, 3J= 5.2 Hz, 1H), 4.48-4.21 (m, 3H), 4.05 (m,
1H), 3.34 (q, 3J= 7.2 Hz, 2H), 1.85 (m, 1H), 1.16 (t, 3J= 7.2 Hz, 3H),
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0.70 (d, 3J= 6.8 Hz, 3H), 0.60 (d, 3J= 6.8 Hz, 3H); 13C NMR (400 MHz,
CDCl3) δ 171.0, 154.5, 143.8, 141.2, 138.7, 138.5, 128.3, 126.9, 124.6,
119.8, 68.3, 66.5, 53.9, 47.2, 34.3, 32.1, 20.9, 14.0; LC-ESI-MS: 10.1
min, [M +H]+=405. S-enantiomer [α]D= -22.37, R-enantiomer [α]D=
+25.81 (c 1 in CHCl3).
Deprotection of N-Fmoc group of 3,4-dehydro-β-proline: (76b).
75b (1 eq) was dissolved in a 30% solution of piperidine in DMF and
stirred at room temperature for 10 min. The reaction was quenched with
water and extracted with EtOAc. The crude was purified by flash chro-
matography (silica gel, 7:3 Â14 Cy:EtOAc). Yield of (S)-76b: 52%. Yield
of (R)-12: 55%. 1H NMR (400 MHz, CDCl3) δ 6.30 (m, 1H), 4.57 (bs,
1H), 4.14-4.03 (m, 2H), 3.34 (q, 3J= 7.2 Hz, 2H), 2.36 (m, 1H), 1.17 (t,
3J= 7.2 Hz, 3H), 1.06 (d, 3J= 7.2 Hz, 3H), 0.90 (d, 3J= 7.2 Hz, 3H). 13C
NMR (400 MHz, CDCl3) δ 163.3, 143.1, 138.9, 70.3, 52.6, 34.3, 30.1,
19.4, 15.8. LC-ESI-MS: 1.7 min, [M +H]+=183. S-enantiomer [α]D=
-23.3, R-enantiomer [α]D= +15.8 (c 1 in CHCl3).
Esterification of 3,4-difluorobenzoic acid: (77). SOCl2 (5 eq) was
added dropwise in MeOH (0.15M) at 0 oC. After stirring for 15 min,
3,4-difluorobenzoic acid (1 eq) was added and the mixture was stirred at
room temperature overnight. The solvent was removed under vacuum e
the product was used without further purifications (Y%= 63%). 1H NMR
(400 MHz, CDCl3) δ 7.80 (m, 2H), 7.21 (dd, 3J= 8.4 Hz, 3J= 18 Hz, 1H),
3.91 (s, 3H). 13C NMR (400 MHz, CDCl3) δ 164.5, 153.1 (dd, 2JCF=
13 Hz, 1JCF= 266 Hz), 149.6 (dd, 2JCF= 13 Hz, 1JCF= 247 Hz), 126.9
(dd, 4JCF= 13 Hz, 3JCF= 5 Hz), 126.1 (dd, 4JCF= 3 Hz, 3JCF= 7 Hz),
118.3 (d, 2JCF= 18 Hz), 116.8 (d, 2JCF= 18 Hz), 51.7. LC-ESI-MS: 8.3
min, [M +H]+=173.
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General procedure for aromatic nucleophilic substitution: (78)
and (80). 77 (1 eq), morpholine or piperazine (2 eq) and K2HPO4 (4 eq)
were dissolvent in DMSO (0.2 ml) and the mixture was refluxed for 8 h.
The solution was then poured into water and washed with EtOAc. The
crude was purified by flash chromatography (silica gel, 8:2 = Cy:EtOAc).
Yield of 78: 89%. Yield of 80: 99%. Compound (78): 1H NMR (400
MHz, CDCl3) δ 7.74 (dd, 3J= 31.6 Hz, 4J= 1.6 Hz, 1H), 7.72 (dd, 3J=
36.8 Hz, 4J= 1.6 Hz, 1H), 6.94 (dd, 3J= 8.3 Hz, 3J= 8.3 Hz, 1H), 3.90
(s, 3H), 3.88 (t, 3J= 4.8 Hz, 4H), 3.21 (t, 3J= 4.8 Hz, 4H); 13C NMR
(400 MHz, CDCl3) δ 165.7, 154.0 (d, 1JCF= 244 Hz), 143.0 (d, 2JCF=
8 Hz), 126.2 (d, 4JCF= 3 Hz), 123.2 (d, 3JCF= 8 Hz), 117.1 (d, 3JCF=
3 Hz), 117.1 (d, 2JCF= 22 Hz), 66.4, 51.7, 49.9; LC-ESI-MS: 7.7 min,
[M +H]+=240.
Compound (80): 1H NMR (400 MHz, CDCl3) δ 7.69 (dd, 3J= 31.6 Hz,
4J= 1.2 Hz, 1H), 7.66 (dd, 3J= 37.2 Hz, 4J= 1.2 Hz, 1H), 6.88 (dd, 3J= 8.4
Hz, 1H), 3.86 (s, 3H), 3.15 (t, 3J= 4.4 Hz, 2H), 3.02 (t, J= 4.4 Hz, 2H),
2.58 (m, 4H); 13C NMR (400 MHz, CDCl3) δ 163.6, 152.2 (d, 1JCF=
241 Hz), 142.8 (d, 2JCF= 7 Hz), 124.7 (d, 4JCF= 2 Hz), 120.8 (d, 3JCF=
8 Hz), 116.0 (d, 3JCF= 4 Hz), 115.2 (d, 2JCF= 4 Hz), 50.0, 44.2, 39.1;
LC(acid)-ESI-MS: 1.3 min, [M +H]+=239.
Hydrolysis of methyl esters: (79), (82) and (84). Esters 78 or 81
or 83 (1 eq) was dissolved in a mixture 1:2=H2O:THF (0.02M), then
LiOH.H2O (2 eq) was added. The mixture was stirred overnight, acidi-
fied and the product extracted with EtOAc. Yield of 79: 99%. Yield of
82, 84: 99%.
Compound (79): m.p. 199-201 oC; 1H NMR (400 MHz, DMSO δ6) δ
7.62 (dd, 3J= 46 Hz, 4J= 1.6 Hz, 1H), 7.60 (dd, 3J= 51.6 Hz, 4J= 1.6 Hz,
1H), 7.06 (dd, 3J= 8.4 Hz, 3J= 8.4 Hz, 1H), 3.72 (t, 3J= 4.4 Hz, 2H), 3.11
(t, 3J= 4.4 Hz, 2H), 2.47 (m, 4H); 13C NMR (400 MHz, DMSO δ6) δ d
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166.2, 153.5 (d, 1JCF= 243 Hz), 143.3 (d, 2JCF= 8 Hz), 126.4 (d, 4JCF=
3 Hz), 123.7 (d, 3JCF= 7 Hz), 118.1 (d, 3JCF= 3 Hz), 116.6 (d, 2JCF=
22 Hz), 66.9, 49.7; LC (acid)-ESI-MS: 1.3 min, [M +H]+=226.
Compound (82): m.p. 218-220 oC; 1H NMR (400 MHz, CDCl3) δ 7.69
(dd, 3J= 29 Hz, 4J= 1.6 Hz, 1H), 7.66 (dd, J= 34.2 Hz, 4J= 1.6 Hz, 1H),
6.88 (dd, 3J)= 6.8 Hz, 3J= 6.8 Hz, 1H), 3.15 (t, J= 4.4 Hz, 4H), 3.02
(t, J= 4.4 Hz, 4H), 1.45 (s, 9H); 13C NMR (400 MHz, CDCl3) δ 170.4,
155.3, 152.9, 144.4, 127.8, 122.8, 117.9, 117.7, 80.2, 49.7, 49.6, 24,4.
LC (acid)-ESI-MS: 6.3 min, [M +H]+=325.
Compound (84): m.p. 223-225 oC; 1H NMR (400 MHz, CDCl3) δ 7.78
(d, 3J= 29.6 Hz, 2H), 7.76 (d, 3J= 34.4 Hz, 1H), 6.91 (dd, 3J= 8.4 Hz,
3J= 8.4 Hz, 1H), 5.56 (bs, 1H), 4.02 (s, 2H), 3.82-3.80 (m, 2H), 3.68 (t,
3J= 4.8 Hz, 2H), 3.24 (t, 3J= 4.8 Hz, 2H), 3.21-3.19 (m, 2H), 1.45 (s,
9H); 13C NMR (400 MHz, CDCl3) δ 169.5, 167.5, 155.6, 153.0, 144.1,
126.9, 123.6, 117.9, 117.8, 79.8, 66.6, 47.2, 38.4, 28.3; LC(acid)-ESI-
MS: 7.9 min, [M +H]+=382.
Synthesis of N-Boc protected compound: (81). Under inert atmo-
sphere, Boc2O (1 eq) was dissolved in dry DCM (0.2M) and 80 (1.1 eq)
was added. TEA (1.5 eq) was added dropwise at 0 oC. The mixture was
stirred at room temperature overnight, then poured into HCl 1 M and ex-
tracted with DCM. The organic layer was washed with NaHCO3 sat. sol.
and brine. The crude (Y%>99%) was used without further purifications.
1H NMR (400 MHz, CDCl3) δ 7.70 (dd, 3J= 29.6 Hz, 3J= 1.6 Hz, 1H),
7.68 (dd, 3J= 34.8 Hz, 3J= 1.6 Hz, 1H), 6.88 (dd, 3J= 8.4 Hz, 3J= 6.8 Hz,
1H), 3.86 (s, 3H), 3.57 (t, 3J= 4.8 Hz, 4H), 3.12 (t, 3J= 4.8 Hz, 4H), 1.50
(s, 9H); 13C NMR (400 MHz, CDCl3) δ 165.3, 154.0, 153.8 (d, 1JCF=
246 Hz), 143.4 (d, 2JCF= 8 Hz), 126.0 (d, 4JCF= 3 Hz), 123.0 (d, 3JCF=
8 Hz), 117.5 (d, 3JCF= 3 Hz), 116.8 (d, 2JCF= 22 Hz), 79.3, 51.4, 49.3,
27.0; LC-ESI-MS: 11.1 min, [M +H]+=339.
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Synthesis of Gly-derivative: (83). Under inert atmosphere, N-(Boc)-
Gly-COOH (1 eq) was dissolved in DMF (0.12M), COMU (1 eq) and
DIPEA (3 eq) were added at 0 oC. After stirring for 10 min, 80 (1 eq)
was added and mixture stirred at room temperature overnight. The reac-
tion was quenched with HCl 1 M and extracted with EtOAc. The organic
layer was washed with NaHCO3 saturated solution and with brine. The
product (Y%>99%) was used without further purifications. 1H NMR
(400 MHz, CDCl3) δ 7.72 (dd, 3J= 27.2 Hz, 3J= 1.6 Hz, 1H), 7.70 (dd,
3J= 32 Hz, 3J= 1.6 Hz, 1H), 6.88 (dd, 3J= 8.4 Hz, 3J= 8.4 Hz, 1H), 3.99
(s, 2H), 3.87 (s, 3H), 3.79 (t, 3J= 5.2 Hz, 2H), 3.55 (t, 3J= 5.2 Hz, 2H),
3.23-3.12 (m, 4H), 1.44 (s, 9H); 13C NMR (400 MHz, CDCl3) δ 166.7,
165.3, 162.1, 153.7 (d, 1JCF= 244 Hz), 142.8 (d, 2JCF= 9 Hz), 125.9 (d,
4JCF= 3 Hz), 123.4 (d, 3JCF= 7 Hz), 117.5 (d, 3JCF= 3 Hz), 116.8 (d,
2JCF= 22 Hz), 78.9, 66.0, 51.5, 46.7, 43.8, 27.7. LC (acid)-ESI-MS: 8.2
min, [M +H]+=396.
General procedure for coupling reaction: (85a,b), (86b), (88b),
(89b) and (91b). Under inert atmosphere, acid 79 or 82 or 84 (1.5
eq) was dissolved in dry DCM and thionyl chloride (1.5 eq) was added
dropwise at 0 oC. The mixture was stirred at room temperature for 1
h and pyridine (5 eq) was added. The mixture was stirred for 30 min
and cyclic amine 56a,b or (S)-76b or (R)-76b (1 eq) was added. The re-
action was stirred for 3 h and then quenched with water and extracted
with DCM. The crude was purified by flash chromatography (silica gel,
1:1=Cy:EtOAc) to isolate the product. Yield of 85b: 90%. Yield of 85a:
90%. Yield of 86b: 87%. Yield of 88b: 88%. Yield of 89b: 93%. Yield
of 91b: 90%.
Compound (85b): 1H NMR (400 MHz, CDCl3) δ 7.55 (dd, 3J= 22.4,
4J= 1.6 Hz, 1H), 7.52 (dd, 3J= 27.6 Hz, 4J= 1.6 Hz, 1H), 6.98 (dd, 3J= 8.4
122
CHAPTER 4. APPLICATIONS OF ISOXAZOLIDIN-5-ONES AND DEHYDRO-β-PROLINES IN
THE SYNTHESIS OF LINEZOLID-LIKE ANTIBIOTICS AND EVALUATION OF THE COMPLEX
BALANCE WITH MAO-INHIBITORY PROPERTIES.
Hz, 3J= 8.4 Hz, 1H), 6.13 (bs, 1H), 5.27 (dd, 3J= 28 Hz, 3J= 6 Hz, 1H),
3.88 (t, 3J= 4.4 Hz, 4H), 3.40 (d, 3J= 28 Hz, 1H), 3.33-3.16 (m, 6H), 2.14
(m, 1H), 1.13 (t, 3J= 7.2 Hz, 3H), 1.03 (d, 3J= 6.8 Hz, 6H). 13C NMR
(400 MHz, CDCl3) δ 171.4, 171.1, 162.4, 153.9 (d, 1J= 245 Hz), 143.3
(d, 3J= 8 Hz), 126.4 (d, 3J= 4 Hz), 124.7 (d, 2J= 13 Hz), 117.5 (d, 2J= 24
Hz), 117.3 (d, 3J= 4 Hz), 66.6, 66.0, 50.1, 50.0, 49.6, 35.2, 31.5, 17.9,
17.8, 14.3. LC-ESI-MS: 8.5 min, [M +H]+=408, [M +Na]+=430.
Compound (85a): 1H NMR (400 MHz, CDCl3) δ 7.54 (dd, 3J= 23.6 Hz,
4J= 2 Hz, 1H), 7.51 (dd, 3J= 28.8 Hz, 4J= 2 Hz, 1H), 6.90 (dd, 3J= 8.4
Hz, 3J= 8.4 Hz, 1H), 6.12 (bs, 1H), 5.25 (dd, 3J= 6 Hz, 3J= 28 Hz, 1H),
3.86 (t, 3J= 4.8 Hz, 4H), 3.44 (d, 3J= 28 Hz, 1H), 3.36-3.13 (m, 6H),
1.80 (m, 1H), 1.32-1.05 (m, 5H), 1.12 (t, 3J= 7.2 Hz, 3H), 0.89-0.82 (m,
5H); 13C NMR (400 MHz, CDCl3) δ 171.6, 171.1, 162.8, 153,6 (d, 1J=
245 Hz), 143.2 (d, 2J= 8 Hz), 126.4 (d, 3J= 3 Hz), 124.9, 117.6 (d, 2J=
23 Hz), 117.3 (d, 3J= 4 Hz), 66.7, 65.7, 50.1, 49.9, 41.2, 35.2, 28.5, 28.3,
25.9, 25.6, 14.2; LC-ESI-MS: 10.3 min, [M+H]+=448, [M+K]+=486,
[2M +Na]+=917.
Compound (86b): 1H NMR (400 MHz, CDCl3) δ 7.54 (d, 3J= 20.4 Hz,
1H), 7.51 (d, 3J= 25.2 Hz, 1H), 6.90 (dd, 3J= 8.4 Hz, 3J= 8.4 Hz, 1H),
6.15 (bs, 1H), 5.26 (dd, 3J= 28 Hz, 3J= 6 Hz, 1H), 3.58 (m, 4H), 3.34-
3.25 (m, 2H), 3.16-3.09 (m, 4H), 2.12 (m, 1H), 1.46 (s, 9H), 1.12 (t, 3J=
7.2 Hz, 3H), 1.02 (d, 3J= 6.8 Hz, 6H); 13C NMR (400 MHz, CDCl3) δ
171.6, 171.0, 162.1, 154.6, 154.0 (d, 1J= 144 Hz), 143.4 (d, 3J= 8 Hz),
126.4 (d, 3J= 3 Hz), 124.9 (d, 3J= 8 Hz), 117.8 (d, 3J= 3 Hz), 117.6 (d,
2J= 24 Hz), 80.0, 65.9, 49.7 (d, 3J= 4 Hz), 49.6, 35.3, 31.6, 28.3, 18.0,
17.8, 14.4; LC-ESI-MS: 11.0 min, [M + H]+=507, [M + Na]+=529,
[M +K]+=545.
Compound (88b): 1H NMR (400 MHz, CDCl3) δ 7.46 (bs, 1H), 7.36
(d, 3J= 24.8 Hz, 1H), 7.34 (d, 3J= 30 Hz, 1H), 7.05 (dd, 3J= 8.4 Hz, 3J=
8.4 Hz, 1H), 6.37 (m, 1H), 5.44 (m, 1H), 4.49 (d, 3J= 15.6 Hz, 1H), 4.17
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(d, 3J= 16.4 Hz, 1H), 3.78 (t, 3J= 4.4 Hz, 4H), 3.26 (m, 2H), 3.16-3.07
(m, 4H), 2.28 (m, 1H), 1.10 (t, 3J= 7.2 Hz, 3H), 0.97 (d, 3J= 6.8 Hz,
3H), 0.90 (d, 3J= 6.8 Hz, 3H); 13C NMR (400 MHz, CDCl3) δ 169.8,
163.3, 154.5 (d, 1J= 247 Hz), 141.9 (d, 3J= 8 Hz), 139.1, 135.1, 129.4,
124.6 (d, 2J= 60 Hz), 117.8, 116.0 (d, 2J= 24 Hz), 67.6, 66.7, 57.4, 50.3,
34.3, 32.7, 19.3, 17.6, 14.6. LC-ESI-MS: 11.5 min, [M + H]+=390,
[2M + Na]+=412; S-enantiomer [α]D= -58, R-enantiomer [α]D= +41
(c 1 in CHCl3).
(Compound (89b): 1H NMR (400 MHz, CDCl3) δ 7.28 (dd, 3J= 13.6
Hz, 4J= 1.6 Hz, 1H), 7.25 (dd, 3J= 18 Hz, 3J= 1.6 Hz, 1H), 6.90 (dd,
3J= 8.4 Hz, 3J= 8.4 Hz, 1H), 6.33 (m, 1H), 5.78 (bs, 1H), 5.47 (m, 1H),
4.36 (d, J= 14.4 Hz, 1H), 4.16 (d, 3J= 14.8 Hz, 1H), 3.58 (t, 3J= 5.2
Hz, 4H), 3.38-3.31 (m, 2H), 3.13-3.05 (m, 4H), 2.31 (m, 1H), 1.49 (s,
9H), 1.16 (t, 3J= 7.2 Hz, 3H), 1.02 (d, 3J= 7.2 Hz, 3H), 0.94 (d, J= 7.2
Hz, 3H); 13C NMR (400 MHz, CDCl3) δ 169.7, 163.3, 155.8, 154.6,
142.0, 139.1, 129.7, 129.4, 124.3, 118.3, 116.0, 79.9, 67.6, 57.4, 50.0,
34.3, 29.2, 28.4, 17.6, 14.6. LC-ESI-MS: 9.3 min, [M + H]+=489,
[M+Na]+=511, [M+K]+=527, [2M+H]+=976, [2M+Na]+=999;
S-enantiomer [α]D= -47, R-enantiomer [α]D= +40 (c 1 in CHCl3).
(Compound (91b): 1H NMR (400 MHz, CDCl3) δ 7.30-7.27 (m, 2H),
6.89 (dd, 3J= 8.4 Hz, 3J= 8.4 Hz, 1H), 6.33 (m, 1H), 5.73 (bs, 1H),
5.47 (m, 1H), 4.36 (dd, 3J= 16.4 Hz, 3J= 3.6 Hz, 1H), 4.15 (d, 3J= 15.6
Hz, 1H), 3.99 (d, 3J= 4.4 Hz, 2H), 3.80-3.78 (m, 2H), 3.57-3.54 (m,
2H), 3.39-3.32 (m, 2H), 3.14-3.07 (m, 4H), 2.33 (m, 1H), 1.44 (s, 9H),
1.16 (t, 3J= 7.2 Hz, 3H), 1.02 (d, 3J= 7.2 Hz, 3H), 0.94 (d, 3J= 7.2 Hz,
3H); 13C NMR (400 MHz, CDCl3) δ 169.6, 166.9, 163.3, 155.7, 153.4,
141.3, 139.1130.3, 129.3, 124.3, 118.4, 116.0 (d, 3J= 22 Hz), 79.7, 67.6,
66.6, 57.4, 49.7, 44.3, 34.3, 29.6, 28.3, 19.3, 17.8,14.6. LC-ESI-MS:
7.27 min, [M +H]+=546, [2M +Na]+=569. S-enantiomer [α]D= -30,
R-enantiomer [α]D= +31 (c 1 in CHCl3).
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General procedure for N-Boc deprotection: (87b), (90b) and (92b).
Carbammate 86b or 89b or 91b (1 eq) was dissolved in DCM (0.1M) and
TFA (15 eq) was added at 0 oC. The mixture was stirred at room tem-
perature overnight and then evaporated under vacuum. The product was
used without further purifications. Yield of 87b, 90b, 92b: 99%.
(Compound (87b): 1H NMR (400 MHz, Acetoneδ6) δ 7.56 (dd, 3J= 8.4
Hz, 4J= 1.6 Hz, 1H), 7.48 (dd, 3J= 13.6 Hz, 4J= 2 Hz, 1H), 7.18 (dd, 3J=
8.8 Hz, 3J= 8.8 Hz, 1H), 5.10 (m, 1H), 3.77 (d, 3J= 2 Hz, 1H), 3.57 (m,
8H), 3.20 (q, 3J= 7.2 Hz, 2H), 2.04 (m, 1H), 1.10 (t, 3J= 7.2 Hz, 3H),
1.03 (d, 3J= 6.8 Hz, 3H), 1.01 (d, 3J= 6.8 Hz, 3H); 13C NMR (400 MHz,
Acetoneδ6) δ 171.1, 171.6, 165.9, 154.8 (d, J= 233 Hz), 142.7, 128.0 (d,
J= 8 Hz), 127.0 (d, J= 3 Hz), 119.3 (d, J= 3 Hz), 117.9 (d, J= 23 Hz),
68.5, 50.7, 47.7, 44.3, 35.2 (d, J= 13 Hz), 32.5, 18.4, 18.0, 14.6. LC-
ESI-MS: 1.5 min, [M +H]+=407, [2M +H]+=813.
(Compound (90b): 1H NMR (400 MHz, Acetoneδ6) δ 7.44 (d, 3J= 14.4
Hz, 1H), 7.36 (d, 3J= 13.2 Hz, 1H), 7.16 (dd, 3J= 8.8 Hz, 3J= 8.8 Hz,
1H), 6.37 (m, 1H), 5.43 (m, 1H), 4.52-4.47 (m, 2H), 4.03 (q, 3J= 7.2 Hz,
2H), 3.67-3.53 (m, 6H), 3.30-3.24 (m, 2H), 2.29 (m, 1H), 1.10 (t, 3J= 7.2
Hz, 3H), 0.98 (d, 3J= 6.8 Hz, 3H), 0.91 (d, 3J= 6.8 Hz, 3H); 13C NMR
(400 MHz, Acetoneδ6) δ 169.0, 163.4, 159.2, 140.5, 138.6, 131.2, 128.7,
124.6, 117.3, 114.4, 67.8, 57.4, 47.0, 43.8, 38.8, 33.73, 18.8, 17.0, 14.0;
LC-ESI-MS: 1.5 min, [M +H]+=390, [2M +H]+=777; S-enantiomer
[α]D= -38, R-enantiomer [α]D= +14 (c 1 in CHCl3).
(Compound (92b): 1H NMR (400 MHz, CH3OHδ4) δ 7.34 (d, 3J= 14
Hz, 1H), 7.31 (d, 3J= 18.4 Hz, 1H), 7.10 (dd, 3J= 8.4 Hz, 3J= 8.4 Hz,
1H), 6.34 (m, 1H), 5.43 (m, 1H), 5.48 (d, 3J= 16.4 Hz, 1H), 4.16 (d, 3J=
16.4 Hz, 2H), 3.98 (s, 2H), 3.78 (q, 3J= 7.2 Hz, 2H), 3.65-3.58 (m, 2H),
3.27-3.16 (m, 6H), 2.29 (m, 1H), 1.13 (t, 3J= 7.2 Hz, 3H), 1.01 (d, 3J=
6.8 Hz, 3H), 0.94 (d, 3J= 6.8 Hz, 3H); 13C NMR (400 MHz, CH3OHδ4)
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δ 169.7, 166.8, 163.1, 153.4, 141.1, 139.2, 130.5, 129.4, 124.2, 118.3,
117.0 (d, 3J= 22 Hz), 67.5, 57.7, 49.3, 38.5, 34.1, 29.2, 19.1, 17.5, 14.3;
LC-ESI-MS: 1.6 min, [M +H]+=446, [M +Na]+=478; S-enantiomer
[α]D= -17, R-enantiomer [α]D= +32 (c 1 in CHCl3).
4.5 Notes and references
The log PKow values were calculated by using EPI SuiteTM soft-
ware. The spectroscopic data and the synthetic procedures have been
adapted from Ref.[38], with the proper reuse license. See Appendix.
This study has been carried out with the fundamental contribution of
"‘Italian Cystic Fibrosis Research Foundation"’, "‘Fondazione del Monte
di Bologna e Ravenna"’, MIUR and University of Bologna. The biologi-
cal data were produced with the collaboration of E. Lonati, A. Bulbarelli,
R. Musumeci and C. Cocuzza in the Department of Medicine and Surgey,
University of Milano-Bicocca, Via Cadore 48, 20900, Monza, Italy. The
docking experiments have been developed with the collaboration of M.
Lombardo, Department of Chemistry, University of Bologna, Vial Selmi
2, 40126, Bologna, Italy.
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Chapter5
Applications of dehydro-β-prolines and isoxazolines in
the synthesis of integrin ligands as recognition and
delivery systems in ligand-receptor interplay
5.1 Introduction
The interactions existing between cells and between cells and extra-
cellular matrix components are determinant to understand the regulation
of cellular events behind the mechanisms of cellular growth, differentia-
tion and migration, but also to clarify the phenomena that induce biolo-
gical and medical processes like inflammation, immune response and tu-
mor cell metastases (Figure 5.1). In the last decades, the strict connection
between inflammatory processes and the onset of tumors was found: epi-
demiological studies revealed, in fact, that chronic inflammations predis-
pose to several forms of cancer since the two phenomena share the same
microeviromental conditions. It seems that the two processes are de-
pendent each other since, through an intrinsic pathway, different classes
of oncogenes drives the appearance of inflammatory response, while,
through an extrinsic pathway, inflammatory conditions promote cancer
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Figure 5.1: Integrin role.
development [114]. In neoplastic processes, the cells act as promoters
of tumor growth and proliferation, through genomic instability and pro-
moting angiogenesis. At the same time, inflammatory cells influence
all the tumor organs, by differentiation of cell types in the carcinogenic
microenviroment. This connection could be due to an attempt of the tu-
mor to subvert immune cell function, favoring the development of cancer
[115][116]. Many of the cell-surface interactions regulating these patho-
logical events depend on the activity of cell-surface receptors interacting
with adhesion molecules of extracellular matrix. These specific receptors
can be employed for the target-delivery of molecules on ill tissues since
they are normally over-expressed on the surface of affected cells. An-
tibodies, peptides, protein or small molecules can be employed for this
purpose. The main advantage of this approach is that the interaction with
normal tissue is significantly reduced, so in the case of targeted delivery
of drugs it is possible to riduce the side-effects associated to a partic-
ular therapy; therefore, to support this advantage normally cell surface
receptors are preferred to intracellular targets, even because there is no
need to control the internalization mechanisms that can occur. For this
reason, one the most studied family of receptors for targeted delivery of
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chemotherapeutics is the family of integrins [117].
5.1.1 Integrins and their ligands: peptidomimetic-chemistry, new frontier
of chemotherapy
Integrins are non-covalent heterodimeric transmembrane glycopro-
teins existing as 24 combinations of 18α and 8β subunits (each of them is
made up several domains linked through flexible linkers), able to mediate
cell-cell and cell-extracellular matrix (ECM) interactions: they can be
divided in five classes in which the same β subunit is combined with dif-
ferent α ones, producing series of proteins with different ligand-binding
specificities [118]. The half of them binds extracellular matrix proteins
like fibronectin, vitronectin, VCAM-1 and collagen through a specific
recognition sequence, and are fundamental for adhesion, migration, sig-
naling and survival of cells. Integrins exist in different conformational
states that include (i) the bent inactive, in which the inactivators are
bound, (ii) the extended and (iii) the fully activated forms in which inte-
grins are linked to actin and ECM protein together (Figure 5.2). According
to the inside-out activation, a specific protein of the intracellular space
links the integrin in the cytoplasmatic domain: talin links the cytoplas-
matic β-domain of integrin in its inactive form, breaking the bridges be-
tween the two subunits in the extracellular domain inducing changes in
the tilt angle of the protein; kindlins binds the same cytoplasmatic do-
main enhancing the tail-induced activation. For the outside-in activa-
tion, the ECM ligand induces the transition between the "‘closed"’ to
the "‘open"’ conformation of the β-subunit domain, without affecting
the intracellular domain; when the talin in the intracellular space links
the protein, integrin is completely activated [119]. Integrins are widely
involved in cancer progression and several sub-types are highly over-
expressed on cancer cells. Among them it is possible to mention α4β1,
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Figure 5.2: Integrin activation.
α4β7, αvβ3 and α5β1. Integrin-ligand combinations generate four main
classes, based on the nature of the molecular interaction.
α4β1 and α4β7 integrins
α4β1, α4β7, α9β1, the four members of the β2 subfamily, and αEβ7
recognize related sequences in their ligands. In particular, theα4-subclasses
are expressed on the surface of leukocytes [120] and therefore involved
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in inflammatory processes whose disregulation leads to pathogenesis of
chronic inflammations and autoimmune disease like rheumatoid arthritis,
multiple sclerosis and Crohn’s disease [121]. α4β1, known as "VLA-4",
plays a central role in the trafficking of leukocytes and in their activa-
tion and migration through the blood-endothelial barrier while inflam-
matory response is working. It binds its natural ligand, Vascular Cell
Adhesion Molecule-1 (VCAM-1, CD106), and a portion of the type III
connecting segment of fibronectin (FN) [118]; its pivotal role regards
the tumor angiogenesis associated with chronic inflammation, but it is
involved also in the recruitment of progenitor cells in the formation of
new blood vessels. As consequence of their overexpression in melanoma
cells, these integrins are used as markers for prediction of metastatic risk
[115][122] [123] [124] [125]. α4β7 is involved in lymphocyte hom-
ing to mucosal tissue by adhesion to Mucosal Addressed Cell Adhesion
Molecule (MAdCAM), but it links also FN and VCAM-1 [126][127]. It
partecipates to (i) the infiltration of leukocytes in the islets of Langer-
hans in type I diabetes, (ii) the demyelination in multiple sclerosis, (iii)
the migration of T lymphocyte in the gut in inflammatory bowel dis-
ease (IBD) subtypes of Crohn’s disease [128]. When FN and VCAM-1
are bound, α4β1 forms cluster on the cell surface named focal adhe-
sions: this is the cross point between the ECM, the actine cytoskele-
ton and the focal adhesion kinase, that activate a signaling cascade that
involves extracellular regulated kinase (ERK), promoting proliferation
and migration [129]. So, molecules able to interfere with these pro-
teins can be employed for the treatment of inflammations, autoimmune
diseases and cancer therapy. Actually, Natalizumab and Vedolizumab,
anti-α4 and anti-α4β7 antibody respectively, are used as chemothera-
peutics: Natalizumab, for Crohn’s disease and multiple sclerosis even if
in same cases it induces progressive multifocal encephalopathy (PML)
[130][131][132]; Vedolizumab, for treatment of ulcerative colitis and
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Crohn’s disease [133][134]. However, the research of small molecules as
protein ligands rapidly grew up in the last years, leading to the develop-
ment of selective or dual ligands of the two types of integrins. They can
be cyclic or linear peptides, mimicking the LDV, IDS or LDT recognition
sequences: the first is part of fibronectin, the second of VCAM-1 and the
tirth of MAdCAM (Figure 5.3). With the aim to develop analogues of
Figure 5.3: LDV, IDS and LDT recognition sequences.
these sequences, several examples of tyrosine and phenylalanine deriva-
tives have been reported, in particular regarding the chemistry of pep-
tidomimetic molecules [135][136]. To understand the allowed changes
in the development of new ligands, studies on the binding poses of known
compounds have been done by studying the crystal structure of the α4β1
binding fragment of VCAM-1 [137], together to 3D models [138], in sil-
ico screening [139] and 3D QSAR studies [140]. The fundamental fea-
tures for a good binding are the presence of a carboxylate group, a donor
of H-bond (amide, for example) in the central part of the molecule and
a lipophilic chain mimicking the Leu side chain in LDV [135]. More-
over, PUPA (4[(N-2-methylphenyl)ureido]-phenylacetyl motif) gives en-
hancement of activity, like observed in BIO1211 (Figure 5.4) [141].
αvβ3 and α5β1 integrins
αV β3 and α5β1 support cell adhesion and proliferation of cancer
cells, differentiation of mesenchymal stem cells (MSCs) and, in particu-
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Figure 5.4: Structure of the bioactive α4β1 ligand BIO1211.
lar for αvβ3, critical regulation of physiological and pathological angio-
genesis, that is a critical step in the progression of a tumor and its metas-
tasis. In tumor at early stages, the hypoxia can induce the "‘angiogenic
switch"’ in so called dormient cells inducing the production of growth
factors and the upregulation of integrins. By interaction with ECM lig-
ands, this integrin partecipates in the formation of blood vassels, needed
for the trafficking of oxygen and nutrients towards cancer cells. While
αvβ3 can bind several ECM ligands like vitronectin (VN), fibronectin
(FN), osteopontin and bone sialoprotein, α5β1 recognize a specific se-
quence of FN due to the presence on the cell attachment site of the protein
of the synergistic amino acid sequence PHSRN. Them both recognized
the RGD sequence as minimal adhesive binding motif [142]. Among
the drugs active on these integrins reproducing the above-mentioned se-
quence, surely Cilengitide is the most studied antagonist that reached
the clinical phase III in trials for the treatment of glioblastoma and the
phase II for other types of cancers [143] (Figure 5.5). By studying the
X-ray crystallographic results of the complex αvβ3-cilengitide, it was
found that the main interaction is of electrostatic nature in regions of the
protein with opposite charges: the Arg interacts with two Asp residues
on the α domain, while the carboxylate group of the ligand interacts
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Figure 5.5: Structure of RGD sequence and its synthetic analogue Cilengitide.
with the MIDAS centre, the metal-ion-dependent adhesion site [144].
The research toward peptidomimetic analogues of the RGD sequence is
tipically voted to the incorporation of rigid heterocyclic scaffolds with
acidic and basic moieties properly oriented and distanced or enantiopure
non-proteinogenic amino acids. We recently reported a small library of
peptidomimetic isoxazoline-containing molecules designed as αvβ3 and
α5β1 integrin ligands: the isoxazoline core was functionalized in order
to mimic the appendages of arginine and aspartate side chains; the result-
ing structures showed good affinity results, with IC50 in the nanomolar
range for them both the integrins (Figure 5.6) [145].
Figure 5.6: Structure of isoxazoline-containing peptidomimetics and biological data.
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5.2 Results and discussions
5.2.1 Design and synthesis of ligands
A very common trend in the synthesis of peptidomimetic compounds
is the use of five-membered heterocyclic structures as central cores for
the preparation of peptidomimetics designed to be integrin ligands. The
"‘priviliged structures"’, possessing the structural elements for a proper
binding with the biological target, in this case are the heterocycles de-
scribed in Chapter 3: the 3,4-dehydro-β proline and the isoxazoline. By
adding the proper pharmacophoric groups, these heterocycles have been
developed to generate small libraries of integrin ligands, evaluating their
affinity/selectivity for α4β1/α4β7 and αvβ3/α5β1, respectively. As re-
gard the first class of molecules, two different structures have been de-
signed, by changing the substitution pattern on the heterocyclic core and
obtaining compounds of family A or B (Figure 5.7). For the compounds
Figure 5.7: Structure of 3,4-dehydro-β-proline peptidomimetics.
belonging to family A, the acilating group on the two enantiomers of
3,4-dehydro-β-proline ring is the PUPA group leading to the intermedi-
ates (R)-74b and (S)-74b, whose synthesis has been already described.
For the compunds of family B, malonic acid has been introduced on the
nitrogen atom of the heterocycle generating the intermediates (R)-73a,b
and (S)-73a,b, with different appendage group in C2. In both the cases,
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the coupling of the free acid in position 3 of the 3,4-dehydro-β-proline
ring with HBTU/DIPEA with 4-(aminomethyl)aniline led respectively to
intermediates 93b and 94a,b, with yield between 75-85% (Figure 5.8).
Figure 5.8: Synthesis of amides 93b and 94a,b.
Figure 5.9: Synthesis of the final compounds 97b and 98a,b.
The further functionalization of the free aniline was achieved: for
the ligand of class A, by using monotert-butyl malonate , with the same
coupling conditions, with consequent tertbutyl-ester hydrolysis via TFA
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leading to the final ligands 97b; for the ligand of class B, by using 2-
methylbenzene isocianate and proceeding with the methyl ester hydro-
lysis in the usual conditions, leading to ligands 98a,b (Figure 5.9). As
regard the ligands of αvβ3/α5β1, starting from the isoxazoline deriva-
tives shown before, we selected the position 3 to introduce an exposed
anchorage for covalent ligation of diverse spacers with the aim to not
compromise the integrin binding capabilities. For this reason, we intro-
duced the alkyne moiety, like reported in the intermediate 54, to be ex-
ploited in 1,3-dipolar Huisgen cycloaddition with different azide-linkers.
To obtain the "‘clickable"’ intermediate, we proceeded with the selec-
tive removal of tertbutyl ester accomplished with large excess of triflu-
oroacetic acid in dichloromethane. The arginine mimetic chain was in-
troduced by reaction of the resulting acid 99 with 4-aminobenzylamine,
following standard coupling conditions (HBTU/TEA in DCM) to obtain
100 in 76% yield. Hydrolysis of the methyl ester required a particu-
Figure 5.10: Synthesis of the isoxazoline functionalizable ligand 101.
lar effort, since the undesired removal of the malonic side chain, easily
occurred, favoured by the following spontaneous aromatization of the
heterocycle as confirmed by LC-MS analysis. After several trials un-
der different conditions, excellent results were obtained with a 7.10−3 M
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solution of LiOH.H2O in a 2:1 mixture of THF/water, following the re-
action evolution by TLC, and stopping it at the disappearance of the start-
ing ester. The acid 101 was obtained in quantitative yield (Figure 5.10).
In the design of the ligand-linker library, NH2-terminating molecules
were first prepared in order to obtain carriers for molecules with car-
boxylate group, as for example cytotoxic agent like fumagillin and diag-
nostic tools like DOTA. For this aim, N-Boc-2-azido-ethylamine 102 and
N-Boc-3-azido-propylamine 103 were prepared from the corresponding
bromide precursors through substitution with NaN3. They were reacted
with methyl ester 100 in presence of Cu(0) 10 mol% and TEA.HCl salt
at room temperature in a 1:1 mixture of tBuOH and water [146]. The
click-reaction led to the 1,4-disubstituted [1,2,3]-triazole isomer, exclu-
sevely [147], of compounds 104 and 105 in 57% and 67% yield respec-
tively. Removal of the methyl ester with the previous reported condi-
tions led to compounds 106 and 107 with 80% and 87% yields (Figure
5.11). The N-protection was retained in order to avoid unwanted in-
terection during the binding assays, mimicking a carbamate linked pay-
load. For the synthesis of molecules with carboxylate terminal group for
Figure 5.11: Synthesis of the ligand functionalized with amino-terminal moiety with short alkylic chain.
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the delivery of compounds with amine or hydroxyl group, we proceeded
with the functionalization of compound 100 with t-butyl-2-azido-acetate
108 and t-butyl-3-azido propionate 109 via Huisgen cycloaddition. In
this case too, the two azides were prepared from the corresponding bro-
mide. The cycloaddition afforded the products 110 and 111 in low yield
(20% and 34%, respectively). Complete regiocontrol was observed in
this case too. Selective removal of methyl ester was accomplished as
previously described affording the compounds 112 and 113 with 75%
yield (Figure 5.12). The retention of t-butyl group was afforded to avoid
side interaction with the binding site. In order to understand how the
Figure 5.12: Synthesis of the ligand functionalized with carboxylate-terminal moiety with short alkylic
chain.
length of the chain can influence the interaction with the binding site,
we synthesized more complex systems, whose assembly required diffe-
rent protocols, differing for the order of formation of strategic bonds.
The synthetic protocol was optimized for each specific substrate. For the
synthesis of 117, with a succinic moiety as spacer between the carrier
and the payload [148], 3-bromo-propylamine was coupled with mono-
tert-butyl pentandioic acid and the bromide was substituted with NaN3,
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to afford compound 115 in good yield (90%). It was coupled with the
methyl ester 100, with the usual protocol for the cycloaddition, obtain-
ing the compound 116 with 75% yield. Removal of the methyl ester left
the compound 117 with 40% yield (Figure 5.13). The synthesis of com-
Figure 5.13: Synthesis of the ligand functionalized with carboxylate-terminal moiety by introducing
succinic spacer.
pound 119 was realized in one step by cycloaddition of the acid 101 with
ethyl-5-azido-pentanoate. Due to the nature of the substrate 101, the con-
dition of the cycloaddition were modified using Cu(OAc)2 in presence of
sodium ascorbate [148]. The product was obtained with 20% yield, as
consequence of the difficulties in the purification from the copper salts
(Figure 5.14). There are sevaral examples in literature of PEG-linker em-
ployed as drug-ligand connection as consequence of its ability to increase
the solubility and to decrease the immunogenicity of the products [149],
inducing more stability in vivo and reducing the tendency to enzymatic
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Figure 5.14: Synthesis of the ligand functionalized with carboxylate-terminal moiety with long alkylic
chain.
digestion. For this purpose, compound 100 was reacted with commer-
cially available N-Boc-1-amino-3,6-dioxa-8-octaneazide isolating com-
pound 120 in 79% yield; it was then hydrolized to the corresponding
acid 121 (Figure 5.15). In the same way, the acid 101 was reacted with
the azide 122 obtained from the corresponding commercially available
acid. Via Cu(II)-catalysis, compound 123 was isolated in 40% yield as
consequence of the difficult purfication (Figure 5.16).
Figure 5.15: Synthesis of the ligand functionalized with PEG-amino-terminal moiety.
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Figure 5.16: Synthesis of the ligand functionalized with PEG-carboxylate-terminal moiety.
5.2.2 Biological evaluation
The enantiopure ligands designed to be active on α4β1 and α4β7
integrins were evaluated in cell adhesion inhibition assays using Jurkat
cells in presence of VCAM-1. For compounds belonging to class A,
(R)-97b and (S)-97b, moderate affinity was detected with IC50 values in
10−7 M range (entry 1 and 2, Table 5.1), suggesting that the structure de-
signed for these compounds does not guarantee optimal ligand-receptor
interaction, indipendently from the configuration of the stereocenter on
the dehydro-β-proline ring.
Table 5.1: Inhibition of Jurkat cell adhesion by dehydro-β-proline-containing peptidomimetics.
Entry Compound α4β1/VCAM-1 IC50 (nM)a
1 (S)-97b 110±9
2 (R)-97b 250±12
3 (S)-98b >1000
4 (R)-98b 10±3
5 (S)-98a >1000
6 (R)-98a 62±11
[a] Experiments were conducted in quadruplicate and were
repeated at least three times. BIO1211 was used as reference
compound, inhibiting the adhesion with an IC50 of 7.6 nM.
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For compounds belonging to class B, the stereodefinition just mentioned
seems to influence the bioactivity since the S-enantiomers of compounds
98a and 98b (entry 3 and 5) are inactive, while the R-enantiomers showed
excellent activity, expecially for compound (R)-98b (entry 4 and 6). The
conformations of compounds 98a,b have been studied by ROESY expe-
riments that suggested an almost linear disposition of the molecules, as
expected on the basis of structural restrains: in fact, we did not observed
any significative signals with the exception for trivial ones. This result
is in agreement with the preferred conformation of other active α4β1-
integrin ligands [150] [151]. The presence of only one stereocenter in
the molecules justified the lack of further computational minimization in
solvent box since none useful explanation could have been added on the
receptor recognition of the two enantiomers. In the absence of model
for docking, experimental evidences can be explained considering that
the disposition of the alkyl group of the dehydro-β-proline ring in the R-
enantiomer is more favorable than that of the S-enantiomer. Comparing
these two compounds 98a,b with the bioactive BIO1211, we hypotized
that the alkylic chain can mimic those of leucine or valine. The bioactive
(R)-98a and (R)-98b were tested to evaluate their selectivity towards a
specific integrin in cell-adhesion assays. As reported in Table 5.2, the
two compounds have not activity towards none of the β1, β2 and β3
families selected. As regard α4β7, the R-enantiomers of 98a,b showed
significant activity.
Finally, we investigated (R)-98a and (R)-98b on VCAM-1-induced phos-
phorylation of ERK1/2 in Jurkat cells. The focal adhesion kinase (FAK),
activated by integrins α4β, activates ERK in two pathways: according
to the first, FAK recruit C3G and RAP1, which induces B-Raf activity
and ERK activation; according to the second, FAK involves the growth-
factor-receptor-bound-2 and son-of-sevenless complex, which activates
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Table 5.2: Inhibition of cell adhesion through alternative integrins by most effective α4β1 antagonists,
(R)-98a and (R)-98b.
IC50 (nM)a
Compounds α4β7/MAdCAM-1b α5β1/FNc α1β12/ICAM-1d α5β1/FNe
(R)-98b 270±33 >1000 >1000 >1000
(R)-98a 343±26 >1000 >1000 >1000
[a] Experiments were conducted in quadruplicate and were repeated at least three times.b
Performed on RPMI8866 cells. c Performed on K-562 cells.c Performed on Jurkat
cells.d Performed on SK-MEL-24 cells.
Ras-ERK [123]. It was reported that VCAM-1 induces ERK phosphory-
lation in Jurkat cells expressing α4β1 integrin, through the RAF family
of serine/threonine kinases, as sorafenib, a selective B-Raf inhibitor pre-
vents this effect [151]. Jurkat cells were serum-starved in RPMI-1640
containing 1% fetal bovin serum (FBS) for 16h; they were incubated
with compounds (R)-98a and (R)-98b for 60min in suspension and plated
for 60min on VCAM-1 or poly-L-lisine (used as nonspecific substrate).
In cells exposed to VCAM-1, a significant concentration-dependent in-
crease in phosphorylated ERK1/2 was observed 60min after VCAM-1
exposure (Figure 5.17), while poly-L-lysine exposure does not induce
any increment in ERK1/2 phosophorylation. (R)-98b was more active
in the inhibition of phosphorylation of ERK1/2 if compared to (R)-98a.
The IC50 values, obtained in a separate set of experiments in which dif-
ferent concentration of ligands were employed, are 10 and 131 nM for
(R)-98b and (R)-98a, respectively. These results confirm those obtained
from cell adhesion assays, confirming that (R)-98b is the most effective
selective antagonist of α4β1 integrin.
As regard the compounds designed as ligand for αvβ3 and α5β1,
on the basis of our previous knowledge, the modification introduced on
the alkylic side chain should not affect the interaction with the target.
The ability of the synthesized racemic ligands to inhibit the adhesion of
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Figure 5.17: Compounds (R)-98a and (R)-98b prevent VCAM-1-induced phosphorylation of ERK1/2.
Jurkat cells were serum-starved in RPMI-1640 containing 1% FBS for 16h; cells were then preincu-
bated with compounds (R)-98a (A) and (R)-98b (B) for 60 min in suspension. The cells were kept in
suspension (Ctrl) or plated on VCAM-1 coated wells. After 60 min, cells were lysed, and lysates were
analyzed by Western blot using an antibody directed against phosphorylated ERK1/2 (pERK1/2) or to-
tal ERK1/2 (tERK1/2). Representative Western blots show that control cells plated on VCAM-1 had a
much stronger signal for pERK1/2 in Jurkat cells (Ctrl). Preincubation with compound (R)-98a reduced
VCAM-1-induced ERK1/2 phosphorylation significantly only at the concentration 10−7 M. Densito-
metric analysis of the bands (mean± SEM; n?6); the amount of pERK1/2 is normalized to the tERK1/2.
∗∗∗p<0.001 versus Ctrl; ∗p<0.01 versus VCAM-1 60
′
(Newman-Keuls test after ANOVA)
K562 cells (human erythroleukemic cells, expressing α5β1 integrin) or
SK-MEL-24 cells (human malignant melanoma cells, expressing αvβ3
integrin) to immobilized fibronectin was evaluated. These cell models
are widely used to investigate potential antagonists of αvβ3 or α5β1
integrin-mediated cell adhesion. In these experiments, the cells were
seeded onto plates coated with different substrates and allowed to ad-
here before quantification of the number of adherent cells, in presence of
increasing concentrations of the compounds. As a negative control, un-
der these conditions, no significant cell adhesion was observed for BSA-
coated plates or nonspecific substrate-coated plates (i.e., collagen I for
SK-MEL-24 expressing αvβ3 integrin and poly-L-lysine for K562 ex-
pressing α5β1 integrin, data not shown). The ability of the new com-
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pounds to inhibit the adhesion of SK-MEL-24 and K562 cells to fi-
bronectin was compared with that of the standard compounds, Ac-Asp-
Arg-Leu-Asp-Ser-OH (Ac-DRLDS) and H-Gly-Arg-Gly-Asp-Asn-Pro-
OH (GRGDNP), known to be potent inhibitors of cell adhesion mediated
by αvβ3 integrin [152]. The results are summarized in Table 5.3.
Table 5.3: Inhibition of αvβ3 and α5β1 integrin-mediated cell adhesion to Fibronectin in presence of
isoxazoline ligands, or reference standards.
Entry Compound αvβ3 α5β1
IC50 µM[a] IC50 µM[a]
1 101 0.83±0.05 (A) >1000
2 106 0.88±0.07 (I) 0.28±0.03 (I)
3 107 >1000 0.0027±0.0004 (I)
4 112 0.068±0.11 (A) >1000
5 113 0.23±0.08 (A) >1000
6 117 >1000 6.59±0.16 (A)
7 119 0.61±0.08 (A) >1000
8 122 8.84±0.14 (I) >1000
9 123 >1000 >1000
10[b] Ac-RGDDS 0.025±0.003 >1000
11[b] GRGDNP 0.23±0.03 >1000
[a] Values are means of three experiemnts. (I) adhesion inhibition (A)
adhesion activation.[b] Reference compounds.
According to these results, it can be observed that the affinity towards
integrin αvβ3 is generally maintained, while few compounds show high
affinity towards α5β1. Compounds terminating with a carbamate mo-
iety behave as antagonists to integrin receptors, displaying anyway dif-
ferent selectivities. In particular, 106 displayed similar affinity towards
both receptors (entry 2), while the longer 107 is an excellent selective
ligand for α5β1 (entry 3). The opposite preference could be observed
for compound 122 that showed a good affinity for αvβ3 receptor (entry
146
CHAPTER 5. APPLICATIONS OF DEHYDRO-β-PROLINES AND ISOXAZOLINES IN THE
SYNTHESIS OF INTEGRIN LIGANDS AS RECOGNITION AND DELIVERY SYSTEMS IN
LIGAND-RECEPTOR INTERPLAY
8). On the other hand, compounds having a terminal ester group in the
side chain, behaved generally as agonists, inducing an increase in cell
adhesion. All the molecules having a linear chain linked to the triazole
ring displayed high affinity for αvβ3 integrin (entries 4, 5 and 7) in the
submicromolar range. By introducing an amide moiety in the central
part of an elongated linker, as in compound 117, the opposite selectivity
was observed, still maintaining an agonist effect (entry 6). The intro-
duction of a short PEG fragment induced complete loss of the activity
(compound 123, entry 9). To complete the study we also performed the
cell adhesion assay with the alkyne intermediate 101, which showed a
good affinity and selectivity for αvβ3. These data seem to suggest a
possible influence of the terminal moiety on the agonist/antagonist role.
A structure-activity relationship rationalization is still elusive, moreover
because behavior prediction for integrin ligands is known to depend also
on the concentration [153]. A recent study on antagonist/agonist behav-
ior of physiological ligand fibronectin [154], suggests that an antagonist
is able to "‘freeze"’ the receptor in an inactive conformation, while a
ligand subjected to binding/unbinding dynamic events may induce the
persistence of a receptor activated conformation, thus facilitating adhe-
sion. For fibronectin, this has been ascribed to additional stabilizing in-
teractions of vicinal residues, but for small molecule ligands no rational
is still available. Anyway, the good affinity of the members of this class
of peptidomimetics confirms their possible use as shuttle for drugs or di-
agnostic selective delivery to cells overexpressing these two classes of
integrins. To gain further information about the agonist/antagonist role
of our peptidomimetic integrin ligands and to verify the effect on intra-
cellular signalling, we investigated the effects of the most potent α5β1
antagonist, compound 107, and the effects of the only identified α5β1
agonist, 117 on integrin-mediated signalling in K562 cells. The mecha-
nism by which components of extracellular matrix generate intracellu-
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lar signalling through integrins requires indeed an increased phospho-
rylation of cytoplasmatic second messengers. Phosphorylation of ERK
plays a central role in fibronectin-mediated survival signalling through
integrins: in fact, cell adhesion activates ERK by binding of α5β1 in-
tegrins at the cell surface to extracellular matrix proteins such as fi-
bronectin. Experiments were performed by serum-starving K562 cells
in RPMI-1640 containing 1% FBS for 16 h; thereafter, they were pre-
incubated with compound 107 or 117 for 60 minutes and then plated
for 60 minutes on fibronectin or poly-l-lysine (used as nonspecific sub-
strate). Cells treated with the agonist 117 were not incubated with fi-
bronectin. When K562 cells were exposed to fibronectin for 60 minu-
tes the western blots showed a much stronger signal for phosphorylated
ERK1/2, in comparison to vehicle-treated cells (Figure 5.18 (a)). Pre-
incubation with different concentrations of compound 107 (10−7 - 10−9
M) caused a significant concentration-dependent reduction in the amount
of fibronectin-induced ERK1/2 phosphorylation in K562 cells (Figure
5.18 (b)), thus confirming a significant effect of the ligand binding on in-
tracellular signalling cascade. Compound 117, acting as agonist, signif-
icantly increased ERK1/2 phosphorylation in a concentration-dependent
manner in K562 cells (Figure 5.18). Integrin trafficking is an important
mechanism employed by cells to regulate integrin-extracellular matrix
interactions, and thus cellular signaling, during processes such as cell
migration and invasion [155]. α5β1 integrin is internalized, trafficked to
recycling endosomes and then recycled to the plasma [156]. Membrane
trafficking pathways influence the capacity of α5β1 to promote invasion
and metastasis [157]. In order to investigate the effects of peptidomime-
tics on integrin trafficking, α5β1 integrin internalization was observed
by confocal microscopy on HEK293 cells transfected with α5-enhanced
green fluorescent protein (EGFP) plasmid (Figure 5.19). HEK293+α5-
EGFP cells were treated with fibronectin (10 µg/mL) alone or in com-
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Figure 5.18: Effect of compounds 107 and 117 on ERK1/2 phosphorylation mediated by α5β1 inte-
grin expressed in K562 cells. Cells were serum-starved in RPMI-1640 containing 1% FBS for 16 h;
then cells were pre-incubated with different concentrations of the antagonist 107 for 1h and then were
allowed to adhere for 1h on fibronectin. Cells treated with the agonist 117 were not incubated with
fibronectin. Thereafter, cells were lysed and lysates were analyzed in Western blot using an antibody
directed against phosphorylated ERK1/2 (pERK1/2) or total ERK1/2 (tERK1/2). Compound 107 pre-
vented FN-induced phosphorylation of ERK1/2 in a concentration-dependent manner, while agonist 117
significantly increased ERK1/2 phosphorylation. Representative Western blots show that control cells
plated on FN had a much stronger signal for pERK1/2 than vehicle-treated cells (vehicle). Densitomet-
ric analysis of the bands is shown (mean ± SEM; n= 4); the amount of pERK1/2 is normalized to that
of totERK1/2. ∗p<0.05, ∗∗p<0.01 versus FN; #p<0.05, ##p<0.01 versus vehicle (Newman-Keuls
test after ANOVA).
bination with the antagonist 107 (1 µM) or with the agonist 117 (1 µM)
alone. As shown in Figure 5.19, after 15 minutes of treatment with the
endogenous agonist fibronectin α5β1 integrin was mainly localized in
the cytoplasm (Figure 5.19, panels d-f), if compared with vehicle-treated
cells in which the integrin is quite completely located on the plasma
membrane (Figure 5.19, panels a-c). Moreover, when HEK293+α5-
EGFP cells were pre-treated with the antagonist 107 before the addition
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Figure 5.19: Confocal imaging on HEK293+α5-EGFP cells. Cells were pre-treated with compound
107 (1 µM) for 20 minutes and then fibronectin (FN, 10 µg/mL) was added for 1 hour incubation at
4 oC. Cells treated with the agonist 117 (1 µM) were not incubated with fibronectin. Thereafter, cells
were moved to 37 oC for 15 minutes to promote integrin internalization and fixed. Panels a-c: vehicle-
treated cells; panels d-f: FN-treated cellsα5β1 integrin was mainly located in the cytoplasm; panels g-i:
FN-treated cells pre-incubated with the antagonist 107 that prevents FN-induced α5β1 internalization;
panels l-n: cells treated with the agonist 117 that mimicks FN. ompound 117 induced α5β1 integrin
internalization. Scale bar: 10 µm.
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of fibronectin, it prevented integrin internalization, that remained mainly
located on the membrane (Figure 5.19, panels g-i). On the contrary, the
compound 117, mimicking the agonist behaviour of fibronectin, induced
α5β1 internalization (Figure 5.19, panels l-n): in fact, it was mostly lo-
calized in the cytoplasm. The ligands 107 and 117, which showed the
Figure 5.20: Stability assays for 107 (A) and 117 (B) under different pH conditions and in bovine serum.
most interesting results in the biological evaluation, were subjected to
stability assays at neutral (pH=7), basic (pH=10) and acidic (ph=3) con-
ditions. LC-MS injections were performed after 30 min from the prepa-
ration of the samples and then after each 1,5 hour (Figure 5.20). In the
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last synthetic step, the methyl ester deprotection, the amidic bond be-
tween the heterocycle and malonyl group showed high sensitivity to the
basic environment and, as expected, the hydrolyzed A was detected as
the unique degradation product. As a consequence of the spontaneous
aromatization of A, also an increasing amounts of B was observed after
a short period (Figure 5.21). During the acidic treatment and under neu-
tral conditions, both 107 and 117 resulted quite stable and after several
hours only a 5% loss of product was detected, in favor of the formation
of A and B. Under basic conditions, the decomposition to A occurred
in few minutes. Finally the stability was also checked in bovine serum,
confirming that no significant degradation occurs in this physiological
medium. The stability in water solution at different values of pH and in
bovine serum confirms the potential exploitation of these peptidomimetic
molecules for pharmaceutical applications.
Figure 5.21: Typical degradation products under basic conditions.
5.3 Conclusions
On the basis of the fundamental requirements for the interactions of
integrin transmembrane receptors with bioactive ligands, novel classes
of dehydro-β-proline- and isoxazoline-containing peptidomimetics, de-
signed to be effective as integrin ligands, has been developed . To this
purpose, dehydro-β-proline ring properly functionalized with appendages
to the central core have been selected on the basis of previous experience
and on the basis of information from the literature. The synthesized pro-
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ducts have been tested in cell adhesion inhibition assays and in assays
aimed to determine the effect of these α4- antagonists: in particular two
types of integrins have been chosen, α4β1 and α4β7, in order to evaluate
the specificity towards them. A specific compound, (R)-98b, resulted to
be a good integrin ligand, showing IC50 of 10±3 nM and 270±33 nM
on α4β1 and α4β7, respectively. The dependence on the stereochemi-
stry of the heterocyclic central core seems to be related to a preferred
disposition of the lipophilic chain for (R)-enantiomers. These ligands
could be exploited as lead compounds for therapeutic tools development,
considering the great importance of α4β1 integrin (VLA-4) in chronic
inflammation, autoimmune diseases, and inflammation related to can-
cer. In a similar way, the synthesis of a small library of ligands ob-
tained by conjugation of polyfunctionalized linkers to isoxazolidine ring
via Huisgen-click reaction, allowed to verify the possibility to use these
scaffolds as αvβ3 and α5β1 targeting motifs, with the aim to use them
as "‘shuttles"’ for selective delivery of therapeutics and diagnostics to
cancer cells. The different behavior of the members of the library seems
to suggest a correlation between the terminal moiety of the linker chain
and the cell adhesion inhibition or activation. Anyway a rationale in
structure-activity relationship is not predictable and needs further inves-
tigation. Compound 107, that showed affinity towards α5β1 integrin in
the nanomolar range as antagonist, reduced integrin-mediated signaling
induced by fibronectin. On the contrary, compound 117 induced intra-
cellular signaling activation. Moreover, we observed that it acts as α5β1
agonist of endogenous fibronectin. Present data encourage the study of
α5β1 agonists to promote integrin internalization. Further studies are
necessary to understand if the ligands are internalized together with the
integrin and if they are suitable for specific delivery of therapeutic pay-
load to cancer cells. Anyway, the possibility to choose ligands with diffe-
rent behavior during integrin trafficking, suggests a possible exploitation
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of these shuttles to delivery drugs or diagnostics outside or inside the
cell, as required by the payload nature.
5.4 Experimental procedures
5.4.1 General methods
All chemicals were purchased from commercial suppliers and were
used without furhter purification. Microwave-assisted reaction were car-
ried out in Milestone Mycrosynth apparatus, with a dual magnetron sys-
tem with a pyramid-shaped diffuser, 1000 W maximum power output,
and temperature monitor and control by optical fiber up to a vessel tem-
perature of 250 oC. Flash chromatography was carried out on silica gel
(230-400 mesh). Dowex R©50WX2-200(H) ion exchange resin was used
for purification of free amino acids or free amines. NMR spectra were
recorded with a Varian Mercury Plus 400 or Varian Gemini 200 instru-
ments. Chemical shifts are reported as δ values (ppm), and were cali-
brated using the residual solvent peaks of: CDCl3, set a delta = 7.27 ppm
(1H NMR) or δ = 77.0 ppm (13C NMR); CD3OD, set at δ = 3.31 ppm
(1H NMR) and δ = 49.o ppm (13C NMR); D2O, set at δ = 4.79 ppm (1H
NMR); CD3CN, set at δ = 1.93 ppm (1H NMR) and δ = 117.7 ppm (13C
NMR); (CD3)2CO, set at δ = 2.04 ppm (1H NMR) and δ = 29.8 ppm
(13C NMR). Coupling costants are given in Hz. LC-MS analysis was
carried out with an HP1100 liquid chromatograph coupled to an electro-
spray ionization mass spectormeter (LC-ESI-MS), using a Phenomenex
Gemini C18 - 3µ - 110 Å column, H2O/CH3CN as neutral solvent or
H2O/CH3CN with 0.2% formic acid as acid solvent at 25 oC (positive-
ion mode, mz = 100-500, fragmentor 70 V). Another set of experiments
has been performed on an HP1100 liquid chromatograph coupled with
an electrospray ionization-ion trap mass spectrometer MSD1100 usign
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a Phenomenex Zorbax C18 - 3.5µ - 80 Å column, H2O/CH3CN with
0.08% trifluoroacetic acid as acid solvent (positive scan 100-500m/z,
fragmentor 70 eV).
5.4.2 Synthesis and characterization
General procedure for the coupling of acid 73a,b and 74 and 4-
(aminomethyl)aniline: (93b) and (94b). To a stirred solution of each
enantiomer of 73a,b and 74b (1 eq) in dry DCM (0.35M) under inert
atmosphere, HBTU (1.5 eq) and DIPEA (2 eq) were added at rt. The so-
lution was stirred for 10 min and then 4-(aminomethyl)aniline (2 eq) was
added. The reaction mixture was stirred overnight. The organic solution
was washed with H2O, dried over Na2SO4 and solvent was removed un-
der reduced pressure. The crude was purified by flash chromatography
on silica gel (DCM/cyclohexane/methanol 98:1:1 as eluant).
Compound (93b): 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J= 7.6 Hz,
1H), 6.97-7.17 (m, 5H), 6.64 (d, J= 6.4 Hz, 2H), 6.34 (m, 1H), 6.02 (bs,
1H), 5.95 (bs, 1H), 5.05 (bs, 1H), 4.49 (bd, J= 16.4 Hz, 1H), 4.37 (d,
J= 5.6 Hz, 2H), 4.14 (ddd, J= 16.4, 5.2, 1.6 Hz, 1H), 2.35 (m, 1H), 2.25
(s, 3H), 0.96 (d, J= 7.2 Hz, 3H), 0.93 (d, J= 7.2 Hz, 3H); 13C NMR
(100 MHz, CDCl3) δ 163.6, 154.4, 146.0, 138.7, 136.7, 130.3, 129.3,
128.6, 127.5, 126.7, 124.0, 122.6, 115.2, 68.5, 54.3, 43.2, 32.7, 18.6,
18.0, 17.9; LC-ESI-MS: 5.9 min, [M + H]+=393, [2M + H]+=785,
[2M + Na]+=807; S-enantiomer [α]D= +68.2, R-enantiomer [α]D= -
70.7 (c 1 in CHCl3).
Compound (94a): (80:20 trans/cis amide ratio) trans conformer: 1H
NMR (400 MHz, CD3OD) δ 8.55 (bs, 1H), 8.05 (bs, 1H), 7.05 (d, J
= 6.8 Hz, 2H), 6.77 (d, J= 6.8 Hz, 2H), 6.33 (m, 1H), 5.06 (m, 1H),
4.20-4.74 (m, 4H), 3.80 (s, 3H), 3.19 (d, J= 7.4 Hz, 1H), 3.15 (d, J= 7.4
Hz, 1H), 2.10 (m, 1H), 1.45-1.80 (m, 5H), 0.80-1.21 (m, 5H). Cis con-
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former: 1H NMR (400 MHz, CD3OD) δ 8.55 (bs, 1H), 8.05 (bs, 1H),
7.05 (d, J= 6.8 Hz, 2H), 6.67 (d, J= 6.8 Hz, 2H), 6.41 (m, 1H), 5.20 (m,
1H), 4.20-4.74 (m, 4H), 3.78 (s, 3H), 3.67 (d, J= 7.4 Hz,1H), 3.55 (d, J=
7.4 Hz, 1H), 2.10 (m, 1H), 1.45-1.80 (m, 5H), 0.80-1.21 (m, 5H). 13C
NMR (100 MHz, CD3OD) trans conformer δ 167.5, 164.9, 164.5, 145.5,
137.2, 128.0, 127.7, 114.6, 67.3, 53.7, 50.8, 40.5, 28.1, 27.1, 25.7, 25.4.
LC-ESI-MS: 4.9 min, [M +H]+=400, [2M +Na]+=822; S-enantiomer
[α]D= +27.0, R-enantiomer [α]D= -25.2 (c 1 in CH3OH).
Compound (94b): (70:30 trans/cis amide ratio) trans conformer: 1H
NMR (400 MHz, CD3OD) δ 6.95 (d, J= 8.4 Hz, 2H), 6.61 (d, J =8.4 Hz,
2H), 6.45 (m, 1H), 5.05 (m, 1H), 4.31 (m, 2H), 4.27 (bs, 2H), 3.75 (s,
3H), 3.37 (s, 2H), 2.38 (m, 1H), 0.91 (d, J= 7.2 Hz, 3H), 0.87 (d, J= 7.2
Hz, 3H); 13C NMR (100 MHz, CD3OD) δ 168.1, 164.7, 163.4, 144.9,
135.9, 134.3, 127.7, 127.4, 115.1, 67.8, 53.6, 51.9, 41.2, 29.4, 18.1, 17.4.
Cis conformer: 1H NMR (400 MHz, CD3OD) δ 7.05 (d, J= 8.4 Hz, 2H),
6.60 (d, J=8.4 Hz, 2H), 6.12 (m,1H), 4.95 (m, 1H), 4.59 (m, 1H), 4.27
(bs, 2H), 3.98 (m, 1H), 3.76 (s, 3H), 3.41 (s, 2H), 2.38 (m, 1H), 0.94 (d,
J= 6.8 Hz, 3H), 0.91 (d, J= 6.8 Hz, 3H); 13C NMR (100 MHz, CD3OD) δ
166.9, 163.2, 162.9, 145.0, 136.2, 134.6, 127.9, 127.2, 114.7, 68.2, 53.3,
52.0, 41.7, 32.1, 18.4, 17.2. LC-ESI-MS: 12.2 min, [M + H]+=360;
S-enantiomer [α]D= +27.5, R-enantiomer [α]D= -26.5 (c 1 in CH3OH).
General procedure for the coupling reaction with tert-butyl mal-
onate: (95b). To a stirred solution of tert-butyl malonate (1 eq) in dry
DCM (0.8 ml) under inert atmosphere, HBTU (1.5 eq) and DIPEA (2
eq) were added at rt. The solution was stirred for 10 min and then 93b
or 94a,b (1 eq) was added. The reaction mixture was stirred for 2 days.
The organic solution was filtered and the solvent evaporated under re-
duce pressure. The crude product was diluted with DCM and washed
with H2O. The organic phase was dried over Na2SO4 and solvent was
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removed under reduced pressure. 1H NMR (400 MHz, DMSO) δ 8.68
(t, J= 6 Hz, 1H), 7.72 (bs, 1H), 7.47 (d, J= 8.4 Hz, 2H), 7.11 (m, 6H),
6.49 (bs, 1H), 5.95 (bs, 1H), 5.04 (bs, 1H), 4.26 (m, 4H), 3.31 (m, 2H),
2.19 (m, 1H), 2.15 (s, 3H), 1.38 (s, 9H), 0.83 (d, J= 6.8 Hz, 3H), 0.75
(d, J= 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 168.1, 164.5, 163.7,
154.7, 141.8, 139.9, 137.8, 134.5, 132.8, 132.7, 130.0, 129.7, 127.6,
125.7, 120.7, 119.0, 81.4, 67.1, 54.6, 43.9, 37.0, 31.9, 27.7, 18.3, 17.7;
LC-ESI-MS: 8.6 min, [M +H]+=535, [M +Na]+=557. S-enantiomer
[α]D= -9.0, R-enantiomer [α]D= +10.2 (c 1 in DMSO).
General procedure for the preparation of urea-derivative: 96a,b.
1-isocyanato-2-methylbenzene (1 eq) was added to a solution of 94a,b (1
eq), in DCM. The reaction was stirred at rt and followed by TLC. After
20h the reaction was complete and the organic layer was washed with
water, dried with anhydrous sodium sulfate and concentrated in vacuo.
The crude product was purified by flash chromatography on silica gel
(cyclohexane/EtOAc 20:80).
Compound (96a): (70:30 trans/cis amide ratio) 1H NMR (400 MHz,
CD3OD) δ 8.38 (bs, 1H), 7.68 (bs, 2H), 6.94-7.88 (m, 8H), 6.32 (m,
1H, cis isomer), 6.25 (m, 1H, trans isomer), 5.18 (m, 1H, cis isomer),
5.13 (m, 1H, trans isomer), 4.43 (m, 4H), 3.70 (s, 3H), 3.65 (m, 2H),
2.23 (s, 3H), 2.05 (m, 1H), 1.40-1.55 (m, 5H), 0.89-1.32 (m, 5H); 13C
NMR (100 MHz, CD3OD) δ 168.0, 167.6, 167.0, 156.3, 140.3, 139.8,
134.6, 131.9, 13.7, 130.7, 130.0, 129.9, 127.9, 125.9, 124.9, 120.7, 69.9,
56.6, 53.3, 44.0, 43.5, 30.7, 29.8, 28.3, 27.9, 18.5; LC-ESI-MS: 7.7
min, [M + H]+=533, [M + Na]+=555. S-enantiomer [α]D= +20.4,
R-enantiomer [α]D= -17.5 (c 1 in CH3OH).
Compound (96b): (65:35 trans/cis amide ratio) 1H NMR (400 MHz,
DMSO) δ 8.95 (bs, 1H), 8.60 (bs, 1H), 7.84 (bs, 1H), 7.38 (m, 2H),
7.06-7.18 (m, 4H), 6.91 (m, 1H), 6.47 (m, 1H), 4.98 (s, 1H), 4.38 (dd,
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J= 16 Hz, J= 4,4 Hz, 1H), 4.24 (m, 2H), 4.19 (dd, J= 16 Hz, J= 4,4 Hz,
1H), 3.62 (s, 3H), 3.51 (d, J = 15.2, 1H), 3.43 (d, J = 15.2, 1H), 2.22
(m, 1H), 2.20 (s, 3H), 0.78 (d, J= 6.8 Hz, 3H), 0.74 (d, J= 6.8 Hz, 3H);
13C NMR (100 MHz, DMSO) trans conformer δ 169.2, 165.1, 164.6,
154.2, 137.8, 137.5, 136.1, 132.3, 130.0, 127.9, 127.3, 127.2, 126.6,
123.1, 122.9, 114.9, 66.0, 54.4, 51.8, 42.2, 40.6, 30.5, 18.9, 17.6, 16.8;
cis conformer δ 167.9, 166.2, 165.1, 153.8, 137.7, 137.6, 136.1, 133.1,
131.0, 127.8, 127.5, 127.4, 126.8, 123.9, 123.8, 115.6, 66.3, 55.1, 51.6,
41.8, 41.2, 32.1, 18.7, 18.3, 17.0; LC-ESI-MS: 6.6 min, [M +H]+=493,
[M + Na]+=515, [2M + H]+=985. S-enantiomer [α]D= +21.0, R-
enantiomer [α]D= -18.9 (c 1 in CH3OH).
Removal of the tert-butyl ester: (97b) and (99). To a solution of
95b (1 eq) in DCM (0.35M), TFA (10-15 eq) was added and the reac-
tion mixture was stirred at rt until complete consumption of the starting
material. The solvent and the excess of reagent were removed and the
product was used without further purifications.
Compound (97b): 1H NMR (400 MHz, CD3OD) δ 7.51 (d, J= 8.4 Hz,
2H), 7.26 (d, J= 8.4, 2H), 7.13 (m, 4H), 5.14 (m, 1H), 4.38 (s, 2H), 4.31
(m, 2H), 3.28 (s, 2H), 2.32 (m, 1H), 2.23 (s, 3H), 0.91 (d, J= 6.8 Hz,
3H), 0.86 (d, J= 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 168.0,
163.5, 160.4, 154.9, 141.6, 139.2, 137.2, 136.2, 134.8, 133.1, 130.0,
129.0, 127.6, 125.8, 121.6, 119.1, 66.4, 53.9, 42.7, 36.6, 31.4, 19.2, 17.9;
LC-ESI-MS: 5.4 min, [M +H]+=479, [2M +H]+=957. S-enantiomer
[α]D= -32.4, R-enantiomer [α]D= +32.0 (c 1 in DMSO).
Compound (99): 1H NMR (400 MHz, CDCl3) δ 5.36 (m, 1H), 3.73 (s,
3H), 3.63 (d, J= 15.9 Hz, 1H), 3.50 (d, J= 16.0 Hz, 1H), 2.27 (s, 3H), 2.20
(m, 2H), 2.03 (m, 1H), 1.93 (t, J= 2.6 Hz, 1H), 1.78 (m, 1H), 1.65-1.52
(m, 2H); 13C NMR (400 MHz, CDCl3) δ 168.3, 167.9, 167.0, 164.4,
104.2, 83.7, 68.7, 62.9, 52.6, 40.4, 32.3, 23.6, 18.0, 11.8; LC-ESI-MS:
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5.0 min, [M + H]+=296, [M + Na]+=318, [M + K]+=334, [2M +
Na]+=613; HRMS (ESI) [M + H] calcd for C14H18NO6 296.1134
found 296.1131.
Hydrolysis of methyl ester: (98a,b). The ester 96a,b (1 eq) was
dissolved in a mixture of THF/H2O and K2CO3 (1 eq) was added. The
mixture was stirred at room temperature for 2h. The solvent was re-
moved under reduced pressure and the crude dissolved in ethyl acetate
and washed with water. The organic layer was dried on sodium sulphate
and the solvent evaporated. The crude was used without further purifica-
tions.
Compound (98a): 1H NMR (400 MHz, acetone-d6) δ 8.6 (bs, 1H), 8.38
(bs, 1H), 7.68 (bs, 2H), 6.94-7.88 (m, 8H), 6.35 (s, 1H), 5.13 (s, 1H), 4.31
(dd, J= 16 Hz, J= 4,4 Hz, 1H), 4.27 (dd, J= 16 Hz, J= 4,4 Hz, 1H), 4.43 (d,
J= 6 Hz, 2H), 2.23 (s, 3H), 1.40-1.55 (m, 5H), 0.89-1.32 (m, 6H); 13C
NMR (100 MHz, CD3OD) δ 168.7, 165.6, 164.6, 153.8, 137.8, 137.2,
135.8, 132.0, 129.5, 129.2, 128.2, 127.3, 126.3, 125.4, 123.4, 122.7,
122.3, 118.2, 67.4, 54.1, 41.6, 40.9, 28.2, 27.3, 25.8, 25.4, 16.1; LC-ESI-
MS: 19.6 min, [M +H]+=519, [M +Na]+=541, [2M +Na]+=1059.
S-enantiomer [α]D= -37.7, R-enantiomer [α]D= +39.5 (c 1 in CH3OH).
Compound (98b): major and minor isomer on amidic bond; 1H NMR
(400 MHz, acetone-d6) δ 8.6 (bs, 1H), 8.38 (bs, 1H), 7.68 (bs, 2H), 6.94-
7.88 (m, 8H), 6.47 (s, 1H), 5.13 (s, 1H), 4.31 (dd, J= 16 Hz, J= 4,4
Hz, 1H), 4.27 (dd, J= 16 Hz, J= 4,4 Hz, 1H), 4.43 (d, J= 6 Hz, 2H),
2.36 (m, 1H), 2.03 (s, 3H), 0.89 (d, J= 5.6 Hz, 3H), 0.87 (d, J= 5.6 Hz,
3H); 13C NMR (100 MHz, CD3OD) δ 168.9, 165.0, 163.7, 152.6, 137.9,
137.5, 135.7, 131.9, 130.1, 127.8, 127.7, 127.5, 126.0, 122.6, 121.0,
117.9, 66.2, 54.9, 41.6, 40.1, 32.5, 18.3, 17.9, 16.1; LC-ESI-MS: 6.1
min, [M +H]+=479, [2M +H]+=957. S-enantiomer [α]D= -25.2, R-
enantiomer [α]D= +24.5 (c 1 in DMSO).
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Synthesis of isoxazoline- 4-amino benzylamide: (100). Under in-
ert atmosphere, TEA (1.5 eq) and HBTU (1.5 eq) were added to a so-
lution of (99) (1 eq) in DCM (0.12M), and the mixture was stirred at rt
for 5 min. 4-aminobenzylamine (2 eq) was then added and the mixture
stirred for further 4h. The mixture was diluted with DCM and washed
with water. The organic layer was dried over Na2SO4 and then evapo-
rated under reduced pressure. The crude product was purified by flash
chromatography (silica gel, 80/20 cyclohexane/EtOAc). Yield 76%. 1H
NMR (400 MHz, CDCl3) δ 7.06 (d, J= 8.0 Hz, 2H), 6.63 (d, J= 8.0 Hz,
2H), 5.62 (bs, 1H), 5.27 (m, 1H), 4.41 (dd, J= 5.6, 14.0 Hz, 1H), 4.29
(dd, J= 5.2, 14.0 Hz, 1H), 3.70 (s, 3H), 3.58 (d, J= 15.9 Hz, 1H), 3.44
(d, J= 16.0 Hz, 1H), 2.38 (m, 1H), 2.21 (m, 1H), 2.02 (s, 3H), 1.97 (m,
1H), 1.65 (m, 1H), 1.58-1.51 (m, 2H); 13C NMR (100 MHz, CDCl3) δ
168.5, 166.9, 162.0, 159.0, 145.9, 129.1, 127.6, 115.1, 106.5, 83.7, 69.3,
61.6, 52.4, 43.1, 40.5, 38.5, 32.6, 23.0, 17.3, 11.3; LC-ESI-MS: 1.4 min,
[M +H]+=400, [M +Na]+=422, [M +K]+=438, [2M +Na]+=821;
HRMS (ESI) [M+H] calcd for C21H26N3O5 400.1872 found 400.1870.
General procedure for the hydrolysis of malonyl methyl ester:
(101), (106), (107), (112), (113), (117) and (122). LiOH.H2O (1 eq)
was added to a solution of ester (1 eq) in a 2/1 mixture of THF/H2O
(0.007M). The reaction was stopped after disappearance of the starting
material, following the evolution by TLC. The solution was neutralized
adding dropwise HCl 1M solution and then water was evaporated. The
product was purified by flash chromatography (C18 reverse phase silica
gel, 8/2 water/CH3CN). Yield of (101) 99%; Yield of (106) 80%; Yield
of (107) 87%; Yield of (112) 75%; Yield of (113) 75%; Yield of (117)
40%; Yield of (122) 40%.
Compound (101): 1H NMR (400 MHz, CD3OD) δ 7.04 (d, J= 8.2 Hz,
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2H), 6.66 (d, J= 8.2 Hz, 2H), 5.43 (m, 1H), 4.84 (m, 2H), 4.36 (d, J= 14.6
Hz, 1H), 4.17 (d, J= 14.6 Hz, 1H), 2.22-2.11 (m, 2H), 2, 18 (s, 3H), 1.87
(bs, 1H), 1.86 (m, 1H), 1.66 (m, 1H), 1.57-1.48 (m, 2H); 13C NMR (100
MHz, CD3OD) δ 172.4, 172.0, 163.6, 158.3, 146.4, 128.3, 128.1, 115.2,
106.6, 83.2, 68.5, 62.3, 42.3, 39.9, 32.8, 23.5, 17.3, 10.0. LC-ESI-MS:
1.6 min, [M + H]+=386, [M + Na]+=400, [2M + H]+=771; HRMS
(ESI) [M +H] calcd for C20H24N3O5 386.1716 found 386.1714.
Compound (106): 1H NMR (400 MHz, CD3OD) δ 7.64 (s, 1H), 7.61
(bs, 1H), 7.01 (d, J= 8.3 Hz, 2H), 6.90 (bs, 1H), 6.65 (d, J= 8.3 Hz, 2H),
5.45 (m, 1H), 4.85 (m, 2H), 4.39 - 4.32 (m, 3H), 4.18 (d, J= 14.4 Hz, 1H),
3.45 (t, J= 5.6 Hz, 2H), 2.67 (t, J= 8.0 Hz, 2H), 2.17 (s, 3H), 1.87-1.53 (m
4H), 1.37 (s, 9H); 13C NMR (100 MHz, CD3OD) δ 169.7, 163.4, 163.0,
161.9, 158.5, 147.3, 144.9, 129.3, 129.0, 121.9, 115.4, 107.3, 79.8, 61.3,
49.8, 42.7, 40.5, 38.8, 32.4, 28.3, 24.4, 23.2, 11.3; LC-ESI-MS: 1.6 min,
[M +H]+=572; HRMS (ESI) [M +1] calcd for C27H38N7O7 572.2833
found 572.2830.
Compound (107): 1H NMR (400 MHz, CD3OD) δ 7.69 (s, 1H), 7.68
(bs, 1H), 7.00 (d, J= 8.0 Hz, 2H), 6.64 (d, J= 8.0 Hz, 2H), 5.45 (m,
1H), 4.85 (m, 2H), 4.35-4.31 (m, 3H), 4.17 (d, J= 14.6 Hz, 1H), 3.01
(t, J= 6.0 Hz, 2H), 2.67 (t, J= 7.2 Hz, 2H), 2.17 (s, 3H), 2.01-1.98 (m,
2H), 1.86-1.61 (m, 4H), 1.40 (s, 9H); 13C NMR (100 MHz, CD3OD)
δ 171.9, 169.5, 163.6, 161.7, 158.3, 147.4, 146.4, 135.7, 128.2, 122.0,
115.1, 106.5, 78.7, 62.4, 48.4, 42.2, 37.1, 32.8, 30.1, 29.2, 27.3, 24.3,
24.1, 10.0. LC-ESI-MS: 1.6 min, [M + H]+=586, [M + Na]+=608;
HRMS (ESI) [M +1] calcd for C28H40N7O7 586.2989 found 586.2990.
Compound (112): 1H NMR (400 MHz, CD3OD) δ 7.76 (s, 1H), 7.47
(bs, 1H), 7.41 (d, J= 8.0 Hz, 2H), 7.28 (d, J= 8.0 Hz, 2H), 5.51 (m, 1H),
5.20 (s, 2H), 4.50 (d, J= 15.2 Hz, 2H), 4.39 (d, J= 15.2 Hz, 2H), 2.76-
2.69 (m, 2H), 2.20 (s, 3H), 1.85-1.60 (m, 4H), 1.45 (s, 9H); 13C NMR
(100 MHz, CD3OD) δ 173.6, 171.2, 169.9, 169.2,167.2, 147.0, 146.8,
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134.1, 128.2, 122.4, 115.3, 106.6, 82.4, 61.0, 51.4, 43.2, 34.0, 33.3, 27.8,
24.6, 24.0,11.0; LC-ESI-MS(acid eluents): 9.4 min, [M + H]+=543,
[M+Na]+=565; HRMS (ESI) [M+1] calcd for C26H35N6O7 543.2567
found 543.2565.
Compound (113): 1H NMR (400 MHz, CDCl3) δ 7.82 (bs, 1H), 7.80 (s,
1H), 7.44 (d, J= 8.0 Hz, 2H), 7.34 (d, J= 8.0 Hz, 2H), 5.50 (m, 1H), 4.61-
4.56 (m, 3H), 4.46 (d, J= 12.4 Hz, 1H), 2.90-2.85 (m, 2H), 2.75-2.71
(m, 2H), 2.20 (s, 3H), 1.86-1.65 (m, 4H), 1.38 (s, 9H); 13C NMR (100
MHz, CDCl3) δ 173.6, 170.8, 170.2, 169.6, 167.5, 147.0, 146.2, 133.8,
128.6, 122.0, 115.1, 106.4, 80.9, 60.7, 48.2, 43.4, 35.4, 33.9, 30.8, 27.6,
24.8, 24.2,11.5; LC-ESI-MS(acid eluents): 10.0 min, [M + H]+=557,
[M+Na]+=579; HRMS (ESI) [M+1] calcd for C27H37N6O7 557.2724
found 557.2726.
Compound (117): 1H NMR (400 MHz, CD3OD) δ 7.81 (bs, 1H), 7.80
(s, 1H), 7.43 (d, J= 8.0 Hz, 2H), 7.35 (d, J= 8.0 Hz, 2H), 5.52 (m, 1H),
4.86 (m, 2H), 4.51 (t, J= 9.6 Hz, 1H), 4.22-4.35 (m, 3H), 3.18-3.13
(m, 2H),2.78-2.68 (m, 2H), 2.63-2.57 (m, 2H), 2.48-2.44 (m, 2H), 2.21
(s, 3H), 2.08-2.03 (m, 2H), 1.85 (m, 1H), 1.76-1.59 (m, 3H), 1.41 (s,
9H); 13C NMR (100 MHz, CD3OD) δ 172.5, 172.2, 171.7, 169.1, 165.6,
162.7, 147.0, 146.5, 135.2, 128.6, 122.1, 115.3, 106.2, 80.8, 62.0, 48.4,
42.8, 37.0, 33.1, 31.2, 30.8, 29.4, 28.8, 28.0, 24.4, 24.0,11.0; LC-ESI-
MS(acid eluents): 9.4 min, [M + H]+=642, [M + Na]+=664; HRMS
(ESI) [M + 1] calcd for C31H44N7O8 642.3251 found 642.3248.
Compound (122): 1H NMR (400 MHz, CD3OD) δ 7.73 (s, 1H), 7.03
(d, J= 8.4 Hz, 2H), 6.67 (d, J= 8.4 Hz, 2H), 5.47 (m, 1H), 4.82 (m, 2H),
4.51 (t, J= 5.2 Hz, 2H), 4.37 (d, J= 14.6 Hz, 1H), 4.20 (d, J= 14.6 Hz,
1H), 3.87 (t, J= 5.2 Hz, 2H), 3.60-3.57 (m, 4H), 3.46 (t, J= 5.6 Hz, 2H),
3.19 (t, J= 6.0 Hz, 2H), 2.71 (t, J= 6.8 Hz, 2H), 2.20 (s, 3H), 1.85-1.58
(m, 4H), 1.42 (s, 9H); 13C NMR (100 MHz, CD3OD) δ 175.4, 172.4,
170.3, 168.2, 158.2, 156.9, 147.3, 146.4, 128.4, 128.2, 122.5, 115.1,
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107.1, 78.7, 70.0, 69.8, 69.6, 69.0, 49.8, 42.2, 42.1, 39.8, 33.3, 29.3,
27.3, 24.9, 10.3; LC-ESI-MS(acid eluents): 9.9 min, [M + H]+=660,
[M+Na]+=682; HRMS (ESI) [M+1] calcd for C31H46N7O9 660.3357
found 660.3357.
General procedure for the synthesis of azides: (102) and (103).
Under inert atmosphere, to a solution of 2-bromo-ethylamine hydrobro-
mide or 3-bromo-propylamine hydrobromide (1.2 eq) in DCM (0.2M),
Boc2O (1 eq) and TEA (1.5 eq) were added at 0oC and the mixture
stirred at room temperature overnight. The mixture was then washed
with NH4Cl saturated solution, NaHCO3 saturated solution, brine and
evaporated to afford the N-Boc-bromoamine intermediate that was used
without further purifications. The intermediate was dissolved in DMF
and NaN3 (1.4 eq) was added in one portion. The mixture was stirred at
60oC for 4h and then diluted with EtOAc and washed with water. The
organic layer was evaporated after anhydrification over Na2SO4 to give
the azides. Yield of (102) 70%; Yield of (103) 90%.
Compound (102): 1H NMR (400 MHz, CDCl3) δ 4.79 (bs, 1H), 3.40 (t,
J= 5.7 Hz, 2H), 3.28 (m, 2H), 1.43 (s, 9H); 13C NMR (100 MHz, CDCl3)
δ 155.8, 79.9, 50.8, 39.8, 28.2; LC-ESI-MS: 6.5 min, [M +Na]+=209,
[2M +H]+=372, [2M +K]+=395; HRMS (ESI) [M + Na] calcd for
C7H14N4NaO2 209.1014 found 209.1012.
Compound (103): 1H NMR (400 MHz, CDCl3) δ 4.63 (bs, 1H), 3.33
(t, J= 8.0 Hz, 2H), 3.18 (m, 2H), 1.71-1.77 (m, 2H), 1.41 (s, 9H); 13C
NMR (100 MHz, CDCl3) δ 162.2, 78.4, 48.7, 36.1, 31.0, 28.0; LC-ESI-
MS: 7.4 min, m/z: [M + Na]+=223, [2M + Na]+=423. HRMS (ESI)
[M +Na] calcd for C8H16N4NaO2 223.1171 found 223.1168.
Synthesis of tert-butyl 4-((3-bromopropyl)amino)-succinate: (114).
Under inert atmosphere, to a solution of mono tert-butyl pentandioic acid
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(1 eq)) in DCM (1.4M), HBTU (1.5 eq), TEA (1.5 eq) and 3-bromo
propylamine hydrobromide (0.9 eq) were added and the mixture stirred
at room temperature for 4h. The mixture was diluted with DCM, washed
with waterand evaporated. The crude product was purified by flash chro-
matography (silica gel, 9/1 cyclohexane/EtOAc). Yield 50%. 1H NMR
(400 MHz, CDCl3) δ 5.93 (bs, 1H), 3.43-3.36 (m, 4H), 2.62-2.52 (m,
2H), 2.40 (t, J= 6.8 Hz, 2H), 2.07 (m, 2H), 1.44 (s, 9H); 13C NMR (100
MHz, CDCl3) δ 172.3, 172.2, 80.8, 38.0, 32.2, 31.1, 30.8, 30.7, 27.9 ;
LC-ESI-MS: 6.7 min, [2M +Na]+=611.
General procedure for the synthesis of azides: (108), (109), (115)
and (118). Bromo derivative (1 eq) was dissolved in DMF (0.7M) and
NaN3 (1.1 eq) was added. The mixture was stirred at 60oC for 4h and
then diluted with EtOAc and washed with water. Yield of (108): 45
Yield of (109): 45%; Yield of (115): 90%; Yield of (118): 85%.
Compound (108): 1H NMR (400 MHz, CDCl3) δ 3.72 (s, 2H); 1.48 (s,
9H); 13C NMR (100 MHz, CDCl3) δ 167.2, 82.6, 50.6, 27.7.
Compound (109): 1H NMR (400 MHz, CDCl3) δ 3.50 (t, J= 6.4 Hz,
2H); 2.48 (t, J= 6.8 Hz„ 2H); 1.45 (s, 9H); 13C NMR (100 MHz, CDCl3)
δ 169.7, 80.7, 46.6, 35.9, 27.6.
Compound (115): 1H NMR (400 MHz, CDCl3) δ 6.00 (bs, 1H), 3.36-
3.30 (m, 4H), 2.56 (t, J= 6.8 Hz, 2H); 2.40 (t, J= 6.8 Hz, 2H), 1.80-1.72
(m, 2H), 1.43 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 172.4, 172.0, 80.8,
49.2, 37.0, 31.2, 30.8, 28.8, 28.0; LC-ESI-MS: 6.0 min, [M+Na]+=279,
[2M + Na]+=535; HRMS (ESI) [M + Na] calcd for C11H20N4NaO3
279.1433 found 279.1430.
Compound (118): 1H NMR (400 MHz, CDCl3) δ 4.10 (q, J= 7.2 Hz,
2H), 3.27 (t, J= 6.4 Hz, 2H), 2.31 (t, J= 6.8 Hz, 2H), 1.73-1.57 (m,
4H), 1.23 (t, J= 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 172.9,
60.2, 50.9, 33.5, 28.2, 22.0, 14.1; LC-ESI-MS: 8.0 min, [M +H]+=172,
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[M +Na]+=194; HRMS (ESI) [M +1] calcd for C7H14N3O2 172.1086
found 172.1089.
Synthesis Ethyl 2-(2-(2-azidoethoxy)ethoxy)acetate: (124). [2-
(2-azidoethoxy)ethoxy]acetic acid cyclohexylamine salt (1 eq) was dis-
solved in Et2O (1M) and BF3.Et2O (1 eq) was added at 0oC. The mixture
was refluxed for 3h and then evaporated. The crude product was purified
by flash chromatography (silica gel, 1/1 EtOAc/cyclohexane). Yield of
(124): 40%. 1H NMR (400 MHz, CDCl3) δ 4.20 (q, J= 7.2 Hz, 2H), 4.14
(s, 2H); 3.75-3.72 (m, 2H), 3.70-3.66 (m, 4H), 3.38 (q, J= 5.2 Hz, 2H),
1.27 (q, J= 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 170.2, 70.8,
70.7, 70.5, 68.6, 60.6, 50.5, 14.0. LC-ESI-MS: 5.4 min, [M +H]+=218,
[M+Na]+=240. HRMS (ESI) [M+1] calcd for C8H16N3O4 218.1141
found 218.1145.
General procedure for the Huisgen reaction between methyl ester
(100) and azides: (104), (105), (110), (111), (116), (121). In a mixture
of tBuOH:H2O=1:1 (1 ml), TEA (1 eq) and HCl 1M (1 eq) were added
and stirred for 2 min. (100) (1 eq), Cu(0) (10 mol%) and azide (1 eq)
were added and the mixture stirred at room temperature following the
reaction by TLC. The mixture was filtered through celite to remove the
copper powder and evaporated. The crude was purified by flash chro-
matography (silica gel, 9/1 EtOAc/cyclohexane). Yield of (104): 57%;
Yield (105): 67%; Yield (110): 20%; Yield (111): 34%; Yield (116):
75%; Yield (121): 79%.
Compound (104): 1H NMR (400 MHz, CDCl3) δ 7.44 (bs, 1H), 7.29
(s, 1H), 7.13 (d, J= 8.2 Hz, 2H), 6.66 (d, J= 8.2 Hz, 2H), 5.45 (m, 1H),
5.09 (bs, 1H), 4.42-4.35 (m, 4H), 3.69 (s, 3H), 3.56 (d, J = 16.0 Hz, 1H),
3.51 (m, 2H), 3.46 (d, J = 16.0 Hz, 1H), 2.72-2.67 (m, 2H), 2.24 (s, 3H),
1.85 (m, 1H), 1.75 (m, 1H), 1.61-1.55 (m, 2H), 1.39 (s, 9H); 13C NMR
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(100 MHz, CDCl3) δ 168.9, 167.1, 162.2, 158.9, 155.9, 147.3, 144.9,
129.3, 129.0, 121.9, 115.4, 107.3, 79.8, 61.2, 52.4, 49.8, 42.7, 40.5, 32.3,
29.6, 28.3, 24.4, 23.2, 11.3; LC-ESI-MS: 5.6 min, m/z: [M +H]+=586,
[M+Na]+=608; HRMS (ESI) [M+1] calcd for C28H40N7O7 586.2989
found 586.2991.
Compound (105): 1H NMR (400 MHz, CDCl3) δ 7.35 (bs, 2H), 7.12
(d, J= 7.9 Hz, 2H), 6.60 (d, J= 7.9 Hz, 2H), 5.52 (m, 1H), 4.88 (bs,
1H), 4.44 (m, 2H), 4.31 (t, J= 6.9 Hz, 2H), 3.71 (s, 3H), 3.58 (d, J=
16.0 Hz, 1H), 3.48 (d, J= 15.9 Hz, 1H), 3.10-3.05 (m, 2H), 2.27 (s, 3H),
2.03-1.99 (m, 2H), 1.87 (m, 1H), 1.77 (m, 1H); 1.63-1.53 (m, 2H), 1.43
(s, 9H); 13C NMR (100 MHz, CDCl3) δ 168.9, 167.1, 162.2, 158.9,
156.1, 147.2, 145.1, 129.2, 128.9, 121.4, 115.3, 107.3, 79.4, 61.2, 52.4,
47.4, 42.7, 40.5, 37.4, 32.3, 30.5, 28.4, 24.4, 23.0, 11.3; LC-ESI-MS: 6.3
min, [M +H]+=600, [M +Na]+=622; HRMS (ESI) [M +1] calcd for
C29H42N7O7 600.3146 found 600.3148.
Compound (110): 1H NMR (400 MHz, CDCl3) δ 7.54 (s, 1H), 7.02
(d, J= 8.4 Hz, 2H), 6.92 (bs, 1H), 6.58 (d, J= 8.4 Hz, 2H), 5.39 (m,
1H), 4.26 (d, J= 6.0 Hz, 2H), 3.67 (s, 3H), 3.58 (d, J= 16.4 Hz, 1H),
3.50 (d, J= 16.4 Hz, 1H), 2.81-2.70 (m, 2H), 2.17 (s, 3H), 1.81-1.51
(m, 6H), 1.46 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 173.9, 171.0,
169.1,167.3, 163.9, 147.1, 146.4, 134.0, 128.6, 122.2, 115.1, 106.3, 82.2,
60.8, 52.1, 51.6, 43.8, 33.4, 31.5, 27.9, 24.8, 24.3,11.8; LC-ESI-MS: 6.8
min, [M +H]+=557, [2M +Na]+=1135; HRMS (ESI) [M + 1] calcd
for C27H37N6O7 557.2724 found 557.2721.
Compound (111): 1H NMR (400 MHz, CDCl3) δ 7.50 (s, 1H), 7.02
(d, J= 8.4 Hz, 2H), 7.29 (bs, 1H), 6.65 (d, J= 8.4 Hz, 2H), 5.47 (m,
1H), 4.55 (bs, 1H), 4.38-4.34 (m, 3H), 4.18 (d, J= 14.4 Hz, 1H), 3.67
(s, 3H), 3.58 (d, J= 16.0 Hz, 1H), 3.47 (d, J= 16.0 Hz, 1H), 2.80 (t, J=
6.4 Hz, 2H), 2.72 (m, 1H), 2.39 (m, 1H), 2.10 (s, 3H), 1.78-1.54 (m,
4H), 1.38 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 173.7, 170.9, 169.6,
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167.6, 164.2, 147.3, 146.6, 133.7, 128.4, 122.0, 115.3, 106.1, 81.3, 60.6,
52.3, 48.8, 43.6, 35.4, 31.9, 30.4, 27.9, 24.6, 24.2,11.6. LC-ESI-MS: 6.7
min, [M +H]+=571, [M +Na]+=593; HRMS (ESI) [M +1] calcd for
C28H39N6O7 571.2880 found 571.2877.
Compound (116): 1H NMR (400 MHz, CDCl3) δ 7.67 (s, 1H), 7.07
(m, 1H), 7.00 (d, J= 8.4 Hz, 2H), 6.58 (d, J= 8.4 Hz, 2H), 5.39 (m, 1H),
4.50 (m, 2H), 4.26 (d, J= 5.6 Hz, 2H), 3.67 (s, 3H), 3.29 (m, 2H), 3.16
(m, 2H), 2.70-2.66 (m, 2H), 2.53-2.48 (m, 2H), 2.41-2.38 (m, 2H), 2.17
(s, 3H), 2.07-2.00 (m, 2H), 1.83-1.57 (m, 4H), 1.41 (s, 9H); 13C NMR
(100 MHz, CDCl3) δ 172.0, 168.5, 166.8, 161.9, 158.5, 146.9, 145.0,
128.7, 128.5, 121.4, 114.8, 107.0, 80.4, 61.0, 60.0, 52.1, 47.1, 42.3,
40.2, 36.1, 32.0, 30.7, 30.3, 29.6, 27.7, 24.1, 13.8, 10.9; LC-ESI-MS:
6.0 min, [M +H]+=656, [M +Na]+=678; HRMS (ESI) [M +1] calcd
for C32H46N7O8 656.3408 found 656.3406.
Compound (121): 1H NMR (400 MHz, CDCl3) δ 7.53 (bs, 1H), 7.45
(s, 1H), 7.17 (d, J= 8.4 Hz, 2H), 6.72 (d, J= 8.4 Hz, 2H), 5.59 (m, 1H),
4.95 (bs, 1H), 4.50 (m, 2H), 4.47-4.45 (m, 4H), 3.82 (t, J= 5.2 Hz, 2H),
3.71 (s, 3H), 3.61-3.46 (m, 6H), 3.28-3.26 (m, 2H), 3.08 (m, 1H), 2.72
(m, 1H), 2.27 (s, 3H), 1.93-1.76 (m, 2H), 1.63-1.54 (m, 2H), 1.42 (s, 9H);
13C NMR (100 MHz, CDCl3) δ 169.0, 167.0, 162.5, 162.2, 159.0, 155.9,
147.1, 145.2, 129.3, 129.1, 122.2, 115.2, 107.4, 70.5, 70.2, 70.0, 69.5,
61.2, 52.4, 50.1, 42.7, 40.6, 32.3, 36.4, 29.6, 28.4, 24.6, 11.3; LC-ESI-
MS: 6.4 min, [M +H]+=674, [M +Na]+=696; HRMS (ESI) [M + 1]
calcd for C32H48N7O9 674.3514 found 674.3512.
General procedure for the Huisgen reaction between acid (101)
and azides: (119) and (123). In a mixture of tBuOH:H2O=6:4 (0.15M)
(101) (1 eq), Cu(OAc)2 (0.2 mol%), Na-ascorbate (0.4 mol%) and azide
(1 eq) were added and the mixture was stirred at room temperature fol-
lowing the reaction by TLC. The mixture was filtered through celite and
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evaporated. The product was purified by flash chromatography (C18
reverse phase silica gel, 8/2 water/CH3CN). Yield (119): 20%; Yield
(123): 40%.
Compound (119): 1H NMR (400 MHz, CD3OD) δ 7.43 (s, 1H), 7.24
(bs, 1H), 7.04 (d, J= 8.0 Hz, 2H), 6.64 (d, J= 8.0 Hz, 2H), 5.46 (m, 1H),
4.85 (m, 2H), 4.35-4.31 (m, 3H), 4.18 (d, J= 15.0 Hz, 1H), 4.08 (q, J= 7.6
Hz, 2H), 3.19-3.14 (m, 2H), 2.72-2.64 (m, 2H), 2.32-2.30 (m, 2H), 2.20-
2.15 (m, 2H), 2.13 (s, 3H), 2.01-1.98 (m, 2H), 1.87-1.78 (m, 2H), 1.71-
1.52 (m, 2H), 1.28 (t, J= 7.6 Hz, 3H); 13C NMR (100 MHz, CD3OD)
δ 173.5, 172.9, 171.8, 169.4, 164.2, 147.2, 146.6, 133.9, 128.3, 122.2,
115.4, 106.1, 61.4, 60.2, 49.2, 43.9, 36.4, 33.5, 30.5, 28.2, 24.5, 24.2,
22.0, 14.1, 10.2; LC-ESI-MS(acid eluent): 9.0 min, m/z: [M+H]+=557,
[M+Na]+=579; HRMS (ESI) [M+1] calcd for C27H37N6O7 557.2724
found 557.2722.
Compound (123): 1H NMR (400 MHz, CD3OD) δ 7.82 (bs, 1H), 7.27
(s, 1H), 7.07 (d, J= 8.4 Hz, 2H), 6.62 (d, J= 8.4 Hz, 2H), 5.48 (m,
1H), 4.86 (m, 2H), 4.56-4.47 (m, 3H), 4.40 (m, 1H), 4.18 (q, J= 7.2 Hz,
2H), 4.11-4.05 (m, 2H), 3.88-3.85 (m, 2H), 3.75-3.56 (m, 4H), 2.70 (m,
1H), 2.34 (m, 1H), 2.20 (s, 3H), 1.87-1.53 (m, 4H), 1.26 (t, J= 7.2 Hz,
2H)); 13C NMR (100 MHz, CD3OD) δ 175.5, 172.6, 170.5, 170.0,168.5,
147.1, 146.4, 128.6, 128.1, 122.4, 115.3, 107.2, 71.8, 70.8, 70.3, 68.6,
61.6, 60.5, 49.8, 42.3, 39.7, 33.2, 29.3, 24.8, 11.3, 14.0. LC-ESI-MS:
1.6 min, [M +H]+=603. HRMS (ESI) [M + 1] calcd for C28H39N6O9
603.2779 found 603.2782.
5.4.3 Cell culture
SK-MEL-24 cells (expressing αvβ3 integrin) were routinely grown
in MEM supplemented with 10% FBS (Fetal Bovine Serum), nonessen-
tial amino acids, and sodium pyruvate. K-562 cells (expressing α5β1 in-
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tegrin) and Jurkat cells (expressing α4β1 and αLβ2 integrins) were main-
tained as a stationary suspension culture in RPMI-1640 and L-glutamine
with 10% FBS. RPMI8866 cell line (expressing α4β7 integrin; a kind
gift of Prof. Santoni Angela (Dept. of Molecular Medicine, "‘Sapienza"’
University of Rome) were grown in RPMI 1640 with 10% FBS, enriched
with Hepes 5 mM and sodium pyruvate 0,5 mM. Cells were kept at 37oC
in a 5% CO2 humidified atmosphere. Forty hours before the experiment,
K-562 cells were treated with 25 ng/mL PMA to induce differentiation
with an increased level of expression of cell surface antigens.
5.4.4 Cell Adhesion assay
Assays on α4β1 and α4β7: Plates (96 wells) (Corning, New York,
NY) were coated by passive adsorption with integrin ligands: fibronectin
(10 µg/mL), VCAM-1 (2 µg/mL), ICAM-1 (2 µg/mL), MadCam-1 (2
µg/mL) overnight at 4oC. Jurkat cells were seeded onto 96-well plates
coated with different substrata and allowed to adhere before quantita-
tion of the number of adherent cells, in the presence of increasing con-
centrations of the compounds. In particular, the assays tests were per-
formed on wells precoated with VCAM-1 and preincubating Jurkat cells
with the ligand at 37oC for 30 min to reach equilibrium before being
plated. Non-specific binding sites were blocked by incubation with a
BSA (1%)/HBSS (w/v) solution for 30 minutes at 37oC. The efficacy of
putative antagonists (at least seven different concentrations) was deter-
mined by the reduction in adherent cells compared to the untreated con-
trol. Each experiment was conducted in quadruplicate and the data are
presented as the mean± S.E.M. of at least three independent assays. Un-
der these conditions, no significant cell adhesion was observed for BSA-
coated plates (negative control) or nonspecific substrate-coated plates
(poly-l-lysine). BIO1211 was used as reference compound, inhibiting
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the adhesion with an IC50 of 7.6 nM. Adhesion assay with RPMI8866
cells was performed as with Jurkat cells. For the other cell lines, ad-
hesion assay was performed as previously described. Briefly, cells were
counted and exposed to seven different concentrations of each compound
for 30 min at room temperature to allow the ligand-receptor equilibrium
to be reached. At the end of the incubation, cells were plated and incu-
bated at room temperature for 1 h. Then, all the wells were washed with
1% BSA in PBS to remove nonspecifically adherent cells, and 50 µL of
hexosaminidase [4-nitrophenylN-acetyl-β- D-glucosaminide 7.5 mM in
0.09 M citrate buffer solution (pH 5) and mixed with an equal volume of
0.5% Triton X-100 in water was added in each well. The reaction was
blocked by addition of 100 µL of a stopping solution [50 µM glycine and
5 µM EDTA (pH 10.4)], and the plates were read in a Victor2 Multilabel
Counter (Perkin-Elmer, Waltham, MA). Experiments were conducted in
quadruplicate and were repeated at least three times. Data analysis and
IC50 values were calculated using Graph-Pad Prism 5.0 (GraphPad Soft-
ware, San Diego, CA). Assays on α4vβ3 and α5β1: Plates (96 wells)
(Corning Costar, Celbio, Milan,Italy) were coated by passive adsorption
with fibronectin (10 µg/mL) or poly-L-lysine (0.002 %) (Sigma-Aldrich
SRL) overnight at 4oC. Cells were counted with a hemacytometer and
pre-incubated with different concentrations of each compound for 30 min
at room temperature to reach a ligand-receptor equilibrium. Stock solu-
tions (10-2 M) of the assayed compounds were prepared in phosphate-
buffered saline (PBS)/DMSO. At the end of the incubation time, the
cells were plated (50000 cells/well) and incubated at room temperature
for 1 h. Then, all the wells were washed with PBS to remove nonad-
herent cells, and 50 µL of hexosaminidase [4-nitrophenylN-acetyl-β-D-
glucosaminide dissolved at a concentration of 7.5 mM in 0.09 M citrate
buffer solution (pH 5) and mixed with an equal volume of 0.5% Triton
X-100 in water] was added. This product is a chromogenic substrate for
170
CHAPTER 5. APPLICATIONS OF DEHYDRO-β-PROLINES AND ISOXAZOLINES IN THE
SYNTHESIS OF INTEGRIN LIGANDS AS RECOGNITION AND DELIVERY SYSTEMS IN
LIGAND-RECEPTOR INTERPLAY
β-N-acetylglucosaminidase that is transformed in 4-nitrophenol whose
absorbance can be measured at 405 nm. There is a linear correlation
between absorbance and enzymatic activity. Therefore, it is possible to
identify the number of adherent cells among treated wells, interpolating
the absorbance values of unknowns in a calibration curve. The reaction
was blocked by addition of 100 µL of a stopping solution [50 µM glycine
and 5 µM EDTA (pH 10.4)], and the plates were read in a Victor2 Multi-
label Counter (Perkin-Elmer, Waltham, MA). Experiments were carried
out in quadruplicate and repeated at least three times. Data analysis and
IC50 or EC50 values were calculated using Graph-Pad Prism 5.0 (Graph-
Pad Software, San Diego, CA).
5.4.5 Western blotting
Analysis on α4β1 and α4β7: Total protein fractions were obtained
using the commercial T-PER Tissue Protein Extraction Reagent (Pierce):
lysis and resuspension buffer contained a mixture of protease inhibitors
composed of 0,5 mg/mL Benzamidine, 2 µg/mL Aprotinin, 2 µg/mL
Leupeptin, 2 mM phenylmethlysulfonyl fluoride, and a cocktail of phos-
phatase inhibitors 100x (Sigma). Briefly, T-PER Reagent was added to
each sample to permit lysis. After 10 minutes of gently agitation at 4
Â◦C, samples were centrifuged at 10,000 g for 10 minutes to collect su-
pernatants. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and Western blotting were performed according to stan-
dard procedures: proteins from the total extract (100 µg) were separated
by SDS-PAGE (12%). Proteins were transferred onto a Hybond-ECL ni-
trocellulose membrane (GE Healthcare); membranes were blocked with
5% non-fat milk in TBS 1X (10mM Tris-HCl, pH 8, containing 150mM
NaCl) plus 0,1% Tween-20 for 1 hour at room temperature for phospho-
rylated ERK1/2 (pERK1/2), and with TBS 1X plus 1% BSA at 37oC for
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total ERK1/2 (tERK1/2), both for 1 hour incubation in gentle agitation.
Then, membranes were incubated overnight at 4oC with specific primary
antobodies (pERK1/2: 1:1000 dilution, Cell Signaling; tERK1/2: 1:5000
dilution, Promega). All the membranes were incubated with peroxidase-
conjugated secondary antibodies at a dilution of 1:8000 (goat anti-Rabbit
HRP conjugated IgG; Santa Cruz), for 1,5 hours at room temperature.
Detection of immunoreactive bands was done by the enhanced chemi-
luminescent method (Immobilon Western Chemiluminescent HRP Sub-
strate - Millipore) and a LAS3000 acquisition camera (Fujifilm, Tokyo,
Japan). The bands were quantified with AIDA software. All data are pre-
sented as mean ± SEM from three independent experiments. Statistical
significance was determined by Newman-Keuls test after ANOVA using
(GraphPad Software Inc., San Diego, CA, USA). P-values <0.05 were
considered to be significant.
Analysis on α4β1 and α4β7: K562 cells were incubated in RPMI-
1640 with 1% FBS for 16 h. Plates were coated with 10 µg/ml of
fibronectin and blocked with 1% BSA (Sigma-Aldrich SRL). Subse-
quently, 4x106 cells were pre-incubated with different compounds for
30 minutes. Cells were allowed to adhere for 1 hour on fibronectin in
RPMI-1640 with 1% FBS. Then, the cells were lysed in M-PER Mam-
malian Protein Extraction Reagent; (M-PER Pierce, Rockford, IL, USA)
supplemented with phosphatase inhibitor (Sigma-Aldrich SRL) for 10
min at 4oC by gently shaking. Cell debris were removed by centrifu-
gation (14,000 x g for 15 minutes at 4oC) and protein concentrations
were estimated by BCA assay (Pierce, Rockford, IL, USA). Protein ex-
tracts (100 µg) were denatured at 95oC for 3 min before being loaded
and separated in 12% SDS-PAGE gels. The membranes were blocked
in 1% BSA and incubated for 2 hours with anti-phospho-ERK 1/2 (ex-
tracellular signal-regulated kinase 1/2) (1:2500) or anti-total ERK 1/2
antibodies (1:5000) (Promega, Madison, WI, USA) and, thereafter with
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anti-rabbit peroxidase-conjugated secondary antibody. Digital images
were acquired and analyzed following previoulsy reported methods.
5.4.6 Compounds (R)-98a and (R)-98b antagonize VCAM-1-induced ERK1/2
phosphorylation
As regards to compounds (R)-98a and (R)-98b, a separate set of ex-
periments (n =3) was conducted in Jurkat cells exposed to 5 different
concentrations of these antagonists (10-6 to 10-10 M) in the presence of
VCAM-1 (2 Î 14g/ml), as previously described. Cells extracts were evalu-
ated in western blotting experiments to quantify phosphorylated as well
as total ERK1/2 levels (data not shown). After densitometric analysis,
the IC50 value was generated from concentration-response curve using
GraphPad Prism software. The densitometric analysis is reported in Fig-
ure 5.22.
Figure 5.22: Pre-incubation with compounds (R)-98a and (R)-98b caused a significant, concentrationde-
pendent decrease in the amount of pERK1/2 in Jurkat cells exposed to VCAM-1. Jurkat cells were
serum-starved in RPMI-1640 containing 1% FBS for 16 h; cells were then pre-incubated with com-
pound (R)-98a or (R)-98b for 60 min in suspension and then with VCAM-1 (2 µg/ml) for 60 min.
Cells were lysed and analyzed by Western blot to detect phosphorylated ERK1/2 (pERK1/2) or total
ERK1/2 (tERK1/2). Densitometric analysis of the bands (mean± SEM; n=3); the amount of pERK1/2
is normalized to the tERK1/2. IC50 values (concentration of ligand causing 50% reduction of pERK1/2
induced by VCAM-1) were (R)-98b 10 nM and (R)-98a 131 nM.
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5.4.7 Confocal laser scanning microscopy
HEK293 cells (not expressing α5 but endogenously expressing β1 in-
tegrin were plated in 6 well plates and at 50-60% confluence were tran-
siently transfected with α5-enhanced green fluorescent protein (EGFP)
plasmid using Lipofectamine2000 transfection reagent (LifeTechnolo-
gies). After 48 h from transfection, HEK293+α5-EGFP cells were as-
sessed to verify integrins expression by flow cytometry (data not shown).
α5-EGFP integrin plasmid was a kind gift from Michael Davidson (Ad-
dgene plasmid #56423). HEK293+α5-EGFP cells were treated at 4oC
with fibronectin (10 µg/ml) or the agonist 217 (1 µM) in MEM for 1
hour. Cells exposed to the antagonist 107 (1 µM), before the addition of
fibronectin, were pre-incubated with the compoun for 20 minutes at 4oC.
After 1 hour incubation, cells were moved to 37oC for 15 minutes. Then,
the cells were washed twice with PBS and fixed with paraformalde-
hyde (3% in PBS, pH 7.4, 10 min). Thereafter, the cover slips were
washed twice with 0.1 M glycine in PBS and twice with 1% BSA(bovine
serum albumin) in PBS. Specimens were embedded in Mowiol and anal-
ysed and imaged using a Nikon C1s confocal laser-scanning microscope,
equipped with a Nikon PlanApo 60X, 1.4-NA oil immersion lens.
5.5 Notes and references
The spectroscopic data and the synthetic procedures have been adapted
from Ref.[76], with the proper reuse license. See Appendix. These stu-
dies have been carried out with the contribution of MIUR (PRIN project
2010 NRREPL: Synthesis and biomedical applications of tumor-targeting
peptidomimetics), "‘Fondazione del Monte di Bologna e Ravenna"’ and
University of Bologna.
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Synthesis of red-shifted fluorescent self-assembled
nanoparticles as diagnostic tools
6.1 Introduction
In the last decades, great attention was paid to the development of
tools resolving issues related to healthcare, focusing in particular on the
research of new material and methods that allow to obtain early diag-
nosis of diseases by the employment of easy and cheap strategies. The
combination of studies on the synthesis, photochemical behaviour and
biological applications of these new architectures led to the introduction
in the field of medicinal chemistry of nanoparticles based on conjugated
polymers as outstanding multifuctional nanostructures with promising
applications as imaging agents and biosensors. The main utilities of these
conjugated polymer nanoparticles (CPNs), making them desirable focus,
are related to (i) the possibility to easily tune their properties in function
of the desidered application, (ii) the easy synthesis and (iii) the reduced
toxicity if compared to the analogue inorganic nanoparticles employed
for the same purposes. [158] In particular, fluorescent nanoparticles have
been widely studied in the last years for application in bioimaging and
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biosensors, since they are small size molecules whose fluorescent proper-
ties can be easily modulate by changing the functionalization of the core
structures, making them versatile biomaterials. They combine the ad-
vantages of inorganic nanoparticles and fluorescent organic ones. Infact,
with respect to the first, fluorescent CPNs overcome the problems related
to the toxicity of metals and inorganic components. As regard the sec-
ond, commonly fluorescent organic nanoparticles were constructed start-
ing from vesicles or micelles by incorporation of a fluorescent dye, with
the possibility to modulate the affinity toward a specific biological tar-
get by chemical modification: with fluorescent CPNs these features are
combined in an unique structure. [159] Among the fluorescent organic
CPNs developed, the self-assembled ones are the most suitable for thera-
nostic applications, where the drug delivery is combined to the bioimag-
ing. Infact, supramolecular architectures obtained by self-assembly are
interesting since they can host ligands inside the self-assembled struc-
tures (like micelles and vesicles do) or they can delivery the payload
through convalent linkage to the main backbone; furthermore, they have
high extravasation in tumor vasculature and prolonged stability in sys-
temic circulation. [160] [161] [162] The self-assembled nanoparticles
can be obtained with, mainly, two metods known as miniemulsion and
reprecipitation. In the first case, the polymer is dissolved in an organic
solvent immiscible with water and injected in a acqueous solution con-
taining a surfactant. The mixture was sonicated allowing the formation
of miniemulsion with droplets of polymer solution. The removal of or-
ganic solvent by evaporation gives nanoparticles disperse in water, with
size related to the concentration of the initial polymer solution. With
reprecipitation method, the polymer is dissolved in a solvent that well
dissolves it, like THF, and injected in a poor solvent, like water, misci-
ble with the previous. This allows the formation of nanoparticles, ob-
tained after removal of the organic solvent by evaporation (Figure 6.1).
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In this case the driving force is the existance of hydrophobic effects be-
tween the polymer and the acqueous media: when it is added to water,
the polymer chains try to reduce the interaction with the solvent and for
this reason the resulting disposition to minimize the exposure to water is
the folding in spherical shapes. In this case, no additives or surfactants
are required and it is possible to choose different solvents to obtain the
desired result. The size of the nanoparticles depends on the concentra-
tion of polymer solution and on the polymer molecular weight. [158]
Fluorescent polymer-based pi-conjugated nanoparticles (PDots) are par-
Figure 6.1: Preparation of polymer nanoparticles by reprecipitation method.
ticularly interesting since their photochemical stability, fluorescence and
chemical manipulation make them good candidates to develop cellular
imaging probes. Several examples are reported in literature of PDots
with high photostability and absorption, together with quantum yield up
to 40%. But self-assembled oligomer-based pi-conjugated fluorescent
nanoparticles represent a further improvement since they keep the ad-
vantage of quantum dots and PDots of incorporation of builiding blocks
in the nanoparticle, allowing at the same time perfect control on the struc-
ture and function of the resulting probe. [163] The presence of aromatic
moieties enhances the stability in water during the self-assembly due to
177
CHAPTER 6. SYNTHESIS OF RED-SHIFTED FLUORESCENT SELF-ASSEMBLED
NANOPARTICLES AS DIAGNOSTIC TOOLS
pi-pi interactions and hydrophobic effects. Considering the hydrophobi-
city of pi-conjugated core, hydrophilic side chain can be introduced in or-
der to obtain amphiphilic properties and self-assembly in water. The self-
assembled pi-conjugated fluorescent nanoparticles employed in bioimag-
ing are mainly based on perylene or fluorene moieties. [164] In this
study, the attention was paid on the second one.
6.1.1 Nanoparticles based on fluorene oligomers
The fluorene unit is made up two benzene connected directly by a
carbon-carbon bond and a methylene bridge. Its application in fluore-
scent studies is due to its high quantum yield, photostability and good
solubility in the most common organic solvents. [165] By attachment
of hydrophilic side chain it is possible to modulate its solubility proper-
ties making it more soluble in acqueous media. Examples were reported
by Yang [166] and Tagawa [167] who reported oligofluorene moieties
functionalized with substituted aniline and alkylic or ethylene glycole
chians, respectively (Figure 6.2). In the first case, red-shifted emission
Figure 6.2: Structures of Yang’s and Tagawa’s fluorene based oligomer.
peak observed in THF moved with ipsocromic-shift when the oligomers
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self-assembly in water. In the second, the blue emission in THF left
place to a green peak in water. These results prove that the assembly
together with the influence of side-chains are responsible for the pho-
tochemical properties of the resulting nanostructure. The extention of
pi-conjugation was reported by Shenning et al. [168] who synthetized
fluorene based oligomer in which the two fluorene units were connected
by a central aromatic moiety like naphtalene (A, Figure 6.3), quinoxa-
line (B, Figure 6.3), benzothiadiazole (C, Figure 6.3) and thienopyrazine
(D, Figure 6.3) in order to obtain different emission wavelenghts. These
oligomers were used for the synthesis of bola-amphiphilic nanoparticles,
with hydrophilic groups at both ends of the hydrophobic central core:
they generate bola-amphiphilic oligomers able to cover all the visible
spectra, with also white emission obtained by mixing them. Since the
Figure 6.3: Structures of Shenning’s bola-amphiphilic fluorene-based oligomers.
resulting nanostructure depends significantly on the structure of the cos-
tituent oligomer, several studies are reported in which changes in the side
chains were performed in order to correlate them with the size and the
shape of the nanoparticles. To this purpose, examples of all polar and all
non polar side chains are reported and they revealed that all the fluorene-
based oligomers well self-assembly in water, but those with polar side
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chains are more dynamic and larger in size if compared with the non-
polar ones (Figure 6.4). [169] In order to develop systems for delivery
Figure 6.4: Structures of fluorene-based oligomer with polar or apolar side chains.
or probes, the fluorene-based oligomer have been widely functionalized,
with azides or mannose attached to the perifery of the oligomer in or-
der to guarantee exposure to acqueous media. The analysis on the shape
and size of the resulting nanoparticles showed that these oligomers self-
assembly in water giving nanoparticles with same size and optical pro-
perties of those without functionalization. So, the introduction of partic-
ular funcitonal groups on the periphery of PEG-side chain does not affect
the self-assembly that, for this reason, is clearly related to the oligomer
central structure. The mannose-oligomer and the azide-oligomer functio-
nalized with a proper ligand (in the second case by means of copper(I)-
catalyzed azide-alkyne cycloaddidion) not only kept the properties of the
not-functionalized ones but, furthermore, expose the ligand at the pe-
riphery of the nanostructure (Figure 6.5). To develop nanoparticles red-
emitting and able to encapsulate drugs, Tuncel et al. reported fluorene-
based nanoparticles that emit in the red region tailing to infrared and
can encapsulate drugs like Camptothecin. The oligomer was synthe-
sized coupling divinyl fluorene and di bromobenzothiazole (Figure 6.6).
The resulting nanoparticles were stable in water for a long time and can
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Figure 6.5: Structures of fluorene-based oligomer functionalized with azide or mannose.
carry Camptothecin; with a pH switch toward acidic values disassem-
bly of the nanoparticles and release the drug were observed, as conse-
quence of the repulsive force due to the formation of ammonium ions.
[170] On the basis of these results, the aim of the work developed in the
Figure 6.6: Structures of red-emitting fluorene-based oligomer, encapping Camptothecin.
prof. L. Brunsveld’s research group has been the design, synthesis and
optimization of fluorene-based oligomer nanoparticles obtained through
Heck-coupling of mono-aminodivinyl fluorene and dibromo benzothio-
diazole monomers, followed by functionalization of the amino moieties
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with tris(dodeciloxy)benzoic acid (Figure 6.7). The photophysical be-
havior of these water dispersible nanoparticles was compared to that of
molecular disperse solutions in THF and to that of analogue structures to
evaluate the entity of the shift in emission and absorption in the region of
red tailing to the near-infrared of the spectrum. Furthermore, each inter-
mediate has been studied in order to understand which was the minimum
structure that allows the formation of nanoparticles.
Figure 6.7: Structures of red-emitting fluorene-based oligomer and emission of its nanoparticles in
water.
6.2 Results and discussions
6.2.1 Molecular design and synthesis
For the synthesis of the nanoparticles, the first step was the optimiza-
tion of the synthesis of the oligomer 126 reported in Figure 6.8, the cen-
tral core of the target structure.
For this purpose, two different pathways were tried according to the
available starting materials (Figure 6.9). The first step, the Stille cou-
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Figure 6.8: Structures of diamminic-fluorene core of the oligomer.
Figure 6.9: Two pathways for the synthesis of intermediate 126.
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Figure 6.10: Synthesis of 126 starting from the nitro-compound.
pling, has been the most critic one since the conversion was not complete
and the separation of the product from the starting material was difficult
as consequence of similar polarity of them both the species. Furthemore,
the not complete conversion at this stage implicates that in the subse-
quence step of coupling it is possible to recover the product of omo-
coupling as byproduct. In a first attempt, tributyl(vinyl)tin, 2,6-di-tert-
butylphenol Pd(PPh3)2Cl2 1.5mol% in toluene were added to 7-bromo-
9,9-bis((S)-3,7-dimethyloctyl)-9H-fluoren-2- amine but the conversion
was around 66-85% as shown by NMR spectra. Increasing the reaction
time and changing the Pd catalyst, choosing Pd(PPh3)4 2mol%, none
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considerable improvement was observed and the conversion was con-
firmed (80%). So, the same procedure with Pd(PPh3)2Cl2, 2,6-di-tert-
butylphenol and tributyl(vinyl)tin was used for the second route with 2-
bromo-9,9-bis((S)-3,7-dimethyloctyl)-7-nitro-9H-fluorene giving in this
case conversion of 98%. The subsequent steps were i) the Heck coupling,
performed with 4,7-dibromobenzo[c][1,2,5]thiadiazole, Pd(PPh3)4 as ca-
talyst and Pd(OAc)2 as co-catalyst in toluene , with yield of 128 of 65%,
and ii) the reduction of nitro-groups with SnCl2 in a mixture of EtOH :
EtOAc at 90oC for 40h, with yield of 126 of 55% (Figure 6.10). During
one of the trials performed, it was possible to isolate a small amount (less
then 5%) of byproduct 129 that has been however charactherized in its
photophysical properties. The intermediate 126 was then mono-acylated
with 0.7 eq of tris(dodecyloxy)benzoic chloride, generated in situ starting
from the corresponding acid, to obtain with 61% yield the intermediate
130 that was acylated again with excess of chloride giving the final 131
with 50% yield (Figure 6.11).
6.2.2 Formation and characterization of self-assembled nanoparticles
For the preparation of nanoparticles of the final product 131 and of
the intermediates 126, 127, 128, 129 and 130, a mother solution of each
compounds in THF (1 mmol/mL) was prepared. 15 µL of mother so-
lution were injected into 5 mL of deionized water in one-pot. Then the
nanoparticles were characterized by DLS obtaining the data reported in
Figures 6.12, 6.13, 6.14. As shown, the smallest nanoparticles have been
obtained with intermediate 126 with a radius of 21 nm. The correspond-
ing nitro-compound 128 gives, instead, bigger nanoparticles with radius
of 36 nm, maybe due to different interactions of nitro groups with the
water compared to amino groups. By adding functionalizations to inter-
mediate 126, the dimension of the resulting nanoparticles increases to 59
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Figure 6.11: Synthesis of 131 starting from 126.
nm, for the mono-acylated 130, and 71 nm, for final product 131.
The optical properties of the molecules in THF and the corresponding
nanoparticle dispersion in water were studied by UV-visible and fluores-
cence spectroscopy (Figure 6.15-6.20) and tabulated in Table 6.1.
UV-vis absorption wavelengths of aforementioned intermediates and
of the final product in THF exhibit a blue-shift compared to the solu-
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Figure 6.12: DLS measurment of 126 (a) and 127 (b).
Figure 6.13: DLS measurment of 128 (a) and 129 (b).
Figure 6.14: DLS measurment of 130 (a) and 131 (b).
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Table 6.1: Summary of abs/em values.
Compound UV-vis absorption Photoluminescence
λmax/nm (log()/M−1cm−1) λmax/nm
water THF water THF
127 342 (4.02) 346 (4.42) - -
128 316 (4.37) 316 (4.40) 575 556
347 (4.42) 399 (4.54) 575 556
126 370 (4.50) 376 (4.85) (415,) 449, 618 465, 652
503 (4.34) 517 (4.78) (415,) 449, 618 465, 652
129 388 (4.51) 393 (4.72) 424 478
130 367 (4.18) 372 (4.40) 635 593
492 (4.00) 500 (4.31) 635 593
131 365 (4.57) 370 (4.57) 618 594
490 (4.37) 495 (4.37) 618 594
tions of the same molecules in water. Moreover, excluding intermediate
129 that is not in the serie of the other compounds, it is possible to ob-
serve a red-shift increasing the polarity from 127 via 128 to 126. The
mono-acylation and the di-acylation give reduction in polarity and so a
blue-shift is observed compared to the previous intermediates: it is less
important for the first peak (transition between orbitals of dibenzoful-
vene), about 2-4 nm, but became a little bit more significative for the
second peak (transition between orbitals of double-bond and dibenzoful-
vene), about 10-17 nm, mostly for the first acylation. The fluorescence
spectra show a red-shift of the solution in water increasing the polarity
from 128 via 126 to 130, while the trend is not rationalizable for the
same solutions in THF or going from THF to water for each compound.
Of great interest is the red-shift of the nanoparticles of intermediate 130
and of the final product in water compared to the results of the same com-
pounds in organic solvent. As regards intermediate 127, it does not emit
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with fluorescence, while intermediate 129, lacking of benzothiodiazole,
emits in the blue region. The changes in the optical properties can be
explained by both inter- and intrachain interaction, as well as the solvent
polarity.
Figure 6.15: Absorption and emission of 126.
To evaluate if the aim of the project has been reached, the results have
been compared with those obtained for analogue structures already re-
ported in literature. Considering the dimensions of nanoparticles, the in-
termediates 128 and 126 have been compared with the structures 132 and
133, reported respectively by Pennakalathil et al. [170] and Shenning et
al. [171]. The first has been chosen because it has the same building core
of the new synthetized ones (dibenzofulvene conjugated through double
bond with benzothiodiazole), while the second because it is the smallest
nanoparticle synthetized previously in the same research group (Figure
6.21). The intermediate 128 and 126 give nanoparticles smaller than
those obtained with the aforereported structures. It is maybe due to the
repulsion of the apolar tails for the polar environment. The dimensions of
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Figure 6.16: Absorption and emission of 127.
Figure 6.17: Absorption and emission of 128.
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Figure 6.18: Absorption and emission of 129.
Figure 6.19: Absorption and emission of 130.
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Figure 6.20: Absorption and emission of 131.
Figure 6.21: Structures of reference compounds 132 and 133.
nanoparticles of intermediate 130 and of the final product 131 have been
compared to Apolar-B e Bola1-B (Figure 6.22), reported by Shenning
et al. [172]. The comparison shows clearly how the introduction of the
double bond between dibenzofulvene e benzothiodiazole does not affect
considerably the dimension of the resulting nanoparticles. Considering
the UV-vis and fluorescence data obtained for the new compounds, they
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Figure 6.22: Structures of reference compounds Apolar-B and Bola1-B.
have been compared with the same structures aforementioned. So, inter-
mediate 126 (λabs,126=503water, 517THF /λem,126=618water, 652THF )
is red-shifted in absorption and emission, in water and THF, if com-
pared to reference 132 (λabs,132=455water, 466THF /λem,132=615water,
605THF ) and 133 (λabs,133=427water, 415THF /λem,133=522water, 533THF ),
while intermediate 128 (λabs,128=348water, 399THF /λem,128=575water,
556THF ) is blue-shifted in absorbtion and in emission, in water and THF,
if compared to reference 132, and it is blue-shifted in absorbtion but red-
shifted in emission if compared to reference 133. Intermediate 130 and
the final product 131 are red-shifted in absorbtion and in emission, in wa-
ter, if compared to Apolar-B (λabs,apolar−B=431water/λem,apolar−B=
527water) and Bola1-B (λabs,bola1−B=429water/λem,bola1−B=550water).
6.3 Conclusions
The optimization of a synthetic pathway for the synthesis of red-
shifted self-assembeld nanoparticles has been developed. The core struc-
ture is a fluorene unit properly functionalized for the scope. Each inter-
mediate and the final product have been employed for the preparation
of nanoparticles by reprecipitation method. The resulting nanostructures
have been characterized in their dimensions and their photochemical pro-
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perties. It results in a significative red-shifted emission, if they are com-
pared with the analogue structures reported in literature. In particular,
considering the dimension and the optical properties of the nanoparticles
obtained from intermediate 126, the next step will be the conjugation of
it with the RGD-mimetics reported in Chapter 5. With this approach,
it is possible to verify if and how the formation of nanoparticles can be
affected by this modification. The resulting structure could be useful to
deeply study how the RGD-mimetics interact with integrins in particular,
and with cancer cells in general, to understand if it can be internalized by
the cells. This is possible because of the optical properties in emission of
intermediate 126, that will act as cargo.
6.4 Experimental procedures
6.4.1 Synthesis and characterization
Synthesis of intermediate 127. In 2-necked round bottom flask,
starting material (1 eq, 300 mg) and 2,6-ditertbutyl phenol (1.5 mol%)
were added and dried under vacuum for 30 min. Degassed toluene (7.4
ml) and tributyl(vinyl)tin (1.2 eq) were added and the mixture was de-
gassed, then Pd(PPh3)2Cl2 (1.5 mol%) was added. The reaction was
stirred at 100 oC overnight and the complete conversion followed by 1H-
NMR of the crude. The solvent was removed under reduced pressure
and the crude was purified by flash chromatography (Silica gel 40-60
µm part. size, 95:5 to 8:2=cyclohexane:dichloromethane) to obtain the
product(Y%=98%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 8.25
(dd, J= 16, 4 Hz, 1H), 8.18 (d, J= 4 Hz, 1H), 7.76 (d, J= 16 Hz 1H),
7.73 (d, J= 16 Hz, 1H), 7.46 (dd, J= 16, 4 Hz,1H), 7.39 (s, 1H), 6.81
(dd, J= 2.8, 2 Hz, 1H), 5.85 (d, J= 36 Hz, 1H), 5.34 (d, J= 24 Hz, 1H),
2.03 (m, 4H), 1.39 (m, 4H), 0.95 (m, 12H), 0.78 (d, J= 12 Hz, 12H), 0.67
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(d, J= 12 Hz, 6H), 0.61-0.25 (m, 4H). 13C NMR (200 MHz, CDCl3)
δ 152.7, 152.1, 147.4, 147.0, 138.7, 138.5, 136.9, 125.7, 123.3, 121.3,
120.7, 119.7, 118.1, 114.6, 77.7, 77.0, 76.4, 55.4, 39.1, 37.4, 36.4, 32.7,
30.4, 27.9, 24.6, 24.5, 22.6, 22.5, 19.4. MALDI-ToF: 518 [M +H]+
Synthesis of intermediate 128. In 2-necked round bottom flask, in-
termediate 127 (2.04 eq, 85 mg) and 4,7-dibromobenzo[c]-1,2,5- thiadi-
azole (1 eq) were added and dried under vacuum for 30 min. Degassed
DMF (730 µl) and an aqueous solution of K2CO3 (5 eq in 731 µl) were
added and the mixture was degassed, then Pd(PPh3)4 (2.1 mol%) and
Pd(OAc)2 (10.2 mol%) were added. The reaction was stirred at 90 oC
overnight. The solvent was removed under reduced pressure and the
crude extracted with chloroform and purified by flash chromatography
(Silica gel 40-60 µm part. size, 95:5 to 8:2=cyclohexane:ethyl ether) to
obtain the product (Y%=98%) as an orange solid. 1H NMR (400 MHz,
CDCl3) δ 8.28 (d, J= 4 Hz, 2H), 8.22 (s, 2H), 8.17 (d, J= 16 Hz, 2H),
8.11 (d, J= 8 Hz, 2H), 7.81 (m, 4H), 7.77 (s, 2H), 7.73 (d, J= 4 Hz, 2H),
7.64 (s, 2H), 2.11 (m, 8H), 1.41 (m, 4H), 1.17 (m, 4H), 1.05 (m, 20H),
0.90 (m, 4H), 0.77 (d, J= 8 Hz, 24H), 0.71 (d, J= 4 Hz, 12H), 0.54 (m,
8H). 13C NMR (400 MHz, CDCl3) δ 153.96, 153.01, 152.22, 147.31,
147.14, 139.04, 138.73, 133.60, 130.81, 129.45, 127.49, 126.41, 125.28,
123.45, 121.53, 119.85, 118.19, 55.61, 39.17, 37.51, 37.43, 36.57, 32.82,
30.53, 27.83, 24.60, 24.52, 24.46, 22.63, 22.40, 19.49. MALDI-ToF:
1166 [M ]+
Synthesis of intermediate 126. In 2-necked round bottom flask, in-
termediate 128 (1 eq, 40 mg) was dissolved in a 1:1=EtOAc:EtOH mix-
ture (2.2 ml) and the mixture sparged with Ar for 10 min. SnCl2 (16 eq)
was added and the reaction was stirred at 90 oC overnight. The solvent
was removed under reduced pressure and the crude poured in EtOAc and
washed with NaOH 1M. The crude was purified by flash chromatography
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(Silica gel 40-60 µm part. size, 95:5 to 8:2=hexane:EtOAc) to obtain the
product (Y%=55%) as a red solid. 1H NMR (400 MHz, CDCl3) δ 8.08
(d, J= 12 Hz, 2H), 7.72 (s, 2H), 7.67 (d, J= 16 Hz, 2H), 7.58 (m, 4H),
7.53 (s, 2H), 7.49 (d, J= 8 Hz, 2H), 6.67 (s, 4H), 3.80 (bs, 4H), 1.97 (m,
8H), 1.43 (m, 4H), 1.11 (m, 24H), 0.90 (m, 4H), 0.78 (d, J= 8 Hz, 24 H),
0.70 (d, J= 4Hz, 12H), 0.54 (m, 8H). 13C NMR (400 MHz, CDCl3) δ
154.02, 153.07, 150.28, 146.19, 142.19, 134.81, 133.96, 132.19, 129.29,
126.58, 125.99, 122.76, 120.94, 120.65, 118.55, 114.02, 109.62, 54.62,
39.24, 39.22, 38.02, 37.89, 36.65, 36.60, 32.99, 32.96, 30.51, 30.45,
27.92, 24.68, 24.57, 22.70, 22.69, 22.59, 22.57, 19.55, 19.52. MALDI-
ToF: 1106 [M ]+
Synthesis of intermediate 130. In 2-necked round bottom flask,
tris(dodecyloxy)benzoic acid (1 eq) was dissolved in dry DCM (88 µl)
and a catalytic amount of DMF (30 µl) and oxalyl chloride (1.5 eq) were
added. The mixture was stirred at room temperature overnight in ab-
sence of light. After completion, the solvent was removed under vacuum
and the crude added to a solution in dry DCM (200 µl) of intermediate
126 (1.5 eq) and TEA (1.5 eq). The mixture was stirred overnight. The
solvent was removed under vacuum and the crude purified by flash chro-
matography (Silica gel 40-60 µm part. size, 99:1=cyclohexane:EtOAc)
to obtain the product (Y%=61%) as a red solid. 1H NMR (400 MHz,
CDCl3) δ 8.03 (m, 2H), 7.73 (s, 2H), 7.68 (m, 4H), 7.61 (m, 4H), 7.51
(m, 2H), 7.46 (m, 2H) 7.41 (m, 2H), 7.03 (s, 2H), 6.59 (s, 2H), 3.98 (m,
6H), 1.97 (m, 4H), 1.77 (m, 2H), 1.70 (m, 2H), 1.20 (m, 54H), 1.03 (m,
18H), 0.80 (t, J= 4 Hz, 9H), 0.69 (d, J= 4 Hz, 12H), 0.64 (d, J= 4 Hz,
6H), 0.48 (m, 4H). MALDI-ToF: 1106 [M ]+
Synthesis of final product 131. In 2-necked round bottom flask,
tris(dodecyloxy)benzoic acid (1.5 eq) was dissolved in dry DCM (130
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µl) and a catalytic amount of DMF (30 µl) and oxalyl chloride (2.25
eq) were added. The mixture was stirred at room temperature overnight
in absence of light. After completion, the solvent was removed under
vacuum and the crude added to a solution in dry DCM (400 µl) of in-
termediate 130 (1 eq) and TEA (1 eq., 3.6 µl). The mixture was stirred
overnight. The solvent was removed under vacuum and the crude puri-
fied by flash chromatography (Silica gel 40-60 µm part. size, 98:2=cy-
clohexane:EtOAc) to obtain the product (Y%=50%) as a red solid. 1H
NMR (400 MHz, CDCl3) δ 8.1 (m, 2H), 7.73-7.54 (m, 18H), 7.1 (s,
2H), 4.06 (m, 12H), 2.04 (m, 4H), 1.84 (m, 2H), 1.76 (m, 2H), 1.27 (m,
114H), 1.06 (m, 18H), 0.88 (t, J= 4 Hz, 18H), 0.76 (d, J= 4 Hz, 12H),
0.70 (d, J= 4 Hz, 6H), 0.54 (m, 4H). MALDI-ToF: 2421 [M ]+
6.4.2 Preparation of nanoparticles
The nanoparticles were prepare injecting 15 µl of 1 mM THF solu-
tion in 5 ml of deionizated water, which results in 3 µM nanoparticle
solution.
6.4.3 Optical Characterization
UV-vis and PL measurments were performed on a Jasco V-650 spec-
trophotometer and Jasco FP-6500 spectrofluorometer, respectively. The
optical density of the samples for fluorescence measurement was below
0.1. Solutions were measured in liquid cells with a 1 cm path length for
UV-vis and fluorescence, at room temperature.
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6.4.4 Dynamic Light Scattering
DLS experiments were performed on an Zetasizer Nano ZSP. The in-
cident beam was produced by a HeNe laser operating at 633 nm. The in-
tensity signal was sent to a digital correlator. The nanoparticles solutions
were prepared via the reprecipitation method described before followed
by a filtration via a 0.4 µm pore size cellulose filter to remove dust parti-
cles. The calculation of the particle size distribution for all nanoparticles
was performed using CONTIN fits.
6.5 Notes and references
This work has been developed during the period abroad in Tech-
nische Universiteit of Eindhoven, in the research group of prof. Luc
Brusveld who supervisioned this work together with dr. L.G. Milroy and
ir. A.H.A.M. van Onzen.
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The reuse licenses for those pubblished articles cited in this work,
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